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Abstract 
Renal cell carcinoma (RCC) is a notoriously difficult cancer to treat.  RCC has an 
unpredictable course, is radio- and chemo-resistant and survival in response to 
treatment with current therapies for the metastatic disease is generally very poor.  
This underscores the necessity for novel therapeutics for this condition.  The tumour 
suppressor p53 is rarely mutated in RCC and up-regulation of p53 and its negative 
regulator, MDM2, has recently been shown to be an independent prognostic 
indicator for patients with poor outcome.  The function of p53 in RCC cells in 
culture appears to be partially intact and is regulated by MDM2.  Rescue of p53 from 
the inhibitory effects of MDM2 using inhibitors of the p53-MDM2 interaction results 
in cell cycle arrest or senescence, not apoptosis, three cell fates that p53 can induce 
depending on the tissue or tumour type.  Because of the potentially deleterious 
effects of senescent cells on the tissue microenvironment, it was decided that 
apoptosis would be the preferable cell fate for the therapeutic reactivation of p53 in 
RCC cells.  To that end, the MDM2 inhibitor Nutlin-3 was combined with the Bcl-2 
family inhibitor ABT-737.  This combination of drugs synergistically inhibited the 
proliferation of RCC cells harbouring wild type p53 but not in cells harbouring 
mutant p53.  This synergistic inhibition of proliferation was shown to be p53-
dependent and was confirmed to be inducing apoptosis, but only in RCC cells that 
had high levels of p53 protein.  The synergistic inhibition of proliferation was not 
recapitulated when an inhibitor of MDM2 ubiquitin ligase activity was combined 
with ABT-737.  The combination of Nutlin-3 and ABT-737 induced pro-apoptotic 
Puma and Noxa in RCC cells and the apoptosis was shown to be substantially Bax-
dependent.  This study suggests that the combination of Nutlin-3 and ABT-737 
II	  	  
should be considered as a candidate for pre-clinical development in the treatment of 
RCC. 
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Chapter 1: Introduction 
The aim of this thesis was to explore the possibility of the therapeutic restoration of 
wild type p53 apoptotic function in renal cell carcinoma (RCC) using a 
combinatorial approach.  The purpose of this section therefore is to lead the reader 
through the background and concepts pertinent to this study.  Section 1.1 introduces 
RCC and discusses the incidence, risk factors, epidemiology, the molecular biology 
of the disease and current strategies used in the treatment of RCC and how the 
underlying molecular biology of the disease is targeted in its treatment.  Section 1.2 
addresses the tumour suppressor p53 in greater depth and includes an overview of 
three important effects of p53 activation: cell cycle arrest, senescence and apoptosis.  
Section 1.3 addresses MDM2, the main negative regulator of p53 and how p53 is 
regulated by both MDM2 and other factors.  Section 1.4 is a brief discussion about 
the theoretical basis underlying combination treatment of cancer.  Section 1.5 
summarizes the aims of this thesis. 
 
1.1 Introduction to renal cell carcinoma 
This section will address the epidemiology, incidence and risk factors associated 
with RCC including a discussion regarding commonly mutated genes in RCC and the 
underlying molecular biology of the disease.  A discussion on the treatment of RCC 
is at the end of this section so that the relevant grounding in the molecular biology of 
RCC is provided before a detailed discussion of targeted therapy. 
 
1.1.1 Introduction to kidney cancer 
Cancer of the kidney represents 4% of all diagnosed cancer cases in men and over 
2% of cancer cases in women in the UK (Cancer Research UK Statistics, 2010).  
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Over 102,000 patients die from this disease annually worldwide, and the number is 
rising by approximately 2-3% per decade (Gupta et al., 2008).  Overall, the incidence 
of the disease has doubled over the past thirty years.  In the UK, the incidence of the 
disease has increased from 4.9 cases per 100,000 of the population in 1975 to 11.8 
per 100,000 in 2010 (Cancer Research UK Statistics).  Approximately 200,000 new 
cases of kidney cancer are diagnosed every year internationally.  The incidence of 
kidney cancer varies between different populations in different regions (Chow et al., 
2010).  Clear cell renal cell carcinoma, which is cancer derived from the renal 
epithelium, is the most common type of kidney cancer, representing over 75% of 
cases.   
 
1.1.2 RCC 
RCC is believed to originate from the tubular structures of the kidney (Lubensky et 
al, 1996) and is a heterogeneous disease, comprising a number of different subtypes.  
Approximately 4 % of RCC cases are hereditary and the remaining 96 % are 
sporadic. RCC has been classified into four major histological subtypes: clear cell 
RCC (ccRCC) is the most frequently encountered, representing 75-80% of all RCC.  
Other types are papillary (10-15%), chromaphobe (5%) and collecting duct (1%) 
(Lopez-Beltran et al., 2006; Pavlovich et al., 2004; Zbar et al., 2003). 
 
1.1.3 Risk factors 
A number of risk factors are believed to be associated with increased susceptibility to 
RCC.  Age is the most important risk factor for RCC and age-standardized incidence 
rates of RCC have generally been observed to be higher among men than women, a 
pattern repeated consistently throughout the world (Cancer Research UK Statistics, 
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2010). Tobacco smoking has been identified as a risk factor for RCC by a number of 
studies.  A meta-analysis of 24 studies showed that there was an increased risk 
associated with smoking and this was estimated to be 54% in men and 22% in 
women.   A clear dose-response relationship was shown, with heavier smoking 
associated with increased risk (Hunt et al., 2005; Theis et al., 2008).  Excess body 
weight has been associated with increased risk of RCC in several studies.  In a meta-
analysis and systematic review of studies into body mass index (BMI) and incidence 
of cancer, an association between risk of RCC and a 5kg/m2 increase in BMI was 
proposed (relative risk = 1.24 p < 0.0001) (Renehan et al., 2008). 
 
1.1.4 Prognostication of RCC tumours 
RCC tumours can be classified based on a number of criteria.  Staging systems 
categorize different tumours according to their anatomical features, thereby 
classifying patients into groups that represent different risks of disease progression 
and death.  This provides useful information for the planning of appropriate 
treatment strategies.   The TNM (tumour node metastasis) staging system is used in 
patients with RCC (table 1.1).  The five year disease specific survival for stages I, II, 
II and IV has been observed to be 89.6 %, 82.7 %, 57.7 % and 18.3 % respectively 
(Elmore et al., 2003).  Another system commonly used in the prognostication of 
RCC is Fuhrman grading, which is used for classification of RCC by evaluating 
nuclear morphology.  Grade 1 cells possess nuclei that less than 10µm in size with a 
round nuclear shape and have inconspicuous nucleoli.  Grade 4 cells, which are of 
the highest grade on the Fuhrman scale, possess nuclei that are greater than 20µm in 
size, have a multilobate nuclear shape and possess enlarged nucleoli (Fuhrman et al., 
1982).  Fuhrman grade has been shown to significantly correlate with tumour size, 	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Table 1.1 Staging of kidney tumours using TNM classification.  Taken from Rini 
et al., 2009. 	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TNM stage of cancer, venous system invasion, lymph node involvement and distant 
metastases.  Further, the Fuhrman grade of a RCC tumour can serve as an 
independent prognostic indicator for survival in RCC cases (Medeiros et al., 1988; 
Bretheau et al., 1995; Ficarra et al., 2001; Zhang et al., 2012).	  	  
1.1.5 Genetic abnormalities in RCC	  
Cancer is a disease that results from de-regulated growth and survival signals that 
promotes the unrestrained proliferation of cells resulting in tumour formation.  The 
step-wise accumulation of mutations in genes that are involved in processes such as 
proliferation, growth, survival and angiogenesis (amongst other processes) can 
confer a survival advantage to cells that have undergone this mutation process and 
these cells can proceed to proliferate and form tumours (Hanahan and Weinberg, 
2000).  The study of hereditary kidney cancer syndromes has led to the identification 
of genes involved in the pathogenesis of RCC.  Commonly mutated genes in RCC 
are MET, VHL and FLCN and a discussion of these genes is in the remainder of this 
section.  As the tumour suppressor p53 is rarely mutated in RCC (reviewed in Noon 
et al., 2010) but is of particular relevance to this thesis, a discussion regarding this 
gene in RCC is reserved for section 1.1.6.2.	  	  
1.1.5.1 MET 
Individuals with hereditary papillary renal cell carcinoma (HPRCC), which is an 
inherited form of RCC, develop multiple, bilateral RCC with papillary histology 
(Zbar et al., 1994).  Mutation of the tyrosine kinase domain of MET was identified by 
genetic linkage analysis in families with this inherited cancer syndrome (Schmidt et 
al., 1997).  In a study by Schmidt and colleagues, mutation of MET was observed in 
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17 out of 129 (13%) sporadic cases of HPRCC (Schmidt et al., 1999).  Of these 17 
cases of HPRCC that were apparently sporadic, 8 were germline mutations.  The 
MET proto-oncogene encodes a cell surface tyrosine kinase receptor for hepatocyte 
growth factor (HGF), which is important for proliferation, cell migration, 
morphogenesis and differentiation (Perruzi and Bottaro, 2006).  Most of the MET 
mutations associated with HPRCC lie in the Met activation loop or in the ATP 
binding pocket, which causes constitutive Met activation, independent of any ligand 
binding (Jeffers et al., 1997). 
 
1.1.5.2 FLCN 
Birt-Hogg-Dubé syndrome is a genetic disorder that can promote susceptibility to 
renal carcinoma, renal and pulmonary cysts and non-cancerous tumours of the hair 
follicles refered to as fibrofolliculomas.  The condition is caused by mutation in the 
FLCN gene, which encodes a protein called folliculin (Menko et al., 2009).  FLCN 
mutations have been observed in ~90% of families afflicted with this disease 
(Nickerson et al., 2002).  In sporadic RCC, the FLCN gene can be inactivated by loss 
of heterozygosity or promoter methylation. Mutation in this gene was observed in 
2.6% of cases of sporadic RCC tested (Khoo et al., 2003).  Most germline mutations 
of FLCN are predicted to truncate the protein product of the gene, folliculin.   The 
function of folliculin is unclear however, the protein has been observed to form a 
complex with folliculin interacting protein 1 and 2 (FNIP1 and FNIP2).  This 
complex can bind AMPK, a nutrient sensor that can regulate mTOR.  The 
importance of mTOR in RCC will be discussed in section 1.1.6.1 (Baba et al., 2006; 
Hasumi et al., 2008). 
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1.1.5.3 VHL  
The most commonly observed genetic abnormality in RCC is inactivation of the Von 
Hippel Lindau (VHL) tumour suppressor gene.  Von Hippel Lindau disease is a 
hereditary cancer syndrome; individuals affected by the disease have an increased 
risk for the development of tumours in a number of organs, including the kidneys.  
Positional cloning was used to identify the VHL gene locus on the short arm of 
chromosome 3 in patients with Von Hippel Lindau disease (Seizinger et al. 1988). 
Consistent with the Knudson two-hit hypothesis (Knudson 1971), VHL was 
subsequently identified as a tumour suppressor gene based on the observation that 
the gene was mutated at both alleles in hereditary Von Hippel Lindau disease and 
sporadic RCC (Latif et al., 1993).   This hypothesis was further strengthened by the 
observation that the ability of the VHL null RCC cell line 786-O to form tumours in 
nude mice was severely perturbed upon stable transfection of VHL into these cells 
(Iliopoulos et al. 1995).  Further work showed that somatic mutation of VHL were 
present in 57% of RCC cases and that 97% of these exhibited loss of the second VHL 
allele (Gnarra et al. 1994).  Herman et al. showed that a further 10-20% of renal cell 
carcinomas exhibit hypermethylation of typically unmethylated CpG islands near the 
5’ region of the VHL, resulting in the loss of VHL gene expression (Herman et al., 
1994).  Hence, inactivation of the VHL tumour suppressor gene, whether by mutation 
or methylation, is a common occurrence in RCC. 
 
1.1.6 Molecular biology of RCC 
As mentioned briefly in section 1.1.5, mutation of certain genes in cells permits their 
unrestrained replication, which can result in cancer.  The significance of VHL 
mutation will be discussed in the section 1.1.6.1, as this is one of the most commonly 
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mutated genes in RCC and mutation of this gene is important to the development of 
RCC.  A discussion of p53 and MDM2 in RCC follows section 1.1.6.2 and this is to 
give the reader grounding in the significance of this pathway in RCC, as it is central 
to this thesis.   
 
1.1.6.1 VHL and HIF 
The following is a description of pVHL function, the protein product of the VHL 
gene, as it relates to RCC.  Hypoxia inducible factors (HIFs) are a family of oxygen 
sensitive, heterodimeric transcription factors that are involved in regulating oxygen 
delivery and cellular adaptation to oxygen deprivation.  HIF-α can bind the 
constitutively expressed HIF-β subunit and promote the transcription of genes that 
regulate energy metabolism, angiogenesis and other functions required in the 
adaptation to hypoxia by binding hypoxia response elements (HREs) in the relevant 
gene promoters (Semenza, 2010a).  For example, HIFs can promote the transcription 
of vascular endothelial growth factor (VEGF) to promote angiogenesis and glucose 
transporter 1 (GLUT1) to promote glucose uptake (Semenza, 2010b). pVHL forms 
part of a ubiquitin ligase complex that also includes cullin2, elongin B, elongin C and 
Rbx1 which is responsible for targeting HIFs for degradation (Kamura et al., 1999; 
Shen and Kaelin, 2013).  During normoxia, HIF-α is hydroxylated on a critical 
proline residue within the oxygen-dependent degradation (ODD) domain of the 
protein by HIF prolyl hyrdroxylase (PHD) (Cockman et al., 2000).  This reaction is 
dependent on the presence of oxygen.  This modification of HIF-α permits binding to 
pVHL and the subsequent ubiquitination of HIF-α resulting in its degradation by the 
proteasome (Maxwell et al., 1999).  During hypoxia, PHD no longer hydroxylates 
HIF-α and the pVHL-cullin2-elongin B-elongin C-Rbx1 complex does not associate 
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with HIF-α.  This results in the accumulation of HIF-α (Semenza, 2009).  Mutations 
of the pVHL protein due to mutation in VHL perturb the ability of pVHL to associate 
with HIF-α, resulting in the accumulation of HIF-α and subsequent up-regulation of 
the transcriptional targets of HIF (Stebbins et al., 1999; Ohh et al, 2000).  The up-
regulation of the transcriptional targets of HIF is the driver of the angiogenic and 
invasive phenotype of RCC tumours (Baldewijns et al., 2010).  The translation of 
HIF-α can also be regulated by the mammalian target of rapamycin (mTOR), part of 
the mTORC1 complex (Zhong et al., 2000; Hudson et al., 2002).  mTORC1 is a 
protein complex that functions as an energy sensor and can control protein synthesis 
(Laplante and Sabatini, 2012).  Thomas et al. showed that the proliferation of RCC 
cells that possessed up-regulated HIF-1α as a result of VHL knockdown was 
inhibited upon treatment with mTOR inhibitors (Thomas et al., 2006).  This provided 
the rationale for the use of mTOR inhibitors in a clinical setting. The importance of 
the biology of pVHL and HIF in the treatment of RCC will be discussed in section 
1.1.7.  
 
1.1.6.2 p53 and MDM2 in RCC 
p53 is commonly described as the “guardian of the genome” and plays a vital role in 
tumour suppression, primarily through functioning as a transcription factor for genes 
whose protein products are involved in tumour suppression (Lane, 1992).  Upon up-
regulation and activation, p53 can promote, amongst other responses, cell cycle 
arrest, senescence or apoptosis.  The potentially lethal effect of unrestrained p53 
function is countered by MDM2, the main essential regulator of p53 (Iwakuma and 
Lozano, 2003) and a transcriptional target of p53 (Wu et al., 1993).  MDM2 
regulates p53 by acting as an E3 ubiquitin ligase for p53, targeting p53 for 
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degradation by the proteasome, or through direct binding to p53, masking the ability 
of p53 to function as a transcription factor (Honda et al., 1997; Oliner et al., 1993).  
A more detailed discussion of p53 and MDM2 function are found in sections 1.2 and 
1.3, however for the purposes of this section, the role of p53 and MDM2 in RCC will 
be discussed.  p53 is mutated in roughly 50% of cancers, highlighting the importance 
of this gene in tumour suppression (Hainaut et al., 1997).  Several studies have 
examined mutational status of p53 in RCC and levels of p53 and MDM2 in tissue 
samples in RCC (reviewed in Noon et al., 2010) to determine the prognostic value of 
the expression of both of these proteins.  Owing to the differences in tumour grade, 
antibodies used in IHC studies and techniques used to analyse p53 mutation status in 
samples, it has been difficult to assess the significance of p53 mutation status and 
levels of p53 and MDM2 in the progression of RCC when referring to the literature 
(Noon et al., 2010).  Some of the literature regarding p53 and MDM2 expression in 
RCC is summarized below.  Chemeris et al., performed IHC on 88 renal tumours and 
showed that the level of p53 was elevated in renal tumours and using single strand 
conformation polymorphism, it was shown that p53 was always wild type in the 
samples tested (Chemeris et al., 1995).  The authors of this study concluded that 
mutation of p53 was unlikely to contribute to the development of RCC and that the 
elevation of p53 was independent of any mutation in p53.  Moch and colleagues 
showed that elevated p53 was associated with poor prognosis and that p53 positivity 
was strongly associated with MDM2 positivity but positivity for both proteins was 
not associated with reduced survival (Moch et al., 1997).  Using 194 tumour 
samples, of a variety of stages and histological grades, in combination with clinical 
outcome data, Haitel et al. showed that elevated p53 and MDM2 was an independent 
prognostic indicator and that patients with tumours that were positive for both 
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proteins performed worse overall (Haitel et al., 2000).  The apparent contradiction 
between Moch et al. and Haitel et al. regarding the association of p53 and MDM2 
up-regulation and patient outcome may have been due to differences in the staging of 
the tumours between both sets of data and different cut-off points used in each study.  
Noon et al. showed that in a cohort of patients treated by radial nephrectomy, up-
regulation of both p53 and MDM2 was significantly associated with reduced disease 
specific survival and that p53 in these tumours was rarely mutated (Noon et al., 
2011). 
 
The dearth of observed p53 mutations in cases of RCC is consistent with the 
behaviour of p53 in renal epithelial cells, as discussed in Vlatkovic et al., 2011: in 
response to stress, p53 in cells of the renal epithelium is up-regulated but apoptosis 
does not take place (MacCallum et al., 1996; reviewed in Vlatkovic et al., 2011).  
The p53-dependent transcription of Bax, an important effector of apoptosis 
commonly up-regulated by p53 in response to ionizing radiation in a number of 
tissues (Miyashita et al., 1994), did not take place in renal epithelium tissue, whereas 
transcription of p21, an important mediator of cell cycle arrest (El-Deiry et al., 
1993), was up-regulated in these cells (Bouvard et al., 2000).  Taken together, these 
observations suggest that p53 is incapable of mediating a pro-apoptotic response in 
renal epithelial cells in response to stress.  Hence, there is little requirement for 
mutation of p53 in these cells for subsequent development of cancer in this tissue.  
The behaviour of p53 in renal tissue is reflected in the behaviour of p53 in RCC cells 
in vitro.  p53 in cultured RCC cells that possess wild type p53 is at least partially 
able to function as a transcription factor, insofar as p53 can promote the transcription 
of p21 in response to UV radiation and down-regulation MDM2 by siRNA resulted 
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in increase p53 and and p21 protein level (Warburton et al., 2005).  Further, RCC 
cells cultured in vitro can spontaneously increase p53 and MDM2 expression and 
this increase in expression of both proteins results in increased motility (Polanski et 
al., 2010).  Increased motility and by extension, increased metastasis, as a result of 
up-regulation of p53 and MDM2 may be a possible explanation for the poor outcome 
of patients with p53/MDM2 positive RCC tumours, however this remains to be 
elucidated (Noon et al., 2011).  Having addressed the relevant molecular and cell 
biology of RCC in this section, the next section will address treatment strategies for 
RCC.  A more detailed general discussion about p53 and MDM2 structure and 
function will follow the next section. 
 
1.1.7 Treatment of RCC 
RCC is both radio-resistant and chemo-resistant; hence these treatment modalities 
are not used as treatment options in RCC patients.  Surgical resection of the primary 
tumour is the most favoured therapeutic option if the tumour is sufficiently localized 
(Rini et al., 2009).  Partial nephrectomy, which is surgical resection of the tumour 
whilst leaving the remainder of the kidney intact, is becoming a preferred method for 
dealing with renal masses.  Comparisons of radical nephrectomy, which is complete 
removal of the kidney, with partial nephrectomy have shown that there is no 
significant difference between both approaches in relationship to patient outcome 
(Uzzo and Novick, 2001; Kopp et al., 2013).  Spontaneous regression of metastatic 
RCC lesions in response to nephrectomy is a rare but recognized occurrence. 
Spontaneous regression has been observed to take place in <1% of patients that have 
undergone nephrectomy (Snow and Schellhammer, 1982) however, this phenomenon 
has also been observed in the absence of surgery and spontaneous regression may not 
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necessarily be associated with nephrectomy (De Riese et al., 1991; Lekanidi et al., 
2007).  A possible explanation for spontaneous regression in response to 
nephrectomy is that removal of the primary tumour removes a source of 
immunosuppressive factors.  Alternatively, nephrectomy may remove an important 
source of pro-angiogenic and growth factors (Biswas and Eisen, 2009).  These 
observations led to an increased interest in immunotherapy in the treatment of RCC.   
Before the advent of targeted therapy for the treatment of RCC, interferon-α (IFNα) 
and high dose interleukin-2 (IL-2) were treatments used in patients that suffered from 
the metastatic disease (Fyfe et al., 1995; Jonasch and Haluska, 2001).  High dose IL-
2 is the only treatment for metastatic RCC that has been shown to mediate a 
complete response although this has been typically in less than 5% of patients (Fyfe 
et al., 1995; McDermott et al., 2005).  An increased understanding of the underlying 
molecular biology of RCC has driven the use of targeted therapy for the treatment of 
the metastatic disease.  All of the current targeted therapies for the treatment of 
metastatic RCC are directed towards inhibition of downstream effects of VHL 
mutation.  Sorafenib, Sunitinib, Axitinib and Pazopanib are all multikinase inhibitors 
that can inhibit isoforms of the VEGF receptor, c-kit and PDGF receptor.  
Bevacizumab is a monoclonal antibody that can target VEGF-A and Temsirolimus 
and Everolimus both target mTOR, the inhibition of which can lower HIF-1α 
production (Linehan et al., 2010).  The use of targeted therapy has been met with 
limited success in the clinic, with targeted therapies increasing median progression 
free survival and overall survival by only a few months over placebo or other 
controls (Hutson, 2011).  In a recent trial of patients that had failed first line therapy 
of either Sunitinib, Bevacizumab in combination with IFN-α, Temsirolimus or 
cytokine therapy, patients were treated with Axitinib, a second generation 
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multikinase inhibitor, or Sorafenib (Rini et al., 2011).  There was a statistically 
significant increase in progression free survival (PFS) in the group treated with 
Axitinib when compared to the Sorafenib-treated group and the median PFS was 6.7 
months vs 4.7 months and both drugs had a similar safety profile.  Axitinib may 
therefore become the future second line therapy for metastatic RCC.  Overall, 
targeted therapy has increased median overall survival from roughly 12 months in 
patients treated with immunotherapy (McDermott et al., 2005), to over 24 months 
(Hutson, 2011). However, survival data from all of the current therapeutic regimes 
leave much to be desired in terms of improved treatments for the metastatic 
condition. 
 
1.2 p53 
1.2.1 Introduction to p53 
The tumour suppressor p53 is widely regarded as the “guardian of the genome” 
(Lane, 1992) because of the central position of the protein in connecting multiple 
pathways that maintain the integrity of genetic information upon exposure to 
different types of stress (Fridman and Lowe, 2003).  p53 primarily functions as a 
transcription factor, promoting the transcription of genes whose protein products can 
determine a number of cell fates, however, transcription-independent functions of 
p53 have been described (Speidel, 2010). 
 
p53 was first discovered as a protein that co-precipitated with large T antigen in 
SV40 virus-infected cells by three independent groups (Kress et al., 1979; Lane and 
Crawford, 1979; Linzer and Levine, 1979).  Early studies on p53 suggested a role for 
the protein in promoting cell proliferation.  An increase in the level of p53 mRNA 
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and p53 protein synthesis was observed in growth arrested mouse fibroblasts 
stimulated by the addition of serum, and this peaked at the G1/S boundary (a more 
detailed description of the cell cycle is presented in section 1.2.3), before initiation of 
DNA replication (Reich and Levine, 1984).  Similar observations in normal resting 
lymphocytes (Milner and McCormick, 1980) and normal diploid fibroblasts (Mercer 
et al., 1984) suggested that p53 expression always accompanied cell growth.  The 
observation that co-transfection of what was believed to be wild type p53 
complementary DNA (cDNA) with co-introduced  activated Ras oncogene could 
cause transformation of rat embryonic fibroblasts (Eliyahu et al., 1984) led 
researchers to believe that p53 could function as an oncogene.  It was later 
demonstrated that p53 studied in cancer cells was mutated and that wild type p53 
lacked transforming ability in vitro (Hinds et al., 1989).  Further experiments showed 
that co-transfection of a plasmid coding for wild type p53 reduced the transformation 
potential of plasmids encoding an activated Ha-Ras gene (Eliyahu et al., 1989).  The 
role of p53 as a tumour suppressor was finally confirmed when it was observed that 
the p53 gene was absent or mutated in colorectal carcinoma (Baker et al., 1989).  p53 
activity is important in inducing a number of cell fates in response to stress.  These 
include, but are not limited to: cell cycle arrest, senescence and apoptosis.  The 
following is a summary of each of these cell fates and a description of the 
contribution made by p53 in determining each of these outcomes. 
 
1.2.2 p53: overview of structure and function 
p53 is a 393 amino acid-long protein consisting of a number of functional domains.  
These include an amino-terminus transactivation domain (TAD), a proline-rich 
regulatory domain, a DNA-binding domain (DBD), an oligomerization domain and a 
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carboxy-terminus regulatory domain (Okorokov and Orlova, 2009).  The 
organization of domains of the p53 polypeptide is shown on figure 1.2.1.  Nuclear 
export signals can be found within the TAD and oligomerization domain of p53 and 
three nuclear import signals can be found at the carboxy-terminus regulatory domain 
of the protein (Vousden and Lu, 2002).  What follows is a discussion of the 
contribution made by each domain to the function of the p53 protein.  The TAD, 
encompassing amino acids 1-43, plays a role in the recruitment of the basal 
transcription machinery upon binding of p53 to DNA.  The TAD can be further sub-
divided into two separate transactivation domains, TAD1 and TAD2 (Chang et al., 
1995).  Recent work has suggested that the response of p53 to acute DNA damage is 
dependent upon TAD1 but the response to oncogenic signalling is dependent on both 
TADs (Brady et al., 2011).  General transcription factors (GTFs) are required for 
transcription in eukaryotes (Thomas and Chiang, 2006).  The TAD of p53 has been 
shown to be important in the binding of the TATA binding protein (TBP) subunit of 
TFIID and can promote the recruitment of TFIID (Chen et al., 1993; Liu et al., 
1993).  Mutation of amino acids 22 and 23 of p53 disrupt the interaction between 
p53 and TAFII31, abrogating the ability of p53 function as a transcription factor (Lu 
and Levine, 1995). 
 
As mentioned earlier, p53 is a sequence specific transcription factor which can bind 
DNA via its DBD to a consensus sequence composed of two copies of the following 
DNA bases: 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ (where Pu represents a purine and 
Py represents a pyrimidine) separated by 0-13 base pairs (El Deiry et al., 1992).  The 
importance of the DBD to the function of p53 is highlighted by the observation that 
the overwhelming majority of mutations in p53 that are observed in cancer occur in  
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Figure 1.2.1 Functional domains of p53.  Adapted from Vousden and Lu, 2002. 
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Figure 1.2.2 Structural arrangement of p53.  L1, 2 and 3 indicate loops and LSH 
indicates loop-sheet-helix motif.  Amino acids that tetrahedrally co-ordinate Zinc and 
that make contact with DNA are also indicated.  Reproduced from Soussi and 
Beroud, 2001. 
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this domain (Hollstein et al., 1991; Petitjean et al., 2007).  Structural studies have 
demonstrated that the DBD folds into an anti-parallel ß-sandwich that co-ordinates 
two loops to permit interaction with DNA. These loops are stabilised by a Zn2+ ion to 
form a loop-sheet-helix motif (figure 1.2.2).  The DBD interacts with the DNA minor 
groove and makes contact with the phosphate backbone at the centre of the 
consensus sequence.  Structural studies of the p53-DNA binding complex suggest 
that the amino acid residues most frequently altered in mutant p53 are the residues 
that make direct contact with DNA (Cho et al., 1994). 
 
The carboxy-terminus of p53 harbours an oligomerization domain and nuclear 
import/export sequences.  The carboxy-terminus domain is comprised of a α-helix 
and a ß-strand.  This motif joins three other carboxy-terminus domains, interacting 
via hydrophobic interactions, through an anti-parallel helix–helix interface to form a 
tetramer (Clore et al., 1994; Okorokov and Orlova, 2009). 
 
Upon activation, p53 can promote a number of responses that can contribute to the 
role of p53 as a tumour suppressor, including cell cycle arrest, senescence and 
apoptosis.  The following is a description of each response and how p53 is involved 
in promoting these cell fates. 
 
1.2.3 Cell cycle arrest 
The cell cycle comprises a coordinated series of events where the outcome is the 
duplication of all cell components and division to produce two cells, a mother and a 
daughter cell, each containing the complete cell contents required for further growth 
and division.  A combination of checkpoints and controls within the cell cycle permit 
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the smooth transition between each stage.  Whereas cell growth is continuous, DNA 
synthesis and mitosis are divided into phases: S (DNA synthesis), G2 (post-synthetic 
gap), M (mitosis) and G1 (pre-synthetic gap) (Norbury and Nurse, 1992).  The cell 
cycle is summarised in figure 1.2.3.  Progression through the cell cycle is directed by 
an orchestrated series of regulatory events, chief among them, the sequential 
activation and de-activation of hetero-dimeric cyclin-dependent kinases (CDKs)-
cyclin complexes.  Progression through G1 is dependent on CDKs binding to cyclins 
D and E. S and M phase progression, however is dependent upon CDKs binding to 
cyclins A and B (Diaz-Moralli et al., 2013).  Sensor mechanisms, called checkpoints, 
maintain an accurate sequence of events by ensuring a new phase of the cell cycle is 
not initiated until the completion of the current phase.  A driving force for the 
development and subsequent progression of cancer is DNA damage (Hanahan and 
Weinberg, 2000).  One mechanism that has evolved to permit repair of damaged 
DNA before continuation through the cell cycle is cell cycle arrest.  Cell cycle arrest 
is a temporary pause in the cell cycle that allows damaged DNA to be repaired 
before allowing the cell to continue replication of the DNA or subsequent division. 
 
1.2.4 The role of p53 in cell cycle arrest 
p53 can promote the transcription of a number of genes whose protein products are 
involved in inducing cell cycle arrest.  p53 can promote arrest of the cell cycle at two 
stages: G1 and G2.  p53 can promote the expression of p21 (also known as 
WAF1/Cip1) (El Deiry et al., 1993) which can bind to and inhibit CDK4/6-cyclin D, 
CDK1-cyclin B and CDK1/2-cyclin A. This results in a block to cell cycle 
progression (Xiong et al., 1993; El Deiry et al., 1994).  p21 can also interact with 
PCNA, a DNA replication processivity factor.  Binding of p21 to PCNA perturbs the  
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Figure 1.2.3 The cell cycle.  In response to mitogens, a resting cell in G0 can enter 
the cell cycle.  Cyclin D-dependent CDKs accumulate and initiate the 
phosphorylation of Retinoblastoma, a process that is completed by CDK2-cyclin E.  
The restriction point is the stage at which the cell is committed to continuation of the 
cell cycle.  At S-phase entry, cyclin E is degraded and cyclin A associates with 
CDK2.  This allows continuation of the process to M phase, when a cell undergoes 
mitosis and divides into two daughter cells.  Adapted from Lodish et al., 2000. 
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ability of PCNA to function as a processivity factor for DNA polymerase in DNA 
replication, hence causing cell cycle arrest (Waga et al., 1994).  p53 can promote the 
transcription of GADD45 (Kastan et al., 1992).  Gadd45 has been shown to perturb 
the interaction between Cdc2-cyclin B1, resulting in G2 arrest (Zhan et al., 1999).    
 
p53 can also promote the transcription of 14-3-3σ, a protein which can halt G2-M 
phase progression (Hermeking et al., 1997).  14-3-3σ can sequester CDK1-cyclinB in 
the cytoplasm preventing the entry of this protein into the nucleus.  This inhibits 
progression of the G2 phase of the cell cycle (Katayama et al., 2005).  Reprimo is a 
p53-inducible protein that can inhibit G2/M phase.  The exact mechanism underlying 
Reprimo function has yet to be thoroughly elucidated however, it is believed that 
Reprimo may inhibit nuclear import of the Cdc2-cyclinB complex (Ohki et al., 
2001). 
 
1.2.5 Senescence 
Senescence is defined as irreversible exit from the cell cycle; when a cell remains 
metabolically active but can no longer divide and proliferate.  Most somatic cells 
possess a limited replicative lifespan.  Each cell division is accompanied by erosion 
of telomeres, the repetitive DNA sequence at the end of chromosomes.  Irreversible 
exit from the cell cycle as a result of telomere shortening is described as replicative 
senescence (Acosta and Gil, 2012).  Senescent cells in culture have a large, flattened 
morphology and are associated with increased β-galactosidase activity, also termed 
senescence associated β-galactosidase activity (SA-βgal).  The senescent state can 
also be induced by the action of oncogenes, in a process termed oncogene induced 
senescence.  This was first illustrated in primary human fibroblasts when a 
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constitutively active Ras allele, H-rasV12 was introduced into cells by retroviral 
transduction.  This resulted in accumulation of p53 and the CDK inhibitor p16, 
which was accompanied by senescence (Serrano et al., 1997).  Senescence has since 
been shown to be an important tumour suppressive response at least in some 
scenarios, for example, a p53-dependent senescence program led to the clearance of 
tumours in a mouse model for liver carcinoma (Xue et al., 2007).  p53-dependent 
senescence has also been shown to be important in promoting regression of 
lymphoma in an Eµ-myc model in response to the chemotherapeutic agent 
cyclophosphamide (Schmitt et al., 2002). 
 
Contrary to the important role played by senescence in tumour suppression, it has 
been suggested that senescent cells can have a deleterious affect on surrounding, 
non-senescent cells (Krtolica et al., 2001).  Senescent cells can stimulate the 
proliferation, movement and differentiation of surrounding cells via the secretion of 
several different molecules in what is described as the senescence-associated 
secretory phenotype (SASP) (Coppé et al., 2010).  Secretion of pro-inflammatory 
cytokines and proteases that permit remodelling of the extra-cellular matrix by 
senescent cells provides an environment that favours proliferation and motility of 
surrounding cells (Davalos et al., 2010).  Hence, activation of senescence may not be 
the most desirable outcome of cancer therapy. 
 
1.2.6 The role of p53 in senescence 
In response to DNA damage induced by ionizing radiation (IR), ataxia telangiectasia 
mutated (ATM) kinase and checkpoint kinase 2 (CHK2) can phosphorylate and 
activate p53 (Gire et al., 2004; Larsson, 2011).  p53 can subsequently promote the 
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transcription of p21, which can inhibit cell cycle regulators to induce senescence 
(Brown et al., 1997).  Senescence can also take place independently of both p53 and 
p21 as neither protein is essential for senescence to take place (Medcalf et al., 1996). 
 
1.2.7 Apoptosis 
Apoptosis, also commonly described as programmed cell death, is a programme that 
is essential for the healthy development of multi-cellular organisms that, when 
activated, culminates in destruction of the cell.  Apoptosis can take place as part of 
normal development and as a homeostatic mechanism in the maintenance of healthy 
cell populations in tissues.  Cells undergoing apoptosis are conspicuous by a number 
of morphological features that occur in a step-wise manner.  Shrinkage of the cell is 
followed by chromosome condensation.  This is accompanied by fragmentation of 
the nucleus.  The cell membrane blebs and apoptotic bodies form, which can 
subsequently be engulfed by phagocytes (Kerr et al., 1972).  Asymmetry of 
membrane phospholipids upon apoptosis permits detection of apoptotic bodies by 
phagocytes (Fadok et al., 1992).  There are currently three known pathways that 
result in initiation of the apoptosis cascade, the extrinsic apoptosis pathway, the 
intrinsic apoptosis pathway and the granzyme B pathway.  The extrinsic and 
granzyme B pathways are initiated by extracellular signals and the intrinsic pathway 
is initiated by intracellular signals, however, all three pathways converge at the 
mitochondrial outer membrane (MOM), where members of the Bcl-2 family interact 
to control the release of cytochrome C from the mitochondria (Elmore, 2007) after 
which, the caspase cleavage cascade ensues, resulting in the destruction of structures 
within the cell.  Details of the steps in each of the pathways that result in cytochrome  
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Figure 1.2.4 The Bcl-2 family of proteins.  The Bcl-2 family of proteins regulate 
apoptosis and can be divided into three subfamilies: anti-apoptotic, pro-apoptotic 
multi-BH domain and pro-apoptotic BH3-only proteins.  BH – Bcl-2 homology.  TM 
– trans-membrane.  α represents a α helix in the secondary structure of the protein.  
Figure taken from Cory and Adams, 2002. 
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C release and hypothetical models of apoptosis will be discussed after a discussion of 
the Bcl-2 protein family members involved in this process. 
 
The Bcl-2 family of proteins can broadly be divided into 3 main groups based 
sequence homology and function: the anti-apoptotic Bcl-2 family proteins comprise 
Bcl-2, Bcl-w, Bcl-xL, Mcl-1, Bfl-1/A1 and Bcl-B which suppress apoptosis and  
contain Bcl-2-homology (BH) domains 1-4.  The pro-apoptotic multi-BH domain 
Bcl-2 family effectors, which contain BH1-3 domain comprise of the proteins Bax, 
Bak and Bok. The pro-apoptotic BH3-only domain proteins only possess the BH3 
domain and comprises of Bid, Bim, Puma, Hrk, Noxa, Bad, Bmf and Bik.  Figure 
1.2.4 summarizes the sequence homology and classification of this family of 
proteins.  In response to a death-inducing signal, the pro-apoptotic effector proteins 
Bax and Bak can be activated to oligomerize at the MOM and allow the efflux of 
cytochrome C and other pro-apoptotic proteins such as SMAC/Diablo and Omi/Htra 
from the intermembrane space (IMS) between the MOM and mitochondrial inner 
membrane (Westphal et al., 2013).  Interaction of cytochrome C with Apaf-1 
(apoptosis protease activating factor-1) results in the assembly of the apoptosome.  
The apoptosome is a multi-protein complex that is responsible for the cleavage of 
pro-caspase 9 (Bratton and Salvesen, 2010).  Caspase 9 proceeds to cleave caspase 7 
and caspase 3 and this sets in motion the cleavage of further caspases that are 
involved in demolition of the cell (Elmore, 2007). Whilst the mechanism regarding 
inhibition of Bax and Bak oligomerization by members of the anti-apoptotic Bcl-2 
family such as Bcl-2, Mcl-2, Bcl-2 and Bcl-xL remains controversial (and will be 
discussed in further detail shortly) it is believed that the anti-apoptotic Bcl-2 family 
members prevent oligomerziation of Bax and Bak by i) directly sequestering Bax and 
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Bak at the MOM, which can be impeded by displacement of both of these proteins 
from the anti-apoptotic family members by the BH3-only family; or ii) by abrogating 
the interaction between the ‘direct activator’ BH3-only family members, tBid, Bim 
and Puma and Bax or Bak, preventing the conformational changes necessary in Bax 
or Bak that permit both proteins to oligomerize (Bender and Martinou, 2013). 
 
1.2.7.1 The Extrinsic Apoptosis pathway 
Cellular trans-membrane receptor and ligand interactions are involved in the 
initiation of the extrinsic apoptosis pathway.  This process involves death receptors 
of the tumour necrosis factor receptor (TNF-R) family and Fas receptor (FasR).  
Members of the death receptor family are characterised by the presence of a death 
domain (DD), a 80–100 amino-acid long motif involved in the transduction of the 
apoptotic signal (Tartaglia et al., 1993).  Apoptosis via FasR will be used to illustrate 
the mechanism underlying this pathway.  Upon binding of Fas ligand to FasR, the 
DD of FasR recruits and activates FADD (Fas associated death domain protein).  
FADD subsequently associates with pro-caspase 8 through interaction of the DDs 
from each protein.  At this point, the death induced signalling complex (DISC) is 
formed.  Pro-caspase 8 is activated at the DISC by autocatalysis.  Caspase 8 can then 
cleave caspase 3, at which point the caspase cascade that leads to apoptosis ensues 
(Lavrik and Krammer, 2012).  Caspase 8 can also cleave the BH3-only domain 
protein Bid into the active form of the protein, tBid.  tBid localises to and inserts into 
the MOM where it can either directly activate Bax or Bak or inhibit the anti-
apoptotic Bcl-2 family members to perturb their interaction with Bax and Bak.  This 
promotes efflux of cytochorome C from the IMS, promoting further caspase cleavage 
and an enhancement of the apoptosis cascade (Danial and Korsmeyer, 2004). 
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1.2.7.2 The Intrinsic Apoptosis pathway 
The intrinsic apoptosis pathway is initiated from signals from within the cell itself 
and the initiation of this pathway is independent of extracellular signalling.  A 
number of different stimuli can initiate the intrinsic apoptosis pathway and these 
stimuli include, but are not limited to, growth factor deprivation, DNA damage, 
cytokine deprivation and hypoxia.  Intrinsic apoptosis is mediated by members of the 
BH3-only family of pro-apoptotic proteins such as Bid, Puma, Noxa, Hrk and Bad 
and members of this family are modified by post-translational mechanisms or up-
regulated in response to pro-apoptotic stimuli, before they can contribute to 
apoptosis.  For example, Noxa and Puma are up-regulated by increased transcription, 
Bid is cleaved into its active form, tBid and Bad requires de-phosphorylation for the 
protein to be activated (Happo et al., 2012).  A description of Puma up-regulation 
will be used to illustrate the intrinsic apoptosis pathway.  Puma, also known as Bbc3, 
is a potent pro-apoptotic BH3-only family member that can promote Bax and Bak 
activation through either direct allosteric activation of Bax and Bak or by engaging 
anti-apoptotic Bcl-2 family members such as Bcl-2 and Bcl-xL (Hikisz and 
Kiliańska, 2012).  As stated previously, intrinsic apoptosis can be initiated in 
response to DNA damage or growth factor deprivation.  Puma can be up-regulated 
by p53 in response to DNA damage (Han et al., 2001) or by FOXO3a in response to 
growth factor deprivation (You et al., 2006).  Puma can then localize to the 
mitochondria to promote the efflux of apoptotogenic factors from the IMS and the 
caspase cascade ensues. 
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1.2.7.3 The Granzyme B pathway 
Cytotoxic T lymphocytes (CTL) can eliminate cells infected with a virus or tumour 
cells via apoptosis using the granzyme B pathway.  CTL cells secrete a pore forming 
protein into the membrane of the affected cell called perforin.  This permits the entry 
of granzyme B, which subsequently cleaves caspase 3 and Bid.  Caspase 3 cleavage 
results in the cleavage of downstream caspases and resulting cellular destruction. 
Cleavage of Bid to tBid by granzyme B, promotes the efflux of cytochrome C from 
the mitochondria, which ultimately allows cleavage of caspases upstream from 
caspase 9, thus enhancing downstream caspase signalling and enhancement of the 
apoptotic effect (Elmore et al., 2007; Rousalova and Krepela, 2010). 
 
1.2.7.4 Interactions between the Bcl-2 family members and models of apoptosis 
A complex network of interactions between anti-apoptotic and pro-apoptotic proteins 
determine whether cytochrome C is released from the IMS or maintained in the 
mitochondria.  What follows is a discussion regarding structure function 
relationships of the Bcl-2 family members, regulation of members of the Bcl-2 
family and current models of Bax/Bak-mediated apoptosis.   
 
Pro-apoptotic effectors Bax and Bak and the anti-apoptotic Bcl-2 family proteins 
have a similar tertiary structure.  They are small globular proteins that exhibit a 
characteristic arrangement of 7-8 amphipathic α-helices surrounding the central 
hydrophobic helix 5 (Chipuk et al., 2010).  This α-helical bundle folds to form a 
conserved hydrophobic surface groove.  Several structural and biochemical studies 
have shown that the interaction between members of the anti-apoptotic Bcl-2 family 
and the pro-apoptotic proteins of the Bcl-2 family occurs between this groove on the  
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Figure 1.2.5 Specificity of BH3-only proteins for anti-apoptotic Bcl-2 family 
members.  Cartoon depicting the specificity of each member of the BH3-only family 
for members of the anti-apoptotic Bcl-2 family.  Figure taken from Chipuk et al., 
2010. 
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anti-apoptotic proteins and the ~26 amino acid-long, alpha helical BH3 domain of 
the pro-apoptotic proteins (Sattler et al., 1997).  Subtle differences in the BH3-alpha 
helix-groove interaction confers specificity of interaction between the pro-apoptotic 
BH3-only proteins and anti-apoptotic Bcl-2 family members.  Bim, Puma and tBid 
will bind to any of the anti-apoptotic Bcl-2 family member, others are more specific 
in their interactions.  For example, the Noxa BH3-only protein is a potent interacting 
partner and thus inhibitor, of the anti-apoptotic protein Mcl-1.  However, Noxa has  
poor affinity for Bcl-2, Bcl-w and Bcl-xL.  Conversely, Bad has a high affinity for 
Bcl-2, Bcl-w and Bcl-xL but not to Mcl-1 (Chen et al., 2005; Certo et al., 2006; 
Deng et al., 2007).  The different specificties of the BH3 family and the anti-
apopototic Bcl-2 family are summarized in figure 1.2.5. 
 
Bak and/or Bax are essential for the efflux of cytochrome C from the mitochondrial 
IMS that leads to apoptosis (Wei et al., 2001).  Bak is constitutively localized to the 
outer membrane of the mitochondria and Bax is predominantly cytosolic until pro-
apoptotic signalling promotes Bax translocation to the mitochondria. The events 
leading up to the Bax/Bak pore formation at the mitochondrial OM have been the 
subject of debate for several years.  The “de-repressor” model postulates that the anti 
-apoptotic Bcl-2 family members sequester Bax and Bak at MOM.  Interaction of the 
BH3-only proteins with the anti-apoptotic Bcl-2 proteins results in the displacement 
of the anti-apoptotic family members from Bax and Bak.   Liberation of Bax and Bak 
from the anti-apoptotic proteins permits auto-activation and subsequent 
oligomerization, which results in apoptosis (Chen et al., 2005; Willis et al., 2007; 
Uren et al., 2007). 
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The “direct activation” model, on the other hand, posits that “activator” BH3-only 
proteins tBid, Bim and possibly Puma transiently interact with Bax or Bak, 
promoting a conformational change that results in the activation of Bax or Bak, 
allowing oligomerization of Bax and Bak.  In this model, the remaining BH3-only 
proteins act as “sensitizers” that displace the activators from anti-apoptotic Bcl-2 
family members, permitting the interaction between the activators and Bax and Bak 
(Bender and Martinou, 2013; Westphal et al., 2013). 
 
1.2.7.5 BH3 mimetics 
Irrespective of how apoptosis is promoted at the MOM by Bax and Bak, the Bcl-2 
family of anti-apoptotic proteins are an attractive target for therapeutic intervention.  
Evasion of apoptosis is considered to be one of the hallmarks of cancer (Hanahan 
and Weinberg, 2000).  Because of the important role played by the anti-apoptotic 
Bcl-2 family in preventing the initiation of apoptosis, the design of small molecule 
inhibitors of this group of proteins has been an area of intense research for several 
years.  The hydrophobic groove formed by the BH1, BH2 and BH3 domains within 
proteins that are members of the anti-apoptotic Bcl-2 family lends itself to the design 
of small molecule mimetics, because of the importance of the groove in acting as the 
interface for the interaction between the anti-apoptotic Bcl-2 family members and the 
pro-apoptotic Bcl-2 family members (Letai, 2003).  Abbot Laboratories developed a 
BH3 mimetic in 2005 (Oltersdorf et al., 2005) by linking two separate small 
molecules that bound the hydrophobic groove of Bcl-xL at two proximal sites in the 
groove.  Further iterative manipulations of the lead molecule resulted in the 
development of ABT-737, a small molecule inhibitor of Bcl-2, Bcl-w and Bcl-xL 
that has a Ki < 1nM.  Because of the affinity of ABT-737 to these anti-apoptotic 
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proteins, the compound has been described as a mimetic for the pro-apoptotic protein 
Bad (figure 1.2.5; Van Delft et al., 2007).  Of the putative BH3 mimetics tested by 
the study of Van Delft et al., only ABT-737 was capable of promoting cell death via 
Bax and Bak activity, suggesting that ABT-737 was the first BH3 mimetic 
discovered that genuinely promoted the intrinsic apoptosis pathway.  Further, it was 
shown that levels of Mcl-1 could modulate resistance to ABT-737-mediated 
apoptosis.  Because Noxa is a potent Mcl-1 inhibitor, resistance to ABT-737 could 
be reversed by either reducing Mcl-1 protein levels or increasing Noxa protein levels 
(Van Delft et al., 2007).  Intriguingly, treatment of a number of cell lines from a 
variety of different tissue backgrounds with ABT-737 or its derivatives has resulted 
in the increased de novo synthesis of Noxa protein (Hauck et al., 2009; Sale and 
Cook, 2013).  This has since been shown to be dependent on transcriptional up-
regulation of Noxa by E2F1/pRb (Bertin-Ciftci et al., 2013). 
 
1.2.8 The role of p53 in apoptosis 
As described previously, p53 functions predominantly as a transcription factor hence 
one of the major functions of p53 in apoptosis is to promote the transcription of 
genes whose protein products are involved in apoptosis.  The p53-mediated 
transcription of several genes preceding apoptosis is highly dependent on the nature 
of pro-apoptotic stimulus and the tissue type (reviewed in Vlatković et al., 2011). 
p53 can promote the transcription of a mitochondrial effector of apoptosis Bax 
(Miyashita and Reed, 1995).  p53 can also promote the transcription of BH3-only 
family members Noxa (Oda et al., 2000) and Puma (Nakano et al., 2001; Yu et al., 
2001), both of which can be important in promoting apoptosis at the mitochondria.  
p53 can repress the transcription of the anti-apoptotic protein Bcl-2, due to the 
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presence of p53 negative response elements in the promoter of the BCL-2 gene, 
though the precise mechanism of how this takes place is not fully understood 
(Miyashita et al., 1994).  p53 can also promote the up-regulation of proteins involved 
in the extrinsic apoptosis pathway.  p53 can promote the transcription of Fas/APO-1 
(Owen-Schaub et al., 1995), LRDD (also known as PIDD, Lin et al., 2000) and DR5 
(Wu et al., 1997).  A role for the direct involvement of cytosolic p53 at the 
mitochondria has been described (Chipuk et al., 2003, 2005).  It is thought that 
during apoptosis, cytosolic p53 can translocate to the mitochondria where p53 can 
directly activate Bax or interact with anti-apoptotic Bcl-2 family members to 
promote apoptosis. 
 
1.3 MDM2 and regulation of p53 
1.3.1 Introduction to MDM2 
MDM2 is one of two essential regulators of p53. MDM4, also known as MDMX, is 
the second essential regulator of p53.  The importance of MDM2 and MDM4 as 
regulators of p53 is best illustrated by knockout mouse models.  Mice that lack 
Mdm2 or Mdm4 are embryonic lethal.  Knockout of p53 concomitant with Mdm2 or 
Mdm4 knockout rescues the lethal phenotype, highlighting the deleterious effect of 
unrestrained p53 activity and the importance of both MDM2 and MDM4 in 
regulating p53 (Jones et al., 1995; Parant et al., 2001).  A comparison of the 
functional domains in both MDM2 and MDM4 is shown in figure 1.3.1.  A brief 
discussion regarding the interaction of MDM4 with MDM2 and the role of MDM4 in 
the regulation of p53 will follow shortly however the remainder of this section will 
be devoted to MDM2. 
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MDM2 is the main negative regulator of p53 (Iwakuma and Lozano, 2003).  
Interaction of MDM2 with p53 is mediated by the p53-binding domain located at the 
N-terminal of MDM2 (figure 1.3.1) (Chen et al. 1993).  MDM2 also possesses a 
nuclear import and nuclear export sequence that allows shuttling of the protein from 
the cytoplasm to the nucleus (Roth et al., 1998).  Arguably the most important 
functional domain on the MDM2 protein is the RING finger domain, which mediates 
ubiquitination of p53 and MDM2 itself. This ultimately targets p53 for degradation 
at the proteasome (Honda et al., 1997; Fang et al., 2000).  Within the RING finger 
domain of MDM2, there is a nucleolar localization sequence, which is involved in 
the localization of the p14Arf-MDM2 complex to the nucleolus (Lohrum et al., 2001; 
Weber et al., 2000), the importance of which will be discussed shortly. 
 
Because of the potentially deleterious effects of unfettered p53 activity, as illustrated 
by the embryonic lethal phenotype observed in mice lacking the Mdm2 gene, one 
mechanism that has evolved to regulate p53 levels in the cell is the transcriptional 
induction of MDM2 by p53 (Wu et al., 1993).  Transcription of the MDM2 gene can 
occur from two promoters, P1 and P2 (Perry et al., 1993).  A basal level of MDM2 
protein in the cell is dependent upon transcription from the P1 promoter of the 
MDM2 gene.  In unstressed cells, p53 is maintained at low levels by MDM2. In 
response to stress signals, the interaction between p53 and MDM2 is typically 
abrogated by post-translational modification of both proteins, one of a number of 
steps (the remainder will be discussed in section 1.3.2), which results in increased 
p53 levels.  p53 can subsequently promote the transcription of MDM2 from the P2 
promoter, elevating levels of MDM2 protein, which can lower p53 protein back to 
basal levels observed before the stress response was initiated.  Hence, p53 and  
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Figure 1.3.1 Functional domains of MDM2 and MDM4.  Comparison of the 
functional domains present in MDM2 and MDM4.  Adapted from Marine et al., 
2007. 
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MDM2 are engaged in an auto-regulatory feedback loop (Saucedo et al., 1999; 
Mendrysa and Perry, 2000; Vousden and Lu, 2002; Wu et al 1993). 
 
MDM2 can also regulate p53 by controlling the sub-cellular localization of p53.  
Mono-ubiquitination of p53 by MDM2 can promote the exposure of the carboxy-
terminus nuclear export sequence within the oliogomerization domain of p53.  This  
allows p53 to be exported from the nucleus to the cytoplasm (Stommel et al., 1999; 
O’Keefe et al., 2003).  MDM4 is a homologue of MDM2 that can associate with p53 
but lacks the ubiquitin ligase function that MDM2 possesses.  MDM4 can 
heterodimerize with MDM2 and this interaction takes place via the RING finger 
domain of each protein (Tanimura et al., 1999).  MDM4 is thought to stimulate the 
ability of MDM2 to ubiquitinate p53 (Linares et al., 2003) 
 
1.3.2 Regulation of p53 by MDM2 and other proteins 
As discussed earlier, p53 is maintained at low levels in an unstressed cell by MDM2.  
When a cell is exposed to stress, it is important that p53 levels increase rapidly to 
mount a swift response to this.  Rescue of p53 from its main negative regulator, 
MDM2, allows rapid accumulation of the protein when compared to de novo 
synthesis of p53, hence one of the main mechanisms for the up-regulation of p53 is 
the post-translational modification of both p53 and MDM2 such that the interaction 
between both proteins is abrogated until a time when a p53-mediated stress response 
is no longer required (Prives and Hall, 1994).  For example, in response to IR, p53 is 
phosphorylated on Serine 15 by ATM kinase (Banin et al., 1998; Canman et al., 
1998) whereas in response to UV radiation, p53 is phosphorylated on Serines 15 and 
37 by the ATM-related (ATR) kinase (Tibbetts et al., 1999).  MDM2 can also be 
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phophorylated by ATM kinase in response to ionising radiation (Khosravi et al., 
1999).  These post-translational modifications of both p53 and MDM2 disrupt the 
interaction between both of these proteins, resulting in the rescue of p53 from 
negative regulation by MDM2 and subsequent stabilization of p53. 
 
Alternatively, the p53-MDM2 interaction can be abrogated by interaction of MDM2 
with p14Arf.  p14Arf is an alternative reading frame product of the CDKN2A locus 
and is activated in response to oncogene activation (Quelle et al., 1995; Sherr and 
Lowe, 2003).  The interaction between p14Arf and MDM2 can sequester MDM2 at 
the nucleolus and prevent ubiquitination of p53 by MDM2 (Tao and Levine, 1999).  
 
p53 activity can also be regulated by other post-translational modifications, such as 
acetylation, NEDDylation and SUMOylation but the precise details of how all of 
these modifications affect p53 function are in need of further elucidation (Kruse and 
Gu, 2009). p53 can be acetylated by the histone acetyl transferase, p300 (Gu and 
Roeder, 1997).  Acetylation of p53 at Lysine residues clustered around the C-
terminal of the protein is a post-translational modification that can compete with 
ubiquitination of the same Lysine residues by MDM2.  This is thought to exert an 
effect on the stability of p53 and increased acetylation of p53 correlates with a p53-
mediated stress response (Sakaguchi et al., 1998; Luo et al., 2000).  Within the DBD 
of p53, acetylation at Lysine 120 has been shown to be important in the transcription 
of pro-apoptotic PUMA and BAX and abrogation of this post-translational 
modification by substituting Arginine for Lysine reduces p53-dependent apoptosis 
(Sykes et al., 2006; Tang et al., 2006) 
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1.3.3 Pharmacological restoration of p53 function in cancer 
Because of the central role of p53 in tumour suppression and the fact that p53 is 
mutated in roughly 50% of cancers, much interest has been focused on the 
development of compounds that can restore wild type conformation to mutant p53.  
An example of one such compound is PRIMA-1, which can promote restoration of 
wild type conformation to mutant p53, promoting p53-dependent transcription and 
ultimately senescence or apoptosis (Bykov et al., 2002).  Because these compounds 
have been reviewed elsewhere (Bykov et al., 2009), and the focus of this thesis is on 
RCC, where the overwhelming majority of cases harbour wild type p53, this class of 
compounds will not be discussed here.   In the remaining 50% of cancers that 
maintain wild type p53, one strategy to restore wild type p53 function is to inhibit the 
interaction between MDM2 and p53.  The crystal structure of the amino terminal of 
MDM2 bound by a peptide of the transactivation domain of p53 was resolved in 
1996 (Kussie et al., 1996).    MDM2 contains a deep hydrophobic pocket in its amino 
terminal, residues 25-109, where the transactivation domain of p53 binds MDM2.  
Eighteen years subsequent to this discovery, a small molecule compound, Nutlin-3, 
was identified that could fit into this binding pocket and inhibit the interaction 
between MDM2 and p53 (Vassilev et al., 2004).  The cis-imadazoline analogue 
Nutlin-3 has since been shown to be a potent inhibitor of the MDM2-p53 interaction 
and treatment of cells harbouring wild type p53 from a variety of tumour types with 
this compound has resulted in p53-mediated cell cycle arrest, senescence and 
apoptosis (Vassilev et al., 2004; Tovar et al., 2006; Van Maerken et al., 2006).  Since 
the discovery of Nutlin-3, a number of other compounds have been discovered that 
can displace p53 from the same p53-binding pocket of MDM2, including the MI 
series of compounds (Ding et al., 2005), AM-8553 (Rew et al., 2012) and 
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isoindolinone-based MDM2 inhibitors (Hardcastle et al., 2005).  An alternative 
strategy to liberating p53 from the inhibitory effects of MDM2 in cancer cells is the 
development of inhibitors of the E3 ligase domain of MDM2.  This family of 
compounds, such as HLI373 (Kitagaki et al., 2008) and Sempervine (Sasiela et al., 
2008) have been shown to induce p53-dependent cell cycle arrest or apoptosis in a 
variety of cell lines. 
 
An alternative approach to the restoration of p53 function in cancer has been the 
introduction of adenoviral vectors expressing wild type p53 directly into the tumours 
of cancer patients (reviewed in Tazawa et al., 2013).  This approach is currently in 
clinical trials for patients suffering from non-small cell lung cancer, head and neck 
squamous cell carcinoma and ovarian cancer, amongst other conditions.   
 
1.4 Use of drug combinations in cancer therapy 
Over the past decade, with an increased knowledge of the underlying molecular 
biology of several malignancies, a major focus of cancer research has been the 
development of therapeutic agents that can target specific signalling pathways that 
are dysregulated in cancer.  This approach has been successful in a few cancers, such 
as treatment of chronic myeloid leukaemia with imatinib, which has resulted in 
durable responses in a high number of cases (Druker et al., 2006).  The use of a 
single targeted therapy has proven less successful in RCC and several other cancers 
(see section 1.1.7).  Pathways that regulate proliferation and survival in cancer cells 
consist of multiple feedback loops and compensatory mechanisms that are highly 
adaptive to selective pressures exerted upon them (Hanahan and Weinberg, 2000).  
Indeed, in a model used to determine resistance mechanisms to the anti-angiogenesis 
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agent, Sunitinib, hypoxic cancer cells activated pathways to increase invasion of 
surrounding tissue, to permit access to normal tissue vasculature (Azzam et al., 2010; 
Ebos et al., 2009).  An approach to dealing with adaptation to therapeutic 
intervention is the use of rational drug combinations (Kummar et al., 2010).  The 
concept of combining drugs for the treatment of cancer is not new (DeVita et al., 
1975) and can offer a number of advantages over single agent therapy for example, 
increasing the effectiveness of the therapeutic effect, slowing down drug resistance 
and decreasing dosage of one of the agents to avoid toxicity (Chou, 2006).  The 
targeting of one or more pathways with a combination of agents is an attractive 
concept in cancer therapy because it may address the issue of adaptation of cancer 
cells to a single agent.  Hypothetically, if cancer cells respond to targeted inhibition 
of pathway A by up-regulating or activating pathway B, which can compensate for 
inhibition of pathway A, then inhibition of pathway A alone would be fruitless.  
However, if both pathways A and B are inhibited, and both pathways regulate a 
process that is essential to cell survival and there are no other compensatory 
mechanisms, death would be the only outcome to this hypothetical scenario.  This is 
a very simplified description of the underlying theoretical basis of how combining of 
agents can result in cell death (Yeh and Kishony, 2007; Chan and Giaccia, 2011).   
 
The interaction of two or more drugs in a biological system can broadly be 
categorized into an additive interaction between the drugs used, a synergistic 
interaction or an antagonistic interaction.  When two or more compounds act without 
interaction and the total effect does not differ from what can be expected from the 
dose-effect relations of the individual agents, this is described as an additive effect 
(Goldoni and Johansson, 2007). When there is a greater than additive effect, this is 
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termed synergy. Conversely, when one drug reduces the effectiveness of another 
drug in a combination, this is termed antagonism.  What follows is a brief discussion 
of two commonly used methods to measure drug interactions in biological systems, 
Bliss independence and Loewe additivity. 
 
1.4.1 Bliss independence 
The central assumption underlying the Bliss independence model is that the toxic 
agents applied act independently of each other (Bliss, 1939).  For two compounds, A 
and B, the expected inhibition by the combination of compounds, f(AB) is: 
 
f(AB) = f(A) + f(B) –  f(A) x f(B) 
 
Where f(A) and f(B) are the individual levels of inhibition for compounds A and B.  
If the observed level of inhibition is greater than the expected inhibition, the 
interaction is synergistic.  Conversely, if the observed level of inhibition is less than 
the expected level of inhibition, the interaction is antagonistic.  Otherwise, there is no 
interaction and the combination is additive.  The Bliss model, whilst very simple, 
suffers from a number of limitations.  In many experimental situations, two drugs 
may be acting on targets that are not completely independent of each other.  The 
Bliss model does not take into account the shape or the slope of those dose response 
curve for each drug used; in extreme examples where the dose response curve for a 
drug is particularly steep, a single compound can be shown to be synergistic with 
itself. 	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1.4.2 Loewe additivity 
The basic assumption of the Loewe additivity model is the opposite of the Bliss 
model: all toxicants in the mixture act on the same biological site by the same 
mechanisms of action and differ only in their potency (Loewe, 1953).  The 
combination index (CI) for a combination of drugs A and B at a given level of 
inhibition is calculated using the following equation: 
 
[A]comb./[A]alone + [B]comb./[B]alone  
 
where [A]comb. represents the concentration of A used in the combination treatment 
and [A]alone represents the concentration of A used alone.  CI < 1 is considered to be 
a synergistic interaction and CI  > 1 is considered to be an antagonistic interaction.  
CI = 1 suggests no net effect and is considered to be an additive interaction.  Table 
1.4 summarizes different degrees of synergism and antagonism that are observed 
upon analysis of drug interaction using the combination index (Chou, 2006).  
Combination indices can also be expressed graphically using isobolograms.  This is 
discussed further in section 3.2.1.  One limitation of the Loewe model is that the 
individual dose response curves for both drugs need to have similar shapes and 
slopes.  Further, from a practical point of view, more data points are required than 
the Bliss model for calculation of the drug interaction (Goldoni and Johansson, 
2007). 
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Table 1.4 Description and symbols of synergism or antagonism in drug 
combination studies analysed by the combination index.  Table reproduced from 
Chou, 2006. 
Range of combination 
indices 
Description Graded symbols 
<0.1 Very strong synergism + + + + + 
0.1-0.3 Strong synergism + + + + 
0.3-0.7 Synergism + + + 
0.7-0.85 Moderate synergism + + 
0.85-0.90 Slight synergism + 
0.90-1.10 Nearly additive + 
1.10-1.20 Slight antagonism - 
1.20-1.45 Moderate antagonism - - 
1.45-3.3 Antagonism - - - 
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1.5 Aims 
RCC is a notoriously difficult cancer to treat.  Current therapies for the metastatic 
disease do not prolong life beyond 20 months on average; therefore there is a need 
for novel therapeutic strategies to deal with this (Section 1.1.7).  p53, a potent 
tumour suppressor, is typically wild type in RCC and is expressed at high levels, 
with MDM2, the negative regulator of p53, in patients that have the worst prognosis 
(Section 1.1.5.3).  Rescue of wild type p53 from the inhibitory effects of MDM2 in 
RCC cells in culture using inhibitors of the p53-MDM2 interaction has resulted in 
cell cycle arrest or senescence, not apoptosis (Tsao and Corn, 2010; Polanski et al., 
submitted).  This response may be related to the nature of the behaviour of p53 in 
renal epithelial cells, the tissue from which RCC is derived (Section 1.1.5.3).  
Because of the potentially deleterious effects of senescent cells in the tumour 
microenvironment (Section 1.2.5), we intend to restore p53 function in RCC cells 
harbouring wild type p53 to commit the cell fate decision to apoptosis rather than 
senescence.  Because an important aspect of cancer cell survival is the de-regulation 
of multiple signalling pathways that control growth, survival and resistance to death 
signals, this thesis describes experiments aimed at investigating a combinatorial 
approach that targets more than one molecular entity in the cell to restore wild type 
pro-apoptotic p53 function in RCC cells. 
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Chapter 2: MATERIALS AND METHODS 
 
2.1 List of reagents 
2.1.1 General list of reagents 
REAGENT/PRODUCT      SUPPLIER 
Acrylogel 40% solution (acrylamide:bis-acrylamide, 37.5:1) VWR 
Ammonium persulfate (APS)      Sigma 
Aprotinin        Roche 
Albumin from bovine serum (BSA), 96%    Sigma 
Blotting grade blocker, non-fat dry milk    Bio-rad 
Bromophenol blue       Sigma 
CHAPS        Calbiochem 
Dimethyl Sulphoxide (DMSO)     Sigma 
Dithiothreitol (DTT)       Sigma 
ECL Prime        GE Healthcare 
ECL Select        GE Healthcare 
Ethanol, absolute       Sigma 
Ethylene diamine tetra-acetic acid disodium salt   Sigma 
Glycerol        Sigma 
Glycine        Fisher-Scientific 
HEPES free acid, molecular biology grade    Calbiochem 
HybondTM Nitrocellulose membrane     GE Healthcare 
Leupeptin        Roche 
Magnesium chloride       Sigma 
Mannitol        Sigma 
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Methanol, analytical grade      Fisher Scientific 
Pepstatin        Roche 
Phenylmethylsulphonyl fluoride (PMSF)    Sigma 
Ponceau S        Sigma 
Pre-stained protein marker, broad range, 7-175 kDa   NEB 
Protein assay dye reagent      Bio-rad 
Sodium chloride       VWR 
Sodium dodecyl suphate      Fisher Scientific 
Sodium dihydrogen phosphate dihydrate (NaH2PO4·2H20)  Sigma 
Sodium phosphate dibasic dihydrate (Na2HPO4·2H20)  Sigma 
Sucrose        Sigma 
N, N, N’, N’-tetramethylenediamine (TEMED)   BDH 
Tris base        Calbiochem 
Triton X-100        Amersham 
Biosciences 
Trypsin inhibitor from soybean (STI)    Roche 
Tween-20        Sigma 
 
All H2O used was ultra-pure >18 MΩ cm H2O produced in a MilliQ water purifier. 
 
2.1.2 Tissue culture reagents 
REAGENT/PRODUCT      SUPPLIER 
Dulbecco’s Phosphate buffered saline    Sigma 
Eagle’s Minium Essential Medium (M5650)    Sigma 
Fetal Bovine Serum       Sigma 
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McCoy’s 5a Medium (M8403)     Sigma 
Non-essential amino acids (100x)     Sigma 
RPMI-1640 Medium (R8758)     Sigma 
Sodium bicarbonate solution (7.5%)     Sigma 
Sodium pyruvate solution (100mM)     Sigma 
Trypsin-EDTA solution (1x)      Sigma 
 
2.1.3 Drugs 
ABT-737.  Stock solution prepared by dissolving to 30mM in DMSO.  Supplied by 
Selleck Chemicals.  Long-term storage was at -80°C. 
 
Nutlin-3.  Stock solution prepared by dissolving to 30mM in DMSO.  Supplied by 
Selleck Chemicals.  Long-term storage was at -80°C. 
 
Staurosporine.  Stock solution prepared by dissolving to 1mM in DMSO.  Supplied 
by LC Laboratories.  Long-term storage was at 4°C. 
 
2.1.4 Antibodies for Western Blotting 
 
2.1.4.1 Primary Antibodies for Western Blotting 
For western blotting, antibodies from stock were diluted in 5% blotting grade milk-
PBS-Tween solution.  Table 2.1.4.1 lists primary antibodies used for western blotting 
in this study. 
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Table 2.1.4.1.  Primary antibodies used for western blotting in this study. 
Antibody Supplier Catalogue 
number 
Epitope Working 
dilution 
Actin  
(C2), mouse 
monoclonal 
Santa Cruz 
Biotechnology 
sc-8432 Epitope between amino 
acid 350-375 of human 
actin 
3µg/ml 
Bak  
(G-23), rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
sc-832 Internal region of 
human Bax 
3µg/ml 
Bax  
(N-20), rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
sc-493 Antibody raised against 
peptide mapped to N-
terminus of human Bax 
3µg/ml 
Bcl-2  
(50E3), rabbit 
monoclonal 
Cell 
Signalling 
Technology 
#2870 Antibody raised against 
peptide mapped to 
carboxy terminus of 
human Bcl-2 
1:2000 
Bcl-w  
(G-21), rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
sc-130701 Antibody raised against 
peptide mapped to N-
terminus of human 
Bcl-w 
3µg/ml 
Bcl-xL 
(54H6), rabbit 
polyclonal 
 #2764 Antibody raised against 
peptide corresponding 
to residues surrounding 
Asp61 on human Bcl-
xL 
1:2000 
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Antibody Supplier Catalogue 
number 
Epitope Working 
dilution 
COX4  
(D-20), goat 
polyclonal 
Santa Cruz 
Biotechnology 
sc-69359 Antibody raised against 
peptide mapped to N-
terminus of human 
COX4 
3µg/ml 
Histone H3, 
rabbit 
polyclonal 
Abcam ab1791 Antibody raised against 
peptide corresponding 
to amino acids 100 to 
the C terminus of 
Histone H3 
1µg/ml 
Mcl-1 
(D35A5), 
rabbit 
monoclonal 
Cell 
Signalling 
Technology 
#5453 Antibody raised against 
peptide corresponding 
to residues surrounding 
Leu210 on human Mcl-
1 
1:2000 
MDM2  
(IF-2), mouse 
monoclonal 
Calbiochem OP46 Within amino acids 26-
169 of human MDM2 
3µg/ml 
PARP 
(42/PARP), 
mouse 
monoclonal 
BD 
Transduction 
Laboratories 
P76420 Within amino acids 22-
219 of human PARP 
3µg/ml 
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Antibody Supplier Catalogue 
number 
Epitope Working 
dilution 
p53  
(DO-1), 
mouse 
monoclonal 
Calbiochem OP43 Amino acids 21-25 of 
human p53 
3µg/ml 
Noxa 
(114C307), 
mouse 
monoclonal 
Calbiochem OP180 Data not available 3µg/ml 
Puma,  
rabbit 
polyclonal 
Cell 
Signalling 
Technology 
#4976 Antibody raised against 
peptide corresponding 
to carboxy-terminal 
region of human Puma 
1:2000 
Tubulin 
(DM1A), 
mouse 
monoclonal 
Sigma T6199 Amino acid 426-430 
on human tubulin 
1:2000 
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Table 2.1.4.2.  Secondary antibodies used for western blotting in this study. 
Antibody Manufacturer Catalogue number Working dilution 
Sheep anti-
mouse 
GE Healthcare RPN4201 1:2 500 
Donkey anti-
rabbit 
GE Healthcare NA934 1:5 000 
Rabbit anti-goat Jackson 
ImmunoResearch 
Laboratories 
305-036-003 1:20 000 
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2.1.4.2 Secondary antibodies used for western blot 
Secondary antibodies used in this study were conjugated to horseradish peroxidase 
for detection by chemiluminescence.  Antibodies from stock were diluted in 5% 
blotting grade milk-PBS-Tween solution.  Secondary antibodies used are 
summarised in table 2.1.4.2. 
 
2.2 Cell lines 
2.2.1 Cell lines used in this study 
A498, ACHN and Caki2 renal cell carcinoma lines were obtained from the American 
Type Culture Collection (ATCC).  Renal cell carcinoma lines 111, 117 and 154 were 
a kindly provided by Professor W M Linehan.  HL-60 cells were a gift from the 
Haematology Department, University of Liverpool. 
 
2.2.2 Cell culture medium 
All tissue culture was performed in a class II safety cabinet.  Cells were grown in 
Nunclon flasks (Nunc, Thermo Fisher Scientific) in 5 % CO2 in air at 37 °C.  Culture 
medium for each cell line is described below. 
 
A498, ACHN, U2OS, 117 (and derivatives of these cell lines): Eagle’s minimum 
essential medium supplemented with 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 
0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10% fetal bovine 
serum (FBS). 
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Table 2.2.1 Cell lines used in this study 
Cell line p53 status Site of origin Histology 
ACHN WT1 Renal cell adenocarcinoma derived 
from metastatic site (pleural effusion) 
Clear cell 
A498 WT1 Renal carcinoma, primary site Clear cell 
115 WT2 Renal carcinoma, primary site Clear cell 
Caki2 WT1 Renal carcinoma, primary site Clear cell 
117 WT2 Renal carcinoma, primary site Clear cell 
111 MT2; Codon 
173, Val to 
Gly 
Renal carcinoma, primary site Clear cell 
154 MT2; Codon 
248, Arg to 
Gln 
Renal carcinoma, primary site Clear cell 
U2OS WT3 Osteosarcoma N/A 
H1299 Null4 Non-small cell lung carcinoma, 
derived from metastatic site (lymph 
node) 
N/A 
HL-60 Null5 Acute promyelocytic leukaemia N/A 
HEK293 WT6 Human embryonic embryonic kidney N/A 
1 – See Tomita et al., 1996; 2 – See Reiter et al., 1993; 3 – See Florenes et al., 1994;  
4 – See Mitsudomi et al., 1992; 5 – See Wolf et al., 1985; 6 – See Lehman et al., 
1993.  WT – wild type.  MT – mutant.  N/A – not available. 
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111 and 154: Eagle’s minimum essential medium supplemented with 2mM L-
glutamine, 1.5g/L sodium bicarbonate, 0.1mM non-essential amino acids, 1mM 
sodium pyruvate and 15% FBS. 
 
Caki2: McCoy’s 5a medium with 1.5mM L-glutamine and 2.2g/L sodium 
bicarbonate supplemented with 1% streptomycin and penicillin and 10% FBS. 
 
H1299 and HL-60 cells: RPMI-1640 medium supplemented with 10% FBS. 
 
2.2.3 Sub-culture of cell lines 
Cell lines used in this study grow as an adherent monolayer on cell culture treated 
surfaces, with the exception of HL-60 cells, which grew in suspension.  Once cells 
reach maximum confluence in culture, cell death can occur from overcrowding and 
its ensuing stress.  Thus sub-culture, or passage, of cells was performed to maintain 
cells at optimum health.   Upon reaching of maximum confluence, passaging was 
carried out as follows:  media was aspirated and the cell monolayer was washed in 
PBS (Sigma-Aldrich), typically 5 ml per 175 cm2 of culture.  PBS was aspirated then 
3-5 ml of trypsin-EDTA (Sigma-Aldrich) was added to the monolayer and the 
culture vessel was then incubated at 37 °C.  The culture vessel was agitated as 
appropriate to aid in the detachment of cells from the substrate.  Neutralization of 
trypsin-EDTA was achieved by adding an equal amount of medium to the culture 
vessel.  Cells were then re-suspended to create a single cell suspension and the 
relevant volume of cells in culture medium was aspirated from the vessel.   Media 
was added to the vessel, typically 20-35 ml per 175 cm2 of substrate. 
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2.2.4 Preparation of cryopreserved cells 
For the cryopreservation of cells, cells were harvested by trypsinization as described 
above and centrifuged at 300 x g for 5 min.  The cell pellet was re-suspended in 
freezing media (10% DMSO in FBS) and the cell suspension was transferred to 
cryovials.  The cryovials were then transferred to a pre-cooled stryofoam rack and 
stored at -80°C to permit slow freezing of the cells.  Upon freezing, cryovials would 
be transferred to liquid nitrogen for long-term storage.  Typically, no more than 24 - 
48 h would elapse between freezing at -80°C and transfer to liquid nitrogen. 
 
To recover cells from stocks stored in liquid nitrogen, cryovials were thawed at 37°C 
and re-suspended in 0.5 ml of media at the same temperature.  This suspension was 
transferred to a tissue flask containing at least 25 ml of media that was pre-warmed 
to 37°C. 
 
2.2.5 Transfection of cells with siRNA using Lipofectamine-2000 
Cells were seeded into 6-well multi-well plates (Nunc) for transfection with siRNA 
using Lipofectamine-2000 (Invitrogen).  Cells were seeded 24h before transfection 
such that the cells were 30-50% confluent on the day of transfection.  Serum-free 
(SF) Opti-MEM media and Lipofectamine-2000 were equilibrated to room 
temperature before transfection.  siRNA was thawed before transfection.  Cells were 
transfected with siRNA to a final concentration of 32nM.  For one well of a 6-well 
plate, 80pmol of siRNA were diluted in 250 µl of SF media and 4 µl of 
Lipofectamine-2000 were diluted in an equal amount of SF media.  Both mixtures 
were incubated at room temperature for 5 min.  Following incubation, both mixtures 
were combined and left to incubate at room temperature for a further 20 min.  The 
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combined transfection mixture was added drop-wise to cells that were bathed in 2 ml 
of complete growth medium.  The plate was then rocked gently to ensure even 
distribution of siRNA-liposome complexes in the growth media.  Following 6h 
incubation in at 37°C in a tissue culture incubator, the media was aspirated and 
replaced with complete growth media. 
 
The following siRNAs were used: 
Scrambled (5’-GGA CGC AUC CUU CUU AAU-3’)  
p53  (5’-GCA UGA ACC GGA GGC CCA-3’) 
Bax  siRNA 3 (5’-ACA UGU UUU CUG ACG GCA A-3’) 
 siRNA 4 (5’-CAU UGG ACU UCC UCC GGG A-3’) 
Puma  siRNA 1 (5’-GGC GGA GAC AAG AGG AGC A-3’) 
 siRNA 4 (5’-CGG ACG ACC UCA ACG CACA-3’) 
 
2.3 Cell proliferation and viability assays 
2.3.1 MTT Assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide  (MTT) assay 
was used to measure cell viability, (Mosmann 1983).  The MTT assay is a rapid 
colorimetric assay that relies on mitochondrial function as a surrogate indicator of 
cell viability.  Mitochondrial dehyrodgenase enzymes in living cells are capable of 
cleaving the tetrazolium ring in MTT, reducing yellow MTT into a purple formazan 
precipitate, which can be dissolved with DMSO.  Hence, absorbance at 595 nm can 
be used as a surrogate indicator of how metabolically active and hence how viable 
cells treated with MTT are. 
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Table 2.3.1.1 Seeding densities of cells used in MTT assay. 
Cell line Cells per well 
117 1,000 
ACHN 5,000 
A498 2,000 
Caki2 5,000 
115 2,000 
111 5,000 
154 5,000 
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2.3.1.1 Seeding of cells for MTT assay 
Cells were trypsinized as described above and following three independent counts 
from a Coulter counter (Beckmann Coulter, California, USA) a mean was taken.  
Serial dilutions were performed on the cells in culture medium, ensuring cells were 
thoroughly mixed before each dilution, to give the desired concentration of cells/ml.  
Cells were seeded to 96-well plates (Nunc) using a multichannel pipette (Costar, 
Corning Incorporated).  Cells in culture medium were agitated regularly to ensure 
even uptake of cells into the pipettor.   Seeding densities for each cell line are shown 
in table 2.3.1.1.   Media was replenished every 48 hours. 
 
2.3.1.2 Treatment with MTT and absorbance reading 
The MTT assay was performed by adding 20 µl of 5 mg/mL MTT (Molekula, UK) 
to each well.  The 96-well plate was subsequently incubated at 37 °C for 3.5 h.  
Following incubation, all of the liquid was aspirated from each well and 100 µl of 
DMSO added to dissolve the purple formazan precipitate.  After further incubation at 
37 °C for 30 min, optical absorbance at 590 nm was measured using a Multiskan EX 
plate reader (Thermo Fisher Scientific, Massachusetts, USA). 
 
2.3.2 Detection of apoptotic cells by flow cytometry using Annexin V and Propidium 
iodide 
Phosphatidylserine (PS) is the only known phospholipid to be completely 
sequestered away from the outer monolayer of a cell membrane in mammalian cells 
(reviewed in Schlegel and Williamson, 2001).  During apoptosis, membrane 
asymmetry is lost and subsequently PS is exposed.  Annexin V (AV) is a protein that 
can bind to PS in a calcium-dependent manner (Andree et al., 1990).  Conjugating 
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fluorescent dyes to AV, such as fluoroscein isothiocyanate (FITC) allows the 
detection of apopototic cells (Koopman et al., 1994) by detecting fluorescence 
emission after stimulation with lasers.  Healthy, living cells that have an intact 
plasma membrane can exclude the fluorescent DNA intercalating agent, propidium 
iodide (PI).  Dead cells, or cells with a perturbed plasma membrane, permit the 
influx of PI into the cell (reviewed in Steensma et al., 2003).  Hence, by staining 
cells with both FITC-conjugated AV and PI and measuring the emission of 
fluorescence from the fluorophores using a flow cytometer, it is possible to identify 
four distinct populations of cells: living cells, cells in the early stages of apoptosis, 
dead cells that have undergone apoptosis and necrotic cells (figure 2.3.2.1).  These 
populations can be distinguished, or gated, based on the fluorescence emitted. 
 
2.3.2.1 Reagents used for detection of apoptotic cells by flow cytometry using 
Annexin V and propidium iodide 
FITC-conjugated Annexin V solution (Cambridge Biosciences) 
PI solution – 100µg/ml propidium iodide (Sigma) in 10 mM potassium phosphate 
(pH 7.4), 150mM NaCl. 
10 X Annexin binding buffer: 0.1 M HEPES/NaOH (pH 7.4), 1.4 M NaCl, 25 mM 
CaCl2.  
 
2.3.2.2 Harvesting of cells and detection of apoptotic cells by AV/PI staining and 
flow cytometry 
After treatment with drug or drug vehicle, cells were treated with trypsin as 
described in section 2.2.3 and centrifuged at 150 x g for 5 min in a pre-cooled 
centrifuge to harvest cells.  Cells floating in the media and cells present in the PBS  
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Figure 2.3.2.1 Schematic summarizing populations of cells after Annexin 
V/propidium iodide staining.  Diagram summarizing positions of cell populations 
on a dot plot after treatment with FITC-conjugated Annexin V (A/V-FITC) and 
propidium iodide (PI) and analysis by flow cytometry. 
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washing step were included harvested with the adherent cells.  Samples were kept on 
ice throughout the protocol.  The cell pellet was gently re-suspended in 2 ml FBS to 
disaggregate the cell pellet without damaging cells.  This suspension was then 
centrifuged at 150 x g for 5 min and the pellet re-suspended in 5 ml of ice cold PBS.  
Cells were counted using a Coulter Counter and density was adjusted to 1 million 
cells per sample.  This suspension was centrifuged at 150 x g and washed in PBS as 
described above.  Following a final centrifugation at 150 x g, the cell pellet was re-
suspended in 1 x annexin binding buffer.  5 µl of FITC-conjugated AV was added to 
385 µl of cell suspension and this was incubated in the dark on ice for 10 min.  The 
sample was then treated with 10 µl PI solution before being passed into the flow 
cytometer for analysis.  A BD FACSCalibur flow cytometer was used to detect 
fluorescence from AV and PI.  The data was analysed on CellQuest Pro Software. 
 
2.4 Western Blotting 
2.4.1 Reagents for western blotting 
CHAPS-modified SLIP Buffer (100 ml) 
50mM HEPES pH 7.5 
10% glycerol 
1% CHAPS 
150mM NaCl 
0.5mg/ml BSA 
Solution made up to 100ml with H2O. 
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PBS/Tween (4 litres) 
44.8g Na2HPO4.2H2O 
9.67g NaH2PO4.2H2O 
17.52g NaCl 
4ml of Tween-20 
Solution made up to 4 litres with H2O. 
 
Tris-Glycine Electrophoresis Running Buffer 
25mM Tris 
250mM glycine 
0.1% (w/v) SDS 
 
Tris-Glycine Transfer Buffer 
25 mM Tris 
192 mM glycine 
20% (v/v) methanol 
 
4 X Sample buffer (10ml) 
0.25 M Tris (pH 6.8) 
8% (w/v) SDS 
40% (v/v) glycerol 
4mg/ml bromophenol blue 
600 mM DTT 
Made up to 10 ml with H2O.  Diluted with H2O to make 2X and 1X samples. Stored 
at -20°C. 
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2.4.2 Sample preparation for western blotting 
Western blotting (protein immunoblotting) is a technique used to separate proteins of 
different mass by gel electrophoresis.  Proteins for analysis were extracted from cells 
typically harvested from 10 cm tissue culture dishes by trypsinization and subsequent 
centrifugation at 300 x g.  Supernatant was aspirated from the centrifuge tube and the 
pellet was typically frozen at -80°C.  Cell pellets were lysed by re-suspension in 
CHAPS-modified SLIP buffer supplemented with the following protease inhibitors: 
aprotinin (2 µg/ml), leupeptin (0.5 µg/ml), pepstatin A (1 µg/ml), trypsin inhibitor 
from soybean (100 µg/ml) and PMSF (1mM in ethanol).  Upon incubation on ice for 
10 minutes, lysates were centrifuged for 16,100 x g at 4°C and the supernatant from 
this centrifugation was transferred to a clean 1.5 ml Eppendorf tube.  Concentration 
of protein in a sample was determined by comparison to protein standards in a 
Bradford assay (Bradford 1976).  Typically, 20µg of the protein was mixed with 2X 
or 1X sample buffer to obtain a final concentration of 1X sample buffer and 20 µg of 
protein in the sample. 
 
2.4.3 Gel electrophoresis and protein detection for western blotting 
A SDS polyacrylamide gel was used to separate proteins by gel electrophoresis.  The 
separating gel was prepared as described in table 2.4.3.1.  The percentage of 
acrylamide used corresponded to the size of the protein to be resolved.  A higher 
percentage acrylamide gel permitted the resolution of low molecular weight proteins; 
conversely, a lower percentage polyacrylamide gel permitted the resolution of higher 
molecular weight proteins.  Protein was transferred from the gel to a nitrocellulose 
membrane (Amersham).  The membrane was blocked in PBS/Tween-20 (0.1% w/v) 
containing 5% w/v non-fat milk for 30 minutes.  The membranes were subsequently  
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Table 2.4.3.1 Composition of SDS PAGE gels. 
Separating gel Reagent 
10% 15% 
Stacking gel 
Water 4.8ml 3.55ml 7.225ml 
40% acrylamide 
mix 
2.5ml 3.75ml 1.275ml 
1.5M Tris (pH 
8.8) 
2.5ml 2.5ml _____ 
1.0M Tris (pH 
8.8) 
_____ _____ 1.25ml 
10% SDS 100µl 100µl 100µl 
10% APS 100µl 100µl 100µl 
TEMED 8µl 8µl 10µl 
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incubated with primary antibody for 1 hour at room temperature, washed six times 
for 5 min in PBS/Tween-20 before incubation with secondary antibody for 1 hour at 
room temperature.  After washing in PBS/Tween-20 as described previously, either  
ECL Select or ECL Prime reagents were applied for 5 min., depending on the 
sensitivity required.  Signal was detected by chemiluminescence and recorded on a  
Kodak IM4000 image station using Kodak Molecular Imaging software. 
 
2.5 Crude preparation of mitochondria from tissue culture cells 
2.5.1 Reagents for crude preparation of mitochondria 
RSB buffer 
10mM NaCl 
1.5mM MgCl2 
10mM Tris-HCl, pH 7.5 
Supplemented with the following protease inhibitors: aprotinin (2 µg/ml), leupeptin 
(0.5 µg/ml), pepstatin A (1 µg/ml), trypsin inhibitor from soybean (100 µg/ml) and 
PMSF. 
 
2 x MS buffer 
420mM mannitol 
140mM sucrose 
10mM Tris-HCl, pH 7.5 
2mM EDTA, pH 7.5 
Supplemented with the same protease inhibitors as RSB buffer. 
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2.5.2 Protocol for crude preparation of mitochondria 
Cells were harvested as described in section 2.4.2.  The supernatant was aspirated 
and the cell pellet was re-suspended in 10 ml ice cold PBS and centrifuged again at 
300 x g for 5 min.  All centrifugation was carried out at 4 °C.  This was repeated a 
further two times and the supernatant was aspirated.  The pellet was re-suspended in 
ice cold RSB buffer, and swelling of cells was monitored using a phase contrast 
microscope.  The volume of RSB buffer added was typically 5 x the packed cell 
volume.   After 10-15 min, the cell suspension was transferred to an ice-cold Potter-
Elvejhem homogenizer and cells were homogenized until ~90% of cells were broken 
which was typically after 30-70 strokes.  Disruption of cell membranes was visually 
monitored every 10-20 strokes using a phase contrast microscope.  A volume of 2 x 
MS buffer equal to the homogenate was added to the broken cells in the Potter 
homogenizer and this suspension was transferred to a centrifuge tube.  The 
homogenate was spun at 1,300 x g for 5 min to remove unbroken cells, large 
membrane fragments and nuclei.  The supernatant from this centrifugation was 
transferred to a clean centrifuge tube and the 1,300 x g centrifugation was repeated.  
Transferring the supernatant into a clean centrifuge tube followed by a centrifugation 
at 1 300 x g was repeated until no pellet was observed at the bottom of the centrifuge 
tube.  The supernatant was then transferred into clean centrifuge tubes and 
centrifuged at 17 000 x g for 15 minutes to pellet mitochondria and other organelles.  
The pellet was re-suspended in 500µl MS buffer and centrifuged at 17 000 x g for 15 
min.  The supernatant was discarded and the pellet was again re-suspended in MS 
buffer and centrifuged at 17 000 x g for 15 min.  This pellet was lysed using 
CHAPS-modified SLIP buffer and was analysed for protein as described in the 
section 2.4.2. 
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2.6 Isolation of mitochondria by sucrose density centrifugation 
2.6.1 Reagents for isolation of mitochondria by sucrose density gradient 
centrifugation 
 
Sucrose solutions 
1.0M sucrose    1.5M sucrose  
10mM Tris-HCl, pH 7.5  10mM Tris-HCl, pH 7.5 
1mM EDTA, pH 7.5   1mM EDTA, pH 7.5 
Both solutions supplemented with the following protease inhibitors: aprotinin (2 
µg/ml), leupeptin (0.5 µg/ml), pepstatin A (1 µg/ml), trypsin inhibitor from soybean 
(100 µg/ml) and PMSF. 	  
2.6.2 Protocol for isolation of mitochondria by sucrose density centrifugation 
Harvesting and homogenization of cells was exactly as described in section 2.5.2.  
The homogenate was centrifuged at 1,300 x g for 5 min at 4°C until no visible pellet 
formed.  A two-step discontinuous sucrose gradient was formed by layering 1.5 ml 
1.0M sucrose solution over 1.5ml 1.5M sucrose solution in a 5 ml thin wall 
polyallomer centrifuge tube (Beckman, code 326819).  The homogenate was 
carefully pipetted on top of the gradient.  To prevent collapse of the centrifuge tube 
from centrifugal forces during the ultracentrifugation, tubes were filled to within 3 
mm of the top of the tube.  If the amount of sample was insufficient to fill a tube to 
this level, the remaining volume was made up with 1 x MS buffer.  Tubes that were 
centrifuged opposite each other were balanced to within 0.1 g and centrifuged in a 
MLS-50 rotor at 85,000 x g for 60 min at 4 °C in a Beckman Coulter Optima MAX 
preparative ultracentrifuge.  The slowest acceleration setting was used (setting 9) and 
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the centrifuge was set to stop by coasting from 85,000 x g without braking.  
Following centrifugation, the mitochondria were removed from the interphase of the 
sucrose gradient by lateral suction with a syringe.  This suspension was carefully 
pippetted into a 12 ml polypropylene copolymer centrifuge tube (Beckman, code 
3110-0120).  This mitochondrial suspension was made up to 10 ml 1 x MS buffer.  
To avoid osmotic shock of the mitochondria, 1 x MS buffer was added dropwise to 
the mitochondrial suspension and mixed gently using the lowest setting on a Vortex 
Genie 2 (Scientific Industries Inc.).  Mitochondria in 1 x MS were then centrifuged at 
17 000 x g for 20 min at 4 °C in a SS-43 rotor in a Sorvall RC 5C Plus centrifuge.  
Supernatant was discarded and the pellet was re-suspended in 1 ml of 1 x MS buffer 
before centrifuging at 17 000 x g for 20 min at 4 °C in a bench top centrifuge to wash 
mitochondria.  The pellet was washed a second time and mitochondria were re-
suspended in 1 x MS buffer for subsequent preparation of samples for western 
blotting. 
 
2.7 Live cell imaging 
Live cell imaging is a technique that can be used to visually observe the behaviour of 
cells over a period of time.  A Nikon TE300 microscope was used.  During an 
experiment, a 6-well plate (Corning) was maintained in a humidified atmosphere 
permeated with CO2 and maintained at a temperature of 37°C.  A thermocouple was 
inserted into water placed at the centre of the 6-well plate to monitor the temperature 
inside the microscope chamber.  Each well represented a different treatment 
condition, for example drug and drug vehicle.  Two positions were selected per well 
and positions in each well were imaged with a time lapse of 5 minutes for roughly 24 
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hours.  ImageJ software (National Institute of Health, USA) was used to convert 
collected images into movies. 
 
2.8 Immunoprecipitation 
Immunoprecipitation (IP) is the small-scale affinity purification of antigen using a 
specific antibody.  IP is a commonly used method for detection of protein-protein 
interactions or changes in protein conformation using conformation-specific 
antibodies.  IP was used in this study to detect exposure of the Bax N-terminus using 
the conformation-specific Bax 6A7 antibody.	  	  
2.8.1 Reagents for immunoprecipitation 
Bax N-terminal capture (BNTC) buffer 
142.5mM KCl 
2.0mM CaCl2  
20.0mM Tris-HCl pH 7.4 
Buffer supplemented with the following protease inhibitors: aprotinin (2µg/ml), 
leupeptin (0.5µg/ml), pepstatin A (1µg/ml), trypsin inhibitor from soybean 
(100µg/ml) and PMSF.  Buffer was made up to 1.0% CHAPS or 0.1% Triton X-100 
depending on requirements. 
 
2.8.2 Procedure for immunoprecipitation 
Cells were harvested as described in section 2.4.  The cell pellet was lysed with 
BNTC buffer and protein was extracted and quantified as described in section 2.4.2.  
Typically, 500µg of protein were used for IP and this was made up to 500µl using 
BNTC buffer.  All samples were kept on ice during the procedure.  100µl of Protein 
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G Sepharose beads (Sigma) were washed three times by centrifugation at 16,000 x g 
at 4°C for 1 min and washing with BNTC buffer.  After the final wash, the beads 
were re-suspended in BNTC buffer to obtain a 50% slurry.  50µl of the Protein G 
beads were added to each 500µl sample of protein and incubated at 4°C for 1 h on a 
nutator to remove protein that bound non-specifically to the beads.  Following 
incubation, samples were centrifuged at 16,000 x g at 4°C for 30 sec and the 
supernatant was transferred to a fresh tube.  2µg of Bax 6A7 antibody, or the relevant 
isotype control (table 2.8.1), was added to the sample and the sample was incubated 
overnight on a nutator at 4 °C.  50 µl of Protein G Sepharose beads slurry was added 
to each sample after the overnight incubation step and samples were further 
incubated for 2 h at 4 °C to capture antibody-antigen complexes on the beads.  Beads 
were then collected by centrifugation at 16,000 x g for 30 sec.  The supernatant was 
discarded and the beads were washed three times using 500 µl of BNTC buffer.  All 
of the remaining BNTC buffer was aspirated after the last wash and the beads were 
typically re-suspended in 100µl 1X sample buffer.  For analysis by SDS-PAGE, 
samples were boiled at 100°C for 10 min and 20µl before loading into a SDS-PAGE 
gel. 
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Table 2.8.1 Antibodies used in immunoprecipitation 
Antibody Manufacturer Catalogue number 
Bax 6A7, mouse 
monoclonal 
Trevigen AMSBIO 2281-MC-100 
CD20, mouse monoclonal Becton Dickinson 347201 
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Chapter 3: A study of the effects of the combination of Nutlin-3 and ABT-737 
on the proliferation and survival of renal cell carcinoma cell lines 
 
3.1 Introduction 
As discussed in Section 1.1.1, the incidence of RCC is increasing and novel 
treatments are required for the treatment of this disease.  The tumour suppressor p53 
is rarely mutated in renal cell carcinoma (RCC) (reviewed in Noon et al., 2010) and 
co-up-regulation of both p53 and MDM2 is associated with poor survival in RCC 
(Noon et al., 2011). RCC cells in culture that harbour wild type p53 exhibit intact 
p53 function: upon treatment with UV radiation, p53 is up-regulated and this results 
in the induction of cell cycle inhibitor p21. Furthermore, p53 is regulated by MDM2 
in these cells (Warburton et al., 2005). Taken together, wild type p53 function in 
RCC may represent a therapeutic target for pharmacological restoration. 
 
Attempts to restore wild type p53 function in RCC cells using Nutlin-3, an inhibitor 
of the p53-MDM2 interaction (Tsao and Corn, 2010; Polanski et al., submitted), have 
resulted only in cell cycle arrest and senescence, not apoptosis. A possible 
explanation for this phenotype is that the apoptotic pathway is defective downstream 
of p53 activation in cells of the renal epithelium, from which RCC cells derive 
(Vlatković et al., 2011). A marginal increase in the transcription of the pro-apoptotic 
genes Bax, Puma and Noxa has been observed upon treatment of a number of RCC 
cell lines with Nutlin-3, but this was insufficient to commit the cells to apoptosis 
(Tsao and Corn, 2010). Based on the observation that Nutlin-3 treatment alone is 
inadequate in inducing apoptosis in RCC cells harbouring wild type p53, we 
considered the possibility of combining Nutlin-3 with a pro-apoptotic drug. ABT- 
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737 is a small molecule mimetic of the pro-apoptotic BH3-only family of proteins 
that can inhibit the anti-apoptotic Bcl-2 family members Bcl-2, Bcl-xL and Bcl-w 
(Oltersdorf et al., 2005). 
 
3.2 Results 
3.2.1 The Combination of Nutlin-3 and ABT-737 synergistically inhibits 
proliferation of renal cell carcinoma cells harbouring wild type p53 
A panel of RCC cells harbouring either wild type or mutant p53, and non-
tumorigenic HEK293 cells were treated with either Nutlin-3 alone, ABT-737 alone 
or a combination of both agents. After 72h treatment, a MTT assay was performed 
(as described in Section 2.3). Absorbance at 595nm relative to vehicle-treated cells 
was used as a surrogate measurement to indicate inhibition of cell proliferation for 
each treatment. 
 
Figure 3.2.1.1 shows a western blot that shows the levels of p53 and MDM2 in the 
cell lines used in this study.  Figure 3.2.1.2 shows the survival curves for the treated 
cell lines and Table 3.2.1.1 summarizes the p53 and MDM2 status of each cell line 
together with the IC50 and IC70 data. Overall, RCC cells harbouring wild type p53 
appear to be more sensitive to the inhibitory effects of Nutlin-3 at both 50% and 70% 
levels of inhibition when compared to the mutant p53 cells (as expected from 
previous work in our laboratory, Polanski et al, submitted).  However, it would have 
been expected that difference in sensitivity to Nutlin-3 alone would have been 
greater overall between the wild type p53 RCC cells and the mutant p53 RCC cells.  
This may be attributed to off-target effects of Nutlin-3: there may be other proteins 
that can be inhibited by Nutlin-3 other than MDM2.  Or alternatively, Nutlin-3 may  
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Figure 3.2.1.1 p53 and MDM2 protein level in the cell lines used in this study.  
Cells from sub-confluent cultures of the indicated cell lines were harvested and lysed 
and the concentration of protein was quantified as described in Section 2.4.  Relative 
protein level was analysed by western blot as described in Section 2.4.  10µg of 
protein was analysed in each lane and antibodies used for detection are described in 
table 2.1.   
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Table 3.2.1.1 Summary of IC50 and IC70 values of cells treated with Nutlin-3 or 
ABT-737 
Nutlin-3 (µM) ABT-737 (µM) Cell 
line 
p53 
status 
Relative levels of 
p53/MDM2 protein IC50 IC70 IC50 IC70 
ACHN 
 
WT1 
 
High p53, high 
MDM2 
6 
 
15 
 
10 
 
18 
 
  
A498 
 
WT1 
 
Moderate p53, high 
MDM2 
3.3 
 
20 
 
14 
 
23 
 
  
115 
 
WT2 
 
High p53, moderate 
MDM2 
7 
 
28 
 
17 
 
28 
 
  
Caki2 
 
WT1 
 
Moderate p53, high 
MDM2 
10 
 
30 
 
1.3 
 
2.2 
 
 
117 WT2 Low p53, low MDM2 2.5 7 10 22 
  
111 
 
MT2 
 
Very high p53, high 
MDM2 
18 
 
28 
 
18 
 
23 
 
  
154 
 
MT2 
 
Very high p53, 
moderate MDM2 
12 
 
23 
 
20 
 
28 
 
1 – See Tomita et al., 1996; 2 – See Reiter et al., 1993.  IC50 – concentration at which 
50% inhibition of proliferation occurs.  WT – wild type; MT – mutant. 
 
 
 
 
 
 
77	  	  
 
Figure 3.2.1.2 Survival curves of cells treated with Nutlin-3 and/or ABT-737.  
Cells were seeded as described in section 2.3.1.1 and treated with the indicated drugs 
for 72h.  Cells were then treated with MTT as described in section 2.3.1.2. After 
treatment with MTT, absorbance at an optical density of 595nm was measured. As a 
measure of proliferation, absorbance of drug-treated cells at 595nm was divided by 
absorbance of vehicle treated cells to give proliferation relative to drug-vehicle 
treated cells. WT – wild type.  MT – mutant.  Figures representative of at least 2 
repeats. 
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inhibit the interaction of MDM2 with other proteins that may be involved in survival 
and/or proliferation (Nicholson et al., 2012).  With respect to ABT-737, cell 
lines harbouring both wild type and MT p53 displayed similar sensitivity, the 
exception being the Caki2 cell line, which was 10-fold more sensitive to the 
inhibitory effects of ABT-737.  To illustrate, the IC50 for ABT-737 of Caki2 cells 
was 1.3 µM whereas ACHN and 117 cell lines, the two most sensitive cell lines after 
Caki2 cells both had IC50 values of 10 µM (table 3.2.1.1). 
 
The Loewe additivity model (discussed in section 1.4.2) was selected to analyse drug 
interactions shown in figure 3.2.1.2.  p53 and its transcriptional targets, such as 
Noxa, Puma and Bax interact closely with members of the anti-apoptotic Bcl-2 
family proteins (see section 1.2.8).  Considering that Nutlin-3 promotes the rescue of 
p53 from degradation by MDM2 and potentially the induction of pro-apoptotic 
proteins that interact with the anti-apoptotic Bcl-2 family of proteins, and ABT-737 
is an inhibitor of anti-apoptotic Bcl-2 family proteins Bcl-2, Bcl-xL and Bcl-w, the 
possibility that each compound acted independently of the other could not be 
excluded.  This consideration meant that the Bliss model could not be used to 
analyse drug interactions in these experiments, hence the Loewe model was selected.  
Synergy, additivity and antagonism can be analysed graphically using isobolograms 
(figure 3.2.1.3), which are a graphical representation of the combination index, 
discussed in section 1.4.2. The concentration of each drug is plotted on one of the 
axes and for a specified level of inhibition, a line connecting the vertical and 
horizontal axis, the isobole, is drawn. Drug combination points for the same level of 
inhibition are plotted on the isobologram. Drug combination points that fall on the 
isobole suggest an additive effect. Drug combination points that fall below the 
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isobole suggest a synergistic effect. Drug combination points that fall above the 
isobole suggest an antagonistic effect. The further a drug combination point deviates 
from the isobole, the greater the synergy or antagonism. At 50% inhibition, the 
synergy between Nutlin-3 and ABT-737 can be observed in all of the RCC cells 
harbouring wild type p53 with the exception of the 117 and A498 cell lines (figure 
3.2.1.3, red isoboles).  The for synergy is lower in the mutant p53 RCC cell lines at 
50% inhibition as indicated by the decreased deviation of the combination points 
below the red isobole. At 70% inhibition (figure 3.2.1.3, black isoboles), the synergy 
is much greater in all of the RCC cell lines harbouring wild type p53 when compared 
to the cell lines harbouring mutant p53. This suggests that the synergy between 
Nutlin-3 and ABT-737 may be dependent upon the presence of wild type p53.  
Considering that Nutlin-3 has been shown to be effective in cells that harbour wild 
type p53 but not mutant p53 (Vassilev et al., 2004), this was to be expected. 
 
Combination indices were calculated as described in section 1.4.2.  Table 3.2.1.2 
summarises the combination indices obtained at both IC50 and IC70 from the data 
shown in figure 3.2.1.2 and the corresponding graded symbols denoting the degree of 
synergy (as described in table 1.4) have been included.  Corresponding with the 
isobolgram data above, the synergy between Nutlin-3 and ABT-737 observed at IC50 
is greater in all of the cell lines harbouring wild type p53 with the exception of both 
the 117 and A498 cell lines.  The CI values range from 0.49-1.14 (slight antagonism 
to synergism, as described on table 1.4) in the RCC cells harbouring wild type p53 at  
IC50.  At IC70, treatment of all of the RCC cells harbouring wild type p53 with the 
combination of Nutlin-3 and ABT-737, with the exception of 117 cells resulted in 
combination indices that ranged from 0.20 (strong synergism) to 0.69 (synergism).   
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Figure 3.2.1.3 Analysis of Nutlin-3 and ABT-737 drug interaction in RCC cells.  
Isobolograms produced from data shown in figure 3.2.1.2.  IC50 and IC70 values were 
plotted onto the vertical and horizontal axes for ABT-737 and Nutlin-3 respectively 
to give isoboles.  Drug combination points were then expressed on the isobolograms 
to assess the synergy between both drugs. 
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Table 3.2.1.2 Combination indices at IC50 and IC70 for RCC cells treated with 
Nutiln-3 and ABT-737. 
* - IC50 and IC70 were the levels of inhibition of proliferation selected to perform 
analysis of drug interaction by combination index. 
# - Combination index calculated using the following equation D1comb./D1alone + 
D2comb./D2alone. 
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The weaker synergism associated with the combination treatment of 117 cells (0.71-
0.76; moderate synergism) when compared to the remaining RCC cells harbouring 
wild type p53 may be attributed to the relatively lower levels of wild type p53 in 117 
cells when compared to the other wild type RCC cells (figure 3.2.1.1).  At IC70 there 
is less evidence of synergy in the mutant p53 cell lines, 111 and 154 with CI values 
in the range 0.76 to 1.04 (moderate synergism to nearly additive). Analysis of cell 
proliferation data using both isobolograms and the corresponding combination index 
suggest that both Nutlin-3 and ABT-737 synergise to inhibit proliferation in RCC 
cells harbouring wild type p53 but not in cells harbouring mutant p53. 
 
Consistent with previous studies, we have shown that the proliferation of RCC cells 
that harbour wild type p53 is inhibited by treatment with Nutlin-3 and to some 
degree, mutant p53 cells also respond to Nutlin-3.  Further, we have shown that 
combining the pro-apoptotic drug ABT-737 with Nutlin-3 results in a synergistic 
inhibition of proliferation which is more pronounced in the RCC cell lines that 
harbour wild type p53 over the cell lines that harbour mutant p53.  To summarize, 
although inhibition of proliferation of RCC cells by Nutlin-3 appears to be p53-
dependent, synergy between Nutlin-3 and ABT-737 appears to depend upon p53.  In 
the following section, we discuss the role of p53 in the synergistic inhibition of 
proliferation in these cells. 
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3.2.2 Synergy between Nutlin-3 and ABT-737 is p53-dependent 
Results presented in the previous section showed that Nutlin-3 and ABT-737 
synergise to inhibit the proliferation of RCC cells and the degree of synergy 
observed was greater in the cell lines harbouring wild type p53 when compared to 
those harbouring mutant p53.  Since Nutlin-3 acts to inhibit the interaction between 
MDM2 and p53 and treatment of tumour cell lines that harbour wild type p53 with 
this compound results in the liberation of p53 subsequent activation of p53, this 
result was expected.  If it could be shown that this synergy was indeed p53-
dependent, then we would have succeeded in pharmacologically rescuing p53 
function to inhibit proliferation.  To determine whether reducing p53 expression 
altered the previously observed synergy between Nutlin-3 and ABT-737 in ACHN 
cells (section 3.2.1), we used ACHN cells stably expressing shRNA to p53 and cells 
of the same cell line expressing the scrambled control shRNA that were generated by 
a former lab member (Dr Radoslaw Polanski; Polanski et al., submitted).  Figure 
3.2.2.1 shows the western blot of lysates from the parental ACHN cell line, the 
ACHN cell line harbouring scrambled shRNA (here after referred to as sc-ACHN 
cells) and the ACHN cell line harbouring p53-specific shRNA (hereafter referred to 
as sh-p53-ACHN cells).  As expected, the level of p53 protein is reduced in the clone 
harbouring the shp53ACHN cells relative to scACHN cells.  The reduced level of 
MDM2 protein in the sh-p53ACHN cells is also expected because MDM2 is a 
transcriptional target for p53 (Wu et al., 1993).   
 
Cells were treated with Nutlin-3 or ABT-737 either singly or in combination as 
described in Section 3.2 and a MTT assay as performed 72h post-treatment to  
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Figure 3.2.2.1 Analysis of expression levels of p53 and MDM2 in ACHN cells 
expressing shRNAs.  Subconfluent cultures of ACHN cells and ACHN cells 
modified to express scrambled shRNA or p53-specific shRNAwere harvested and 
lysed and the concentration of protein was quantified as described in Section 2.4.  
Relative protein level was analysed by western blot as described in Section 2.4.  
20µg of protein was analysed in each lane and antibodies used for detection are 
described in table 2.1.   
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Figure 3.2.2.2 Survival curves of ACHN scrambled shRNA and ACHN p53 
shRNA-expressing cells treated with Nutlin-3 and/or ABT-737.  Cells were 
seeded as described in section 2.3.1.1 and treated with the indicated drugs for 72h.  
Cells were then treated with MTT as described in section 2.3.1.2. After treatment 
with MTT, absorbance at an optical density of 595nm was measured. As a measure 
of proliferation, absorbance of drug-treated cells at 595nm was divided by 
absorbance of vehicle treated cells to give proliferation relative to drug-vehicle 
treated cells.  Representative data from at least 2 repeats. 
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Figure 3.2.2.3 Analysis of Nutlin-3 and ABT-737 drug interaction in ACHN 
scrambled shRNA and ACHN p53 shRNA-expressing cells treated with Nutlin-3 
and ABT-737.  Isobolograms produced from data shown in figure 3.2.2.2.  IC50 and 
IC70 values were plotted onto the vertical and horizontal axes for ABT-737 and 
Nutlin-3 respectively to give isoboles.  Drug combination points were then expressed 
on the isobolograms to assess the for synergy between both drugs. 
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analyse the interaction between Nutlin-3 and ABT-737 in these cell lines.  Survival 
curves for both cell lines summarizing the responses to solo and combination 
treatments are shown in figure 3.2.2.2.  Isobolograms derived from figure 3.2.2.2 are 
shown in figure 3.2.2.3 and the combination indices for the combination treatments 
are summarized on table 3.2.2.2.  A simple analysis of figure 3.2.2.2 shows that the 
curves representing Nutlin-3 plus 3 µM ABT-737 and Nutlin-3 plus 10 µM ABT-737 
are shifted further to the left when compared to Nutlin-3 alone on the graph for the 
scACHN cells line but not for the sh-p53ACHN cells.  Synergy is observed in 
response to the combination treatment at both IC50 and IC70 in the scACHN cell line, 
which can be observed on the isobologram in figure 3.2.2.3 showing combination 
points fall below the isoboles.  The combination of 1 µM ABT-737 and Nutlin-3, 3 
µM ABT-737 with Nutlin-3 and 10 µM ABT-737 have combination indices of 0.87, 
0.64 and 0.73 respectively at IC50 (Table 3.2.2.2).  At IC70, the combination indices 
for these treatments are 0.56, 0.26 and 0.41.  At IC50 there is no evidence of synergy 
in the sh-p53ACHN cells, indeed the combination indices for the combinations tested 
in this cell line are >1.  This was expected as these cells harbour less p53 protein than 
their scrambled control counterparts (figure 3.2.2.1) and they were previously shown 
to be less sensitive to treatment with Nutlin-3 (Polanski et al., submitted).  An IC70 
value for Nutlin-3 alone in this cell line was not achieved, most likely due to the 
relatively low level of p53 in these cells; meaning combination indices could not be 
calculated at this level of inhibition.  This lack of synergy in response to the 
combination treatment in the sh-p53ACHN cells was due to the insensitivity of these 
cells to Nutlin-3 (table 3.2.2.1).  If sensitivity to Nutlin-3 alone was determined by 
the presence of wild type p53 (Vassilev et al., 2004) then it would follow that  
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Table 3.2.2.1 Summary of IC50 and IC70 values of ACHN scrambled shRNA and 
ACHN p53 shRNA-expressing cells treated with Nutlin-3 or ABT-737. 
 
Nutlin-3 (µM) ABT-737 (µM) Cell line 
IC50 IC70 IC50 IC70 
ACHN scrambled shRNA 2.8 17 20.5 30 
ACHN p53 shRNA 3 N/A 22 30 
 
N/A – not available. 
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Table 3.2.2.2 Combination indices at IC50 and IC70 for ACHN scrambled 
shRNA and ACHN p53 shRNA-expressing cells treated with Nutiln-3 and ABT-
737. 
IC50* IC70* Cell line 
ABT-
737 
(µM) 
Nutlin-
3 (µM) 
Combination 
index# 
ABT-
737 
(µM) 
Nutlin-
3 (µM) 
Combination 
index# 
1 2.30 0.87 + 1 9.00 0.56 + + + 
3 1.40 0.64 + + + 3 2.80 0.26 + + + + 
ACHN 
scrambled 
shRNA 10 0.67 0.73 + + 10 1.20 0.41 + + + 
  
1 3.00 1.12 - 
3 3.00 1.13 - 
ACHN p53 
shRNA 
10 2.00 1.04 + 
 
 
* - IC50 and IC70 were the levels of inhibition of proliferation selected to perform 
analysis of drug interaction by combination index. 
# - Combination index calculated using the following equation D1comb./D1alone + 
D2comb./D2alone. 
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reduction in the expression of p53 would confer some resistance to the inhibitory 
effects of Nutlin-3.  By extension, if this combination treatment was p53-dependent, 
then reduction in p53 levels would decrease the synergy observed as a result of this 
treatment.  This is indeed what was observed.  To summarise, the synergy observed 
in response to the combination of Nutlin-3 and ABT-737 in RCC cells harbouring 
wild type p53 is p53-dependent. 
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3.2.3 The combination of Nutlin-3 and ABT-737 promotes apoptosis in renal cell 
carcinoma cells harbouring wild type p53 
The data presented in section 3.2.1 of this chapter showed that the combination of 
Nutlin-3 and ABT-737 synergistically inhibited the proliferation of RCC cells 
harbouring wild type p53 and that this inhibition of proliferation is p53-dependent 
(section 3.2.2).  The next issue to address was determining the mechanism by which 
this combination of drugs inhibited proliferation of RCC cells. 
 
As discussed in the Section 3.1, Nutlin-3 treatment alone induces cell cycle arrest 
and senescence in RCC cells that harbour wild type p53 (Tsao and Corn, 2010; 
Polanski et al., submitted).  ABT-737 has been shown to promote apoptotic cell 
death in ACHN and A498 cell lines (Song et al., 2008) and two other studies showed 
that ABT-737 was capable of inducing apoptosis in a variety of RCC cell lines that 
were not used in our present study (Zall et al., 2010; Zhu et al., 2013).  Considering 
ABT-737 was observed to inhibit proliferation, albeit at high does, in the RCC cell 
lines used in this study (figure 3.2.1.2), and this inhibition of proliferation was most 
likely due to the induction of apoptosis (Song et al., 2008) and that Nutlin-3 did not 
promote the death of RCC cells harbouring wild type p53 but acted synergistically 
with ABT-737 in RCC cells harbouring wild type p53 but not mutant p53, we 
envisaged a scenario whereby Nutlin-3 enhanced the pro-apoptotic effect of ABT-
737.  As Nutlin-3 did not promote apoptosis in these cell lines (Tsao and Corn, 
2010), and it was likely that ABT-737 did, it was hypothesised that there was some 
latent pro-apoptotic function to p53 rescued by Nutlin-3 treatment in these cells that 
was insufficient to promote apoptosis alone but could contribute towards ABT-737-
mediated apoptosis.  Indeed a recent study showed that cell lines that possessed wild 
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type p53 that did not respond to Nutlin-3 treatment by undergoing apoptosis could be 
induced to undergo apoptosis upon combination of Nutlin-3 with ABT-263 
(Kracikova et al., 2013), a derivative of ABT-737 that targets the same anti-apoptotic 
proteins as ABT-737, with doses of ABT-263 that did not promote apoptosis alone.  
The authors proposed a threshold model for p53-dependent cell fate decisions 
whereby the threshold for p53-mediated apoptosis could be lowered by combination 
of a Bcl-2 family inhibitor with an inhibitor of the MDM2-p53 interaction 
(Kracikova et al., 2013).  Considering our own observations, that Nutlin-3 did not 
promote apoptosis alone but synergised with ABT-737 to inhibit the proliferation of 
RCC cells in a p53-dependent manner, the next question to address was whether 
apoptosis was taking place in our panel of cell lines in response to the combination 
treatment. 
 
The approach employed initially was to visually observe the response of the cells 
treated with the compounds.  As described in Section 1.7.7, apoptotic cells are 
conspicuous by a number of changes to the cell, some of which can be observed 
visually by phase contrast microscopy, such as cell shrinkage and apoptotic body 
formation.  ACHN wild type p53 cells and 111 mutant p53 cells were used in this 
experiment.  Cells were seeded into six well plates at a density of 100 000 cells per 
well.  Preliminary observations by phase contrast microscopy suggested that none of 
the changes associated with apoptosis could be observed visually in response to any 
of the compounds until ~24 h post-treatment, hence live cell imaging commenced 18 
h after treatment with drug vehicle, 3µM Nutlin-3, 10µM ABT-737 or a combination 
of both treatments and images were acquired at 5 min intervals for 24.5h.  A more  
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Figure 3.2.3.1 Images obtained from live cell imaging of ACHN cells (I).  ACHN 
cells were seeded at a density of 100,000 cells per well.  24h after seeding, cells were 
treated with either drug vehicle (A) or 3µM Nutlin-3 (B) and live cell imaging 
commenced 18h after drug treatment.  Live cell imaging was performed as described 
in section 2.7.  Time is in hours and minutes.  Scale bar = 160µm. 
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Figure 3.2.3.2 Images obtained from live cell imaging of ACHN cells (II).  
ACHN cells were seeded at a density of 100,000 cells per well.  24h after seeding, 
cells were treated with either 10 µM ABT-737 (A) or a combination of 3µM Nutlin-3 
and 10µM ABT-737 (B) and live cell imaging commenced 18h after drug treatment.  
Live cell imaging was performed as described in section 2.7.  Time is in hours and 
minutes.  Scale bar = 160µm. 
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Figure 3.2.3.3 Single cell time-lapse study of ACHN cell dying in response to the 
combination of Nutlin-3 and ABT-737.  The experimental conditions were as 
described in the legend of figure 3.2.3.2.  A.  ACHN cells treated with 3µM Nutlin-3 
and 10µM ABT-737 at 18 h post-treatment, reproduced from figure 3.2.3.2B.  Scale 
bar = 160µm.  B.  Time lapse images of single cell from white box in figure 
3.2.3.3A.    Scale bar = 56µm. 
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detailed description of the protocol for live cell imaging is shown in section 2.7.  
Representative movies that were made from the images collected are included on the 
attached DVD (Appendix 1). 
 
Figure 3.2.3.1 and 3.2.3.2 show images acquired at six-hour intervals from the initial 
image acquired 18 h after drug treatment.  In response to drug vehicle, ACHN cells 
continued to proliferate and divide and appeared healthy (figure 3.2.3.1A and 
supplementary movie 1, Appendix 1) as time progressed.  In response to treatment of 
ACHN cells with Nutlin-3, little death appeared to take place, however at roughly 
18h, cells appeared to form highly motile inclusions that oscillated for the remainder 
of the movie.  Single cells that were not part of these inclusions appeared to be 
motile, but did not divide.  Cells did not appear to proliferate and divide for the 
duration of the movie.  ACHN cells treated with ABT-737 overall appeared to 
proliferate and divide as normal.  Some cells appeared to die towards the end of the 
experiment, however, this appeared to have little affect on overall cell number 
because the remaining cells appeared to proliferate in a manner similar to drug 
vehicle treated cells.  At 18 h, the density ACHN cells treated with the combination 
of Nutlin-3 and ABT-737 was comparable to that observed in the other three 
treatments (figure 3.2.3.2B).  Cell death could be observed taking place immediately 
after the 18h time point.  At 30h, all of the cells appear to be dying and this 
continued for the duration of the movie until no healthy cells were observed.  Figure 
3.2.3.4B is a representative single cell analysis summarizing the key points of the 
cell death taking place in response to the combination of Nutlin-3 and ABT-737.  At 
18:00 until 28:25, the cell appeared healthy.  At 28:25, the cell elongated then at 
28:30, the cell took on a more circular appearance.  At 28:45, the cell appeared to 
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undergo membrane blebbing that is characteristic of cells undergoing apoptosis, 
resulting in the formation of apoptotic bodies.  Dissociation of the apoptotic bodies 
from the main body of the cell appeared to be taking place at 30:10.  This process 
continued, until the remainder of the cell was surrounded by apoptotic bodies that 
had dissociated from the main body of the cell (30:20 and 36:00, figure 3.2.3.4B). 
 
111 cells appeared to proliferate and appeared healthy in response to treatment with 
drug vehicle (figure 3.2.3.5A and Appendix 1, movie 5).  A similar observation was 
made in when 111 cells were treated with Nutlin-3 (figure 3.2.3.5A and Appendix 1, 
movie 6), and the cells appeared to proliferate as normal.  Some cell death could be 
observed in response to ABT-737 alone (figure 3.2.3.5B and Appendix 1, movie 7) 
but overall, cells continued to proliferate.   Dying cells appeared undergo blebbing 
followed by death that was observed in the ACHN cells in figure 3.2.3.4B.  111 cells 
treated with the combination of Nutlin-3 and ABT-737 proliferated in a similar 
manner to the 111 cells treated with ABT-737 alone and some cell death took place 
but overall, combination treated 111 cells were not dissimilar to ABT-737-treated  
111 cells in that the cells continued to proliferate in response to the treatments and 
cell death was minimal.  Interestingly, the dramatic cell death that was observed in 
the ACHN cells in response to the combination treatment was not observed in the 
111 cells, emphasizing the importance of wild type p53 in the response to this 
treatment (compare figure 3.2.3.3B and 3.2.3.6B at 42:00). 
 
To summarise, Nutlin-3 appeared to inhibit the proliferation of ACHN cells but did 
not appear to promote cell death.  ABT-737 treatment induced some cell death in 
ACHN cells but proliferation did not appear hindered.  The combination of both  
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Figure 3.2.3.4 Images obtained from live cell imaging of 111 cells (I).  111 cells 
were seeded at a density of 100,000 cells per well.  24h after seeding, cells were 
treated with either drug vehicle (A) or 3µM Nutlin-3 (B) and live cell imaging 
commenced 18h after drug treatment.  Live cell imaging was performed as described 
in section 2.7.  Time is in hours and minutes.  Scale bar = 160µm. 
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Figure 3.2.3.5 Images obtained from live cell imaging of 111 cells (II).  111 cells 
were seeded at a density of 100,000 cells per well.  24h after seeding, cells were 
treated with either 10µM ABT-737 (A) or a combination of 3µM Nutlin-3 and 10µM 
ABT-737 (B) and live cell imaging commenced 18h after drug treatment.  Live cell 
imaging was performed as described in section 2.7.  Time is in hours and minutes.  
Scale bar = 160µm. 
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Figure 3.2.3.6 Survival curves for ACHN and 111 cells treated with Nutlin-3 
and/or ABT-737.  Cells were seeded as described in section 2.3.1.1 and treated with 
the indicated drugs for 42.5h.  Cells were then treated with MTT as described in 
section 2.3.1.2. After treatment with MTT, absorbance at an optical density of 
595nm was measured. As a measure of proliferation, absorbance of drug-treated cells 
at 595nm was divided by absorbance of vehicle treated cells to give proliferation 
relative to drug-vehicle treated cells.  Red square – 3µM Nutlin-3.  Red circle – 
10µM ABT-737. Red triangle – combination of 3µM Nutlin-3 and 10µM ABT-737. 
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treatments induced dramatic cell death in ACHN cells.  This is consistent with the 
data presented in section 3.2.1.  Nutlin-3 appeared to have no affect on 111 cells.   
 
ABT-737 and combination treatment both had similar affects on 111 cells, such that 
proliferation was not perturbed and little cell death was induced.  This was consistent 
with the finding presented in section 3.2.2, that inhibition of proliferation of RCC 
cells in response to this combination treatment is p53-dependent.  Survival curves for 
ACHN and 111 cells that were treated with Nutlin-3 and ABT-737 for the 
corresponding length of time as the experiment described in this section are shown in 
figure 3.2.3.6 (42.5 h).  The treatments used in the above experiment are highlighted 
on both of the survival curves in figure 3.2.3.6 by red shapes.  Data from these 
survival curves is consistent with the observations from the live cell imaging: 
proliferation of ACHN cells is inhibited by Nutlin-3 treatment, without the 
promotion of cell death, as has been previously established (Tsao and Corn, 2010; 
Polanski et al., submitted).  Nutlin-3 treatment had no effect on the proliferation of 
111 cells, consistent with the absence of wild type p53.  ABT-737 promoted some 
cell death in ACHN cells but proliferation was not hindered; a similar observation 
could be made about 111 cells, although this cell line was slightly more resistant to 
the cell death promoting affect of ABT-737 (figure 3.2.3.5, table 3.2.1.1 and 
compare figures 3.2.3.2A and 3.2.3.5A). 
 
The combination of Nutlin-3 and ABT-737 promoted dramatic cell death in ACHN 
cells (figure 3.2.3.2B) and this is consistent with the data shown in figure 3.2.3.6 (red  
triangle).  111 cells were largely resistant to the cell death promoting affects of the 
combination of Nutlin-3 and ABT-737 and this was reflected in the survival data.  In 
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conclusion, the inhibition of proliferation observed upon treatment of RCC cells 
harbouring wild type p53 with the combination of Nutlin-3 and ABT-737 appeared 
to be due to cell death rather than inhibition of cell proliferation. 
 
In this section, the term apoptosis has not yet been used to describe the nature of the 
cell death observed in response to ABT-737 and the combination treatment, although 
this is the most likely cell fate that is being promoted in response to these treatments, 
considering that the pro-apoptotic effects of ABT-737 are well documented and also 
the nature of cell death observed in figure 3.2.3.3.  To verify whether apoptosis was 
indeed taking place in response to these treatments in this panel of cell lines, FITC-
conjugated Annexin V (AV) and propidium iodide (PI) staining of cells was used, 
followed by quantification of cells expressing the different fluorophores using flow 
cytometry, as described in Section 2.3.2.  Cells were treated with 3µM Nutlin-3, 
10µM ABT-737 or a combination of both treatments for 36h before staining with AV 
and PI and subsequent quantification using a flow cytometer.  Caki2 cells were 
treated with only 1µM ABT-737 because of the increased sensitivity of this cell line 
to ABT-737 (table 3.2.1.1).  Figure 3.2.3.7 and 3.2.3.8 show the dot plots from the 
flow cytometry quantification of cells treated with the single drug or the combination 
and figure 3.2.3.8 summarises the percentages of AV positive cells in each treatment.    
A cursory inspection of all of the dot plots showed that cells treated with drug 
vehicle had low percentages of cells that were positive for AV alone or both AV and 
PI (Figures 3.2.3.7 and 3.2.3.8).  The highest percentage of AV positivity in response 
to drug vehicle was observed in HEK293 cells (14.4%, figure 3.2.3.9).   Considering 
that AV positivity was an indicator that a cell was undergoing apoptosis (discussed 
in Section 2.3.2) and the PI positivity was an indicator of cell death, and that AV and  
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Figure 3.2.3.7 Analysis of apoptosis and cell death in cells treated with Nutlin-3 
and/or ABT-737 (I).  Cells were treated with drug-vehicle, 3µM Nutlin-3, 10µM 
ABT-737 or a combination of both treatments for 36h and passed through a flow 
cytometer as described in section 2.3.2.  Caki2 cells were treated with 1µM ABT-
737 due to the greater sensitivity of this cell line to the compound.  20,000 events 
were counted by the flow cytometer and values in each quadrant indicate the 
percentage of cells in that quadrant relative to the total number of counted cells.  
Representative data from at least 3 repeats. 
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PI positivity was observed at the same time as cells that were positive for AV alone, 
we therefore surmised that most of the AV and PI positive cells (dead cells) were 
cells that had undergone apoptosis earlier than cells that were only AV positive.  
Hence, the cells that were AV (lower right quadrant on the dot plot) positive were 
categorized as apoptotic and AV and PI positive (upper right quadrant) cells were 
categorized as dead cells that had undergone apoptosis. 
 
Nutlin-3 treatment alone had little effect in terms of promoting apoptosis in these cell 
lines (figures 3.2.3.7, 3.2.3.8 and 3.2.3.9).  There was no greater than an 8.6% 
increase in the proportion of apoptotic and dead cell in response to treatment with 
Nutlin-3 over drug-vehicle treated cells across all of the cell lines tested (figure 
3.2.3.9), suggesting that Nutlin-3 treatment alone was ineffective in promoting 
apoptosis in these cells.  This was consistent with previous observations RCC cells 
that harboured wild type p53 (Tsao and Corn, 2010). 
 
When compared to drug-vehicle treated cells, treatment with ABT-737 resulted in an 
increase in apoptosis and cell death due to apoptosis, which was generally greater 
than that observed in response to treatment with Nutlin-3, with the single exception 
of 111 cells (figures 3.2.3.7, 3.2.3.8 and 3.2.3.9).  111 cells exhibited a 1.1% increase 
in apoptosis and cell death in response to Nutlin-3 over that observed in response to 
ABT-737 (figures 3.2.3.8 and 3.2.3.9).  This minor increase was likely due to 
handling of the cells during preparation of the sample rather than any real biological 
effect.  Further, the sensitivity of 111 cells to both Nutlin-3 and ABT-737 is identical 
(IC50 =18 µM, table 3.2.1) therefore it is unlikely that this minor difference in 
percentage of apoptotic cells in response to Nutlin-3 or ABT-737 was a direct effect 
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of either of treatment.  The Caki2 and A498 cell lines were the most sensitive to 
ABT-737, with the percentage of apoptotic and dead cells totalling 19.8 and 20.1% 
relative to their respective drug-vehicle treated controls (figures 3.2.3.7 and 3.2.3.9).   
There was a more modest increase in the proportion of apoptotic and dead cells upon 
ABT-737 treatment in the ACHN, 115 and 154 cell lines with 16.5, 13.2 and 10.5 % 
apoptotic and dead cells relative to respective drug vehicle treated control of each 
cell line (figures 3.2.3.7, 3.2.3.8 and 3.2.3.9).  Overall, the RCC cells harbouring 
wild type p53 appeared to be more sensitive to ABT-737 when compared to their 
mutant counterparts in this assay (figure 3.2.3.9).  This is unsurprising, considering 
that in several tissue and tumour backgrounds, p53 can promote the transcription of 
proteins such as Puma and Noxa, that can interact with anti-apoptotic Bcl-2 family 
members to promote apoptosis (see section 1.2.8). 
 
Treatment with the combination of Nutlin-3 and ABT-737 resulted in an increase in 
the number of apoptotic and dead cells in all of the RCC cells harbouring wild type 
p53 with the exception of the 117 cell line, when compared to both drug-vehicle or 
each of the solo-agents (figures 3.2.3.7, 3.2.3.8 and 3.2.3.9).  The wild type p53 cell 
lines: ACHN, 115, Caki2 and A498 exhibited an increase in apoptosis of 57.8, 35.4, 
37.0 and 31.9% relative to their respective drug-vehicle-treated controls.  The mutant 
p53 cell lines: 111 and 154 also displayed an increase in apoptosis of 5.5 and 11.4% 
relative to their respective drug-vehicle-treated controls in response to the 
combination of Nutlin-3 and ABT-737 (figures 3.2.3.8 and 3.2.3.9), but this is 
considerably less than is observed in the p53 wild type cell lines.  Relative to their 
respective ABT-737 single treatments, the increases in the number of apoptotic cells 
observed in the 111 and 154 cell lines are only 4.1 and 1.0%, suggesting that the  
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Figure 3.2.3.8 Analysis of apoptosis and cell death in cells treated with Nutlin-3 
and/or ABT-737 (II).  Cells were treated with drug-vehicle, 3µM Nutlin-3, 10µM 
ABT-737 or a combination of both treatments for 36h and passed through a flow 
cytometer as described in Section 2.3.2.  20,000 events were counted by the flow 
cytometer and values in each quadrant indicate the percentage of cells in that 
quadrant relative to the total number of counted cells.  Representative data from at 
least 3 repeats. 
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Figure 3.2.3.9 Analysis of Annexin V positive cells treated with Nutlin-3 and/or 
ABT-737.  Summary of flow cytometric analysis of renal cells after 36h treatment 
with drug-vehicle, 3µM Nutlin-3, 10µM ABT-737 or a combination of both 
treatments (Caki2 cells were treated with only 1µM ABT-737, see legend of figure 
3.2.3.7).  Histogram bars represent sum of lower right quadrant events (apoptotic 
cells) and upper right quadrant events (cells that had died as result of apoptosis).	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presence of Nutlin-3 in the combination treatment did very little to contribute to the 
increased apoptosis observed in both of these cell lines relative to their drug-vehicle-
treated controls.  The obvious difference in the responses of the RCC cells that 
harbour wild type p53 ACHN, 115, A498 and Caki2 to the RCC cells that harbour 
mutant p53 in response to the combination treatment underscored the importance of 
wild type p53 to the apoptotic response of these cells to the combination treatment.  
This is consistent with the data presented in section 3.2.2, that the inhibitory response 
to the combination of Nutlin-3 and ABT-737 is p53-dependent.  The 117 wild type 
p53 RCC cell line responded to the combination treatment in similar manner to the 
mutant p53 cell lines in that combining Nutlin-3 with ABT-737 did not particularly 
increase apoptosis over the ABT-737 single treatment.  This was consistent with the 
data presented in section 3.2.1 showing that synergy between Nutlin-3 and ABT-737 
was less apparent in the 117 cell line when compared to the other RCC cell lines that 
harboured wild type p53 (figure 3.2.1.3 and table 3.2.1.2).  This less dramatic 
response to the combination Nutlin-3 and ABT-737 when compared to the other wild 
type p53 RCC cell lines maybe because the 117 cell line possesses an almost 
undetectable level of p53 protein when compared to the other wild type p53 RCC 
cell lines tested (lane 6, figure 3.2.1.1).  It is possible that relatively higher levels of 
wild type p53 are required for this combination of drugs to promote apoptosis in 
RCC cells.  This is an intriguing possibility, since higher levels of wild type p53 and 
MDM2 has been shown to be an independent prognostic indicator for worse outcome 
in patients with RCC (Noon et al., 2011; section 1.1.5.3), this data suggests that this 
drug combination may be p53-level-specific and hence biomarker specific. 
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Interestingly, there was comparatively little apoptosis observed in response to either 
single agents or the combination of agents in the HEK293 cell line.  This is 
consistent with the data presented in section 3.2.1.  The proportion of apoptotic and 
dead cells increased by only 3.9% in response to the combination treatment.  This 
might be evidence that tumorigenicity is a pre-requisite for the effectiveness of this 
combination and may be the basis for a therapeutic index however this is highly 
speculative and xenograft models would be required to begin to address this issue. 
 
To conclude this section, the combination of Nutlin-3 and ABT-737 inhibits the 
proliferation of RCC cells harbouring wild type p53 by promoting apoptosis.  ABT-
737 treatment alone promoted apoptosis in these cell lines, however, combining 
Nutlin-3 with ABT-737 increased the degree to which this apoptosis took place.  
This is consistent with the hypothesis outlined at the beginning of this section 
suggesting that Nutlin-3 enhanced the pro-apoptotic effects of ABT-737.  The p53-
dependent nature of this combination treatment in the RCC cell lines harbouring wild 
type p53 was further supported by the observations made using live cell imaging and 
the decreased apoptotic response observed in the RCC cells harbouring mutant p53. 
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3.2.4 An inhibitor of the ubiquitin-ligase activity of MDM2 does not synergise with 
ABT-737 in RCC cells that harbour wild type p53 
In Section 3.2.1, it was shown that the combination of Nutlin-3 and ABT-737 
synergistically inhibited the proliferation of RCC cells harbouring wild type p53.  In 
the Section 3.2.2, ACHN cells expressing scrambled control shRNA that expressed 
the same level of p53 as parental ACHN cells, and ACHN cells expressing p53-
specific shRNA that possessed a relatively lower level of p53 protein compared to 
the scrambled control were used, to show that this synergistic effect was indeed 
dependent on p53.  In Section 3.2.3, it was shown that this inhibition of proliferation 
described in the first section was actually apoptosis taking place in response to the 
combination treatment.  Nutlin-3 is an inhibitor of the MDM2-p53 interaction 
(Section 1.3.3; Vassilev et al., 2004) and as discussed in the Section 1.3.1, MDM2 
can regulate p53 activity by targeting p53 for degradation at the proteasome upon 
ubiquitination of p53 by MDM2 or to a lesser extent, by directly binding to p53 
(Section 1.3.1; Oliner et al., 1993; Honda et al, 1997; Kubbutat et al., 1997).  
Considering that Nutlin-3 is an inhibitor of the MDM2-p53 interaction, and 
combining this compound with the pro-apoptotic drug ABT-737 synergistically 
promoted apoptosis in the RCC cells harbouring wild type p53, it would have been 
interesting to observe whether the same synergistic effect was observed in upon 
combining ABT-737 with an inhibitor of the ubiquitin ligase activity of MDM2.  
HLI98 is an inhibitor of the E3 ubiqutin ligase activity of MDM2 (Yang et al., 2005) 
and HLI373 (Kitagaki et al., 2008) is a more potent, water-soluble derivative of 
HLI98 (See Section 1.3.3).  Both of these compounds have been shown to promote 
p53-dependent cell cycle arrest or apoptosis in a cell lines derived from different  
 
111	  	  
Table 3.2.4.1 Summary of IC50 and IC70 values of cells treated with HLI373 or 
ABT-737. 
HLI373 (µM) ABT-737 (µM) Cell line 
IC50 IC70 IC50 IC70 
ACHN 1.3 2.3 13.0 20.0 
A498 2.3 4.4 7.0 13.0 
Caki2 3.0 8.0 1.9 4.0 
115 6.0 13.0 19.0 23.0 
117 2.2 3.0 11.0 19.0 
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Figure 3.2.4.1 Survival curves of RCC cells treated with HLI373 and/or ABT-
737.  Cells were seeded as described in section 2.3.1.1 and treated with the indicated 
drugs for 72h.  Cells were then treated with MTT as described in section 2.3.1.2. 
After treatment with MTT, absorbance at an optical density of 595nm was measured. 
As a measure of proliferation, absorbance of drug-treated cells at 595nm was divided 
by absorbance of vehicle treated cells to give proliferation relative to drug-vehicle 
treated cells.  Representative data from at least 2 repeats. 
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Figure 3.2.4.2 Analysis of HLI373 and ABT-737 drug interaction in RCC cells.  
Isobolograms produced from data shown in figure 3.2.4.1.  IC50 and IC70 values were 
plotted onto the vertical and horizontal axes for HLI373 and ABT-737 respectively 
to give isoboles.  Drug combination points were then expressed on the isobolograms 
to assess the for synergy between both drugs. 
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Table 3.2.4.2 Combination indices at IC50 and IC70 for RCC cells treated with 
HLI373 and ABT-737. 
IC50* IC70*  
Cell 
line 
 
p53 
status 
ABT-
737 
(µM) 
HLI373 
(µM) 
Combination 
index# 
ABT-
737 
(µM) 
HLI373 
(µM) 
Combination 
index# 
1 1.5 1.23 - - 1 2.3 1.05 + 
3 1.2 1.15 - 3 1.9 0.98 + 
ACHN WT 
10 0.2 0.92 + 10 0.7 0.80 + + 
  
1 2.2 1.10 - 1 4.4 1.10 - 
3 1.8 1.21 - - 3 2.7 0.84 + + 
A498 WT 
 10 1.2 1.04 + 
  
0.1 2.3 0.81 + + 0.1 7.0 0.90 + 
0.3 1.5 0.66 + + + 0.3 5.0 0.70 + + 
Caki2 WT 
1 1.2 0.93 + 1 2.8 0.60 + + + 
  
1 6.0 1.05 + 1 12.0 0.97 + 
3 4.3 0.87 + 3 10.0 0.90 + 
115 WT 
10 4.0 1.19 - 10 8.0 1.05 + 
  
1 2.0 1.00 + 1 3.0 1.05 + 
3 2.0 1.18 - 3 2.9 1.12 - 
117 WT 
10 0.1 0.95 + 
 
10 1.4 1.00 + 
* - IC50 and IC70 were the levels of inhibition of proliferation selected to perform 
analysis of drug interaction by combination index. 
# - Combination index calculated using the following equation D1comb./D1alone + 
D2comb./D2alone. 
WT – wild type. 
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tumours.  It was hypothesized that combining a MDM2 ubiquitin ligase inhibitor 
with ABT-737 would have resulted in the synergistic inhibition of proliferation of 
RCC cells harbouring wild type p53 in a manner similar to that observed upon 
treatment with the combination of Nutlin-3 and ABT-737 simply because both 
Nutlin-3 and HLI compounds both liberate p53 from inhibitory regulation by 
MDM2.  To test this, a similar approach was taken as that described in section 3.2.1.  
A panel of RCC cells harbouring wild type p53 were treated with HLI373, ABT-737 
or a combination of both treatments for 72 h and a MTT assay was performed as 
described in section 2.3.  Absorbance at 595nm from each drug treatment was 
divided by absorbance at 595 nm from the drug vehicle treatment to give a surrogate 
indicator of viability in response to drug treatment, as performed previously.  Figure 
3.2.4.1 summarises the survival curves for the cell lines treated with HLI373 and 
ABT-737 and table 3.2.4.1 summarises the IC50 and IC70 values for both treatments.  
The IC50 of HLI373 for the RCC cell lines tested ranged between 1.3 and 6.0µM, 
suggesting that the cell lines tested exhibited similar sensitivities to HLI373.  At IC70 
there was roughly a 5-fold difference in the sensitivity to HLI373 between the most 
resistant cell line (115, 13.0µM) and the most sensitive (ACHN 2.3µM).  Sensitivity 
to ABT-737 alone (table 3.2.4.1) was comparable to that observed in the experiment 
described in section 3.2.1 (table 3.2.1).  To understand the nature of the drug 
interaction between HLI373 and ABT-737 in these cells, isobolograms were plotted 
from the data shown in figure 3.2.4.1 (figure 3.2.4.2).  As can be seen from the 
isobolograms, the only cell line in which HLI373 and ABT-737 appear to act 
synergistically is the Caki2 cell line.  The interaction between both compounds in the 
remaining cell lines appears additive, with combination points clustering close to the 
isobole at both IC50 and IC70.  Combination indices at IC50 and IC70 are summarized 
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on table 3.2.4.2.  Excluding Caki2 cells, the combination indices at IC50 and IC70 
range from 0.87 to 1.23 and 0.80 to 1.12 respectively.  This underscored the lack of 
synergism between both of these compounds in the RCC cell lines tested with the 
exception of Caki2 cells.  Some synergy was observed in Caki2 cells at both IC50 and 
IC70, the lowest combination indices at these levels of inhibition being 0.66 and 0.60 
respectively; this was comparable to the synergy observed in response to the 
combination of Nutlin-3 and ABT-737. 
 
Two questions arose from these data: 1) why was there no synergy observed between 
the MDM2 ubiquitin ligase inhibitor and ABT-737 in most of the RCC cell lines 
harbouring wild type p53? 2) Why was synergy observed in Caki2 cells but not in 
the other cell lines?  As discussed in the Section 1.3.1, MDM2 can regulate p53 
activity by functioning as an ubiquitin ligase for p53, targeting p53 for proteolytic 
degradation or masking the transactivation domain of p53, inhibiting the function of 
p53 as a transcription factor.  p53 in RCC cells is subject to regulation by MDM2 
(Warburton et al., 2005) and knockdown of MDM2 using siRNA results in increased 
p53 protein level in RCC cells (Warburton et al., 2005; Polanski et al., 2010).  
Binding of MDM2 to p53 is a prerequisite for MDM2 to function as an ubiquitin 
ligase to p53.  To our knowledge, there is no evidence to suggest that HLI373 
inhibits binding of MDM2 to p53.  It could therefore be speculated, since Nutlin-3 
synergises with ABT-737 but HLI737 does not synergise with ABT-737, that 
inhibition of the ubiquitin ligase activity of MDM2 is less important to the rescue of 
p53 than inhibition of MDM2 binding to p53.  Caki2 was more sensitive to HLI373 
at IC70 than the remaining cell lines tested (table 3.2.4.1).  The synergy observed in 
the Caki2 cell line may be an extension of this increased sensitivity. 
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3.3 Summary 
To restore wild type p53 function in RCC cells that harbour wild type p53, we 
rationally selected the combination of Nutlin-3 and ABT-737, the former for its 
ability to inhibit the MDM2-p53 interaction and the latter for its documented ability 
to promote apoptosis in cells from a variety of tumour backgrounds.  We have 
demonstrated that the combination of both of these agents synergistically inhibits the 
proliferation of RCC cells that harbour wild type p53 but does not have this 
synergistic effect on RCC cells that harbour mutant p53 (Section 3.2.1).  Further, 
using ACHN cells with down-regulated p53, we have shown that this inhibition of 
proliferation is indeed a p53-dependent effect (Section 3.2.2).  To ensure that the 
inhibition of proliferation observed was taking place via a conserved cell death 
pathway and not simply non-specific cell death, we determined the nature of this 
inhibition of proliferation.  Using live cell phase contrast microscopy and AV/PI 
staining, it has been demonstrated that this combination of drugs was promoting cell 
death via apoptosis (Section 3.2.3).  Interestingly, the behaviour of 117 cells, RCC 
cells that have very low levels of wild type p53, is very similar to that observed in 
the p53 mutant RCC cell lines, suggesting a relatively higher level of wild type p53 
is required for this combination to be effective.  Taking this into account, and the fact 
that data presented herein (Section 3.2.2) suggest that the effectiveness of this 
combination treatment in inducing apoptosis in RCC cells is p53-depenent, the 
pharmacological restoration of p53-mediated apoptosis in a biomarker-specific 
subset of RCC cell lines has been demonstrated in this chapter. We have further 
demonstrated that it is inhibition of the MDM2-p53 interaction in combination with 
ABT-737 is synergistic in RCC cells that harbour wild type p53 rather than 
inhibition of the ubiquitin ligase activity of MDM2.  This observation raises an 
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interesting point regarding the nature of MDM2-mediated regulation of p53 in RCC 
cells as whether binding of MDM2 is of greater relevance to regulation of p53 than 
ubiquitination followed by degradation.  Or it may be the case that p53-independent 
effects of HLI373 mask a synergistic interaction between both HLI373 and ABT-
737.  In the following chapter, data are presented that further explore the mechanism 
underlying the induction of apoptosis in response to the combination of Nutlin-3 and 
ABT-737. 
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Chapter 4: A study into the mechanism underlying the p53-dependent apoptosis 
observed in response to the combination of Nutlin-3 and ABT-737 in renal 
carcinoma cells harbouring wild type p53 	  
4.1 Introduction 
In Chapter 3, it was demonstrated that RCC cells harbouring wild type p53 
underwent apoptosis in response to the combination of Nutlin-3 and ABT-737.  It 
was apparent that ABT-737 alone was promoting apoptosis in these cells and that the 
addition of Nutlin-3 to ABT-737 enhanced this pro-apoptotic effect (section 3.2.3).  
Nutlin-3 alone did not promote a detectable increase in apoptosis.  In this chapter, 
understanding the mechanism of action of the apoptosis observed in response to the 
combination treatment was the focus. 
 
ABT-737 has been described as being primarily a mimetic of the BH3-only protein 
Bad (Certo et al., 2006) based on the differential binding affinity of ABT-737 for the 
different members of the anti-apoptotic Bcl-2 family of proteins. ABT-737 is thought 
to promote apoptosis by displacing ‘activator’ BH3-only proteins such as tBid and 
Bim from anti-apoptotic members of the Bcl-2 family members, resulting in 
activation of Bak or Bax which activates the signalling cascade leading to apoptosis 
(Van Delft et al., 2006; Certo et al., 2006; Ren et al., 2010; Garrison et al., 2012). 
 
As discussed in Section 1.2.7.5 of the Introduction, one of the determinants of 
resistance to ABT-737 is the relative expression levels of the different members of 
the anti-apoptotic Bcl-2 family members. ABT-737 has a high affinity for Bcl-2, Bcl-
xL and Bcl-w but has a low affinity for Mcl-1 and Bfl-1. Indeed, over-expression of 
Mcl-1 in a variety of models has been demonstrated to confer resistance to ABT-
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737-mediated apoptosis (van Delft et al., 2006). A further refinement to this model 
suggests that sensitivity to ABT-737 is primarily determined by levels of Bcl-2, 
rather than Bcl-xL or Bcl-w (Rooswinkel et al., 2012), despite there being a high 
binding affinity of ABT-737 for both Bcl-xL and Bcl-w. Thus, we sought to 
determine whether the protein levels of Bcl-2 family member could be implicated in 
resistance or sensitivity to ABT-737. 
 
4.2.1 Relative protein levels of Bcl-2 family members in RCC cells 
To determine whether protein levels of Bcl-2 family members might mediate 
resistance to the combination of Nutlin-3 and ABT-737, western blot analyses on cell 
lysates from the panel of cell lines used in the drug combination studies was 
performed. We sought to observe whether there was a correlation between steady-
state protein levels of members of the Bcl-2 family members and resistance or 
sensitivity to ABT-737. Also included in this analysis, for comparison were H1299 
non-small cell lung cancer cells and HL-60 promyelocytic leukaemia cells.  H1299 
cells have been documented to be relatively resistant to ABT-737 (IC50 > 50µM) and 
express relatively high levels of Mcl-1 and relatively low levels Bcl-2 (Wesarg et al., 
2007).  HL-60 have been documented to be relatively sensitive to ABT-737 (IC50 of 
190nM) and as having relatively low levels of Mcl-1 (Chen et al., 2007). Sub-
confluent cells from each cell line were harvested and subsequently lysed and 
analysed by western blot as described in Section 2.4. The western blots are shown in 
figure 4.2.1.1. Table 4.2.1.1 summarizes the relative levels of protein of Bcl-2, Bcl-
xL, Bcl-w and Mcl-1 in these cell lines. There was no obvious correlation between 
levels of the different Bcl-2 family members and sensitivity to ABT-737 (Table  
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Figure 4.2.1.1 Analysis of relative levels of Bcl-2 family proteins.  Subconfluent 
cells from each cell line were harvested and lysed as described in section 2.4.2.  20 
µg of protein was analysed in each lane and antibodies used for detection are 
described in table 2.1.  The migration of protein standards of the indicated 
approximate molecular weights are shown in kDa. 
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Table 4.2.1.1 Summary of relative protein level of Bcl-2 family members in 
renal cell lines used in this study. WT – wild type, MT – mutant, N/D – not 
detected. N/A – data not available. Protein level refers to relative level of protein 
shown in western blot from figure 4.2.1.1. 
Cell line p53 
Status 
Bcl-2 
level 
Bcl-xL level Bcl-w 
level 
Mcl-1 level ABT-
737 
IC50 
(µM) 
ABT-
737 
IC70 
(µM) 
ACHN WT N/D High High Intermediate 10 18 
A498 WT High High High Low 14 23 
115 WT N/D High Low Low 17 28 
Caki2 WT N/D Intermediate Low Low 1.3 2.2 
117 WT High Intermediate Low High 10 22 
111 MT N/D High Low High 18 23 
154 MT Low High N/D Intermediate 20 28 
HEK293 WT N/D Low N/D Low N/A N/A 
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4.2.1.1). Bcl-2 protein level was low or undetectable in all cell lines tested with the 
exceptions of 117 and A498 cell lines, where the protein was present at relatively 
high levels in comparison to the other cell lines analysed. Both 117 and A498 cell 
lines exhibited similar sensitivities to ABT-737.  Indeed, there was only a two-fold 
difference in the sensitivity to ABT-737 across the RCC cell lines tested, with the 
exception of Caki2 cells and yet the relative levels of Bcl-2 protein are very varied.  
Bcl-xL was expressed at a relatively high or intermediate level in all of the renal 
cells tested with the exception of HEK293 cells, where it was almost undetectable. 
Expression of protein was categorised into three groups – relatively high, 
intermediate and relatively low.  Intermediate was a level of protein lower than the 
proteins that were expressed the highest but present at a level greater than proteins 
that were present at a relatively low level.  Bcl-w protein was present at high levels 
only in ACHN and A498 cell lines, the remaining cell lines having either low or 
undetectable levels of Bcl-w. Mcl-1 protein was present at a relatively high level in 
111 and 117 cell lines, but this was not associated with increased resistance in these 
lines when compared to lines with lower levels of Mcl-1 expression as shown in 
table 4.2.1.1. 
 
Interestingly, the Caki2 cell line, which was the most sensitive cell line to ABT-737 
of the cell lines tested (IC50 and IC70 of 1.3 and 2.2µM respectively) expressed 
relatively low levels of Mcl-1, Bcl-2 and Bcl-w protein and an intermediate level of 
Bcl-xL protein. The low levels of Mcl-1 and other Bcl-2 family members in this cell 
line may be consistent with increased sensitivity to ABT-737 however, cell line 115 
which displayed a similar expression pattern to Caki2, exhibited a roughly ten-fold 
increased resistance to ABT-737 and therefore other factors clearly influence the 
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sensitivity of Caki2 cells to ABT-737.  One simple explanation might be that Caki2 
cells may have relatively higher basal levels of pro-apoptotic proteins than 115 cells. 
 
Correlation between ABT-737 sensitivity and increased level of Bcl-2 protein, or 
resistance to ABT-737 and increased level of Mcl-1 in panels of small cell and non-
small cell lung cancer cell lines have been observed in previous studies (Wesarg et 
al., 2007; Tahir et al., 2007).  The cell lines used in the aforementioned studies 
displayed an approximately binary pattern of expression for Bcl-2 and Mcl-1 and 
their corresponding sensitivity to ABT-737 reflected this.  To elaborate further on 
this statement, cell lines used in these studies possessed either relatively high levels 
of Bcl-2 and relatively low levels of Mcl-1 or relatively low levels of Bcl-2 and 
relatively high levels of Mcl-1.  As expected, cell lines that expressed relatively 
higher levels of Mcl-1 were more resistant to the pro-apoptotic effects of ABT-737 
than the cell lines that expressed relatively lower levels of Mcl-1. 
 
The cell lines used in our study did not display such an obviously binary pattern of 
expression for Bcl-2 and Mcl-1; indeed, Bcl-2 was only expressed at relatively high 
levels in the 117 and A498 cells. The relatively high expression of Mcl-1 the 117 cell 
line may have been responsible for the observed resistance to ABT-737 in the 
presence of high levels of Bcl-2. To summarise, the RCC cell lines tested in this 
study harbour a varied pattern of levels of anti-apoptotic Bcl family members. These 
different levels of protein of Bcl-2 family members do not correlate in an obvious 
manner with sensitivity to ABT-737. 
 
 
125	  	  
4.2.2 The combination of Nutlin-3 and ABT-737 enhances apoptotic signalling in 
RCC cell lines harbouring wild type p53 
In section 4.2.1, the levels of different members of the anti-apoptotic Bcl-2 family 
members in the cell lines used in this study were analysed to attempt to discern a 
relationship between the levels of these proteins and sensitivity or resistance to ABT-
737.  Since no correlation was observed between the levels of the members of this 
family of anti-apoptotic proteins with resistance to ABT-737, a different approach as 
attempted.  We sought to directly address what was taking place in response to the 
combination treatment by attempting to elucidate downstream events taking place in 
response to single agents and also the combination treatment. 
 
Previous studies using renal cell carcinoma cell lines harbouring wild type p53 
showed that in response to Nutlin-3 treatment, up-regulation of Bax does not take 
place, nor does apoptosis (Tsao and Corn, 2010; Polanski et al., submitted) but p53 is 
stabilized and this leads to increased transcription of p21, which results in cell cycle 
arrest or senescence. This phenotype has also been observed in cells from a variety 
of tumour backgrounds (Tovar et al., 2006). Nutlin-3 treatment in other cell line 
models can result in apoptosis and this can be accompanied by up-regulation of Bax 
and other pro-apoptotic proteins (Kojima et al., 2005; Van Maerken et al., 2006). 
Because p53 is a transcription factor that can promote the transcription of a number 
of pro-apoptotic genes, such as PUMA and NOXA, we hypothesised that p53 
rescued from the MDM2 mediated degradation by Nutlin-3 treatment could promote 
the transcription of pro-apoptotic genes other than Bax.  We hypothesized that the 
combined effect of inhibition of Bcl-2 family members by ABT-737 and the 
potential increase in the transcription of pro-apoptotic genes as a result of Nutlin-3- 
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Figure 4.2.2.1 Steady state level of p53, MDM2 and proteins associated with 
apoptosis in wild type p53-harbouring ACHN, Caki2 and 117 cell lines.  Cells 
were treated for 36 h with 3µM Nutlin-3, 10µM ABT-737 or a combination of both 
treatments.  Caki2 cells were treated with only 1µM ABT-737 because of their 
increased sensitivity to this compound.  Cells were harvested and lysates were 
prepared as described in section 2.4.  20 µg of protein was analysed in each lane and 
antibodies used for detection are described in table 2.1.  The migration of protein 
standards of the indicated approximate molecular weights are shown in kDa. 
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Figure 4.2.2.2 Steady state level of p53, MDM2 and proteins associated with 
apoptosis in wild type p53-harbouring A498 and 115 cell lines.  Cells were treated 
for 36 h with 3µM Nutlin-3, 10µM ABT-737 or a combination of both treatments.  
Cells were harvested and lysates were prepared as described in section 2.4.  20 µg of 
protein was analysed in each lane and antibodies used for detection are described in 
table 2.1.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa. 
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Figure 4.2.2.3 Steady state level of p53, MDM2 and proteins associated with 
apoptosis in mutant p53-harbouring 111 and 154 cell lines.  Cells were treated for 
36 h with 3µM Nutlin-3, 10µM ABT-737 or a combination of both treatments.  Cells 
were harvested and lysates were prepared as described in section 2.4.  20 µg of 
protein was analysed in each lane and antibodies used for detection are described in 
table 2.1.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa. 
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Figure 4.2.2.4 Steady state level of p53, MDM2 and proteins associated with 
apoptosis in H1299 and U2OS cell lines.  p53-null H1299 and p53 wild type U2OS  
cells were treated for 36 h with 3µM Nutlin-3, 10µM ABT-737 or a combination of 
both treatments.  Cells were harvested and lysates were prepared as described in 
section 2.4.  20µg of protein was analysed in each lane and antibodies used for 
detection are described in table 2.1.  The migration of protein standards of the 
indicated approximate molecular weights are shown in kDa. 
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mediated rescue of p53 may be responsible for the increase in apoptosis observed 
when comparing the effect of Nutlin-3 and ABT-737 combination treatment with 
ABT-737 treatment alone. 
 
As a preliminary approach to determine which pro-apoptotic proteins were involved 
in the apoptotic response to the combination of Nutlin-3 and ABT-737, western blot 
analysis of lysates from cells that were treated with single agents or a combination 
was performed. RCC cells were treated with drug vehicle, 3µM Nutlin-3, 10µM 
ABT-737 or a combination of both agents for 36h. Caki2 cells were treated with only 
1µM ABT-737 because these cells were found to be approximately ten times more 
sensitive to ABT-737 than the other cell lines tested (see section 3.2.1). The cells 
were subsequently harvested, lysed and subjected to western blot analysis as 
described in section 2.4.  p53 levels were monitored to determine whether the 
treatments rescued p53 from negative regulation by MDM2. Since MDM2 is 
regulated at the transcriptional level by p53 in RCC cells that harbour wild type p53 
(Warburton et al., 2005), we also monitored MDM2 protein levels as a surrogate 
indicator of p53 transcriptional activity.  Cleavage of PARP is a hallmark of 
apoptosis (Duriez and Shah, 1997), hence levels of cleaved PARP were monitored to 
indirectly monitor the occurrence of apoptosis.  Levels of Bax, Puma and Noxa were 
monitored as these proteins are known transcriptional targets of p53 that are involved 
in mediating an apoptotic response (Miyashita et al., 1995; Nakano and Vousden et 
al., 2001; Oda et al., 2000).   
In addition to RCC cells, p53-null H1299 non-small cell lung cancer cells and U2OS 
osteosarcoma cells were analysed for comparison to RCC cells to determine the 
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effects of the combination treatment in p53 null cells and cells harbouring wild type 
p53 respectively from a non-renal background. 
 
Nutlin-3 treatment alone resulted in an increase in p53 protein levels and a 
concomitant increase in MDM2 in the ACHN, Caki2, A498 and 115 cell lines 
(figures 4.2.2.1 and 4.2.2.2) as would be expected in cell lines that harbour wild type 
p53. The 117 RCC cell line that also harbours wild type p53 showed no apparent rise 
in p53 level (figure 4.2.2.1). There was also no detectable change in the p53 protein 
level in either mutant p53 RCC cell line 111 or 154 in response to Nutlin-3 
treatment. MDM2 protein levels remained the same in Nutlin-3-treated 111 and 154 
cells as would be expected of cell lines harbouring mutant p53 (figure 4.2.2.3).  As 
expected, the p53-null H1299 cell line displayed no discernable phenotype in terms 
of p53 or MDM2 protein level as a result of treatment with Nutlin-3, consistent with 
the absence of the p53 gene in these cells (figure 4.2.2.4).  p53 was up-regulated in 
U2OS cells treated with Nutlin-3 (figure 4.2.2.4), with an increase in MDM2 protein 
in a manner similar to that observed in the RCC cells harbouring high levels of wild 
type p53.  All of these observations are consistent with previous studies that have 
shown rescue of p53 from the inhibitory effects of MDM2 promote stabilization of 
p53 and resultant up-regulation of MDM2 in cells that possess wild type p53 
(Vassilev et al., 2004; Tovar et al., 2006). 
 
An increase in MDM2 and p53 protein levels was observed in ACHN, Caki2, A498 
and 115 cell lines in response to the combination of Nutlin-3 and ABT-737 when 
compared to drug-vehicle treated cells (figures 4.2.2.1 and 4.2.2.2); with the 
exception of Caki2 cells (figure 4.2.2.1), this increased level of both proteins was 
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less than the increase observed in response to Nutlin-3 treatment alone.  This maybe 
an intermediate phenotype between the up-regulation of p53 in response to Nutlin-3 
alone and the decrease in p53 in response to ABT-737 alone.  The significance of 
this remains to be elucidated. There was a decrease in the level of p53 in 117 cells in 
response to the combination of Nutlin-3 and ABT-737 in comparison to drug-vehicle 
treated cells (figure 4.2.2.1). In combination-treated U2OS cells, there was an 
increase in MDM2 protein when compared to cells treated with drug-vehicle but this 
increase was not as great as that observed in response to Nutlin-3 treatment alone 
(figure 4.2.2.4). There appeared to be no detectable increase in p53 protein in the 
U2OS cells in response to the combination treatment when compared to drug-vehicle 
treated cells. No change in p53 protein level was observed in the 111 and 154 cells 
lines in response to the combination treatment when compared to cells treated with 
drug-vehicle, which is expected when taking into account the presence of mutant p53 
in these cells (figure 4.2.2.3).  
 
Consistent with data presented in section 3.2.3, cleavage of PARP, an event 
associated with apoptosis, takes place in response to treatment with either ABT-737 
alone or the combination of Nutlin-3 and ABT-737 in most of the cell lines tested. In 
both ACHN and 115 cell lines, there was greater PARP cleavage observed in 
response to the combination treatment relative to treatment with ABT-737 alone 
(figures 4.2.2.1 and 4.2.2.2) and this was consistent with observation made in figure 
3.2.3.9, whereby ABT-737 alone promoted some apoptosis, but this apoptosis was 
enhanced by the addition of Nutlin-3.  PARP was cleaved in Caki2 and A498 cells in 
response to ABT-737 alone and the combination treatment however, there appeared  
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to be increased PARP cleavage in the ABT-737-treated cells when compared to the 
combination treated cells (figures 4.2.2.1 and 4.2.2.2).  Thus, it appeared there was a 
disconnect between PARP cleavage and apoptosis, since both of these cell lines 
responded to the combination treatment with increased apoptosis (figure 3.2.3.8). 
Consistent with observations made in the previous section, the RCC cells harbouring 
mutant p53 showed no increase in cleaved PARP levels in response to the 
combination treatment over that observed in response to ABT-737 alone (figure 
4.2.2.3). These data show that this combination promotes PARP cleavage in the RCC 
cells tested, consistent with data presented in section 3.2.3 although PARP cleavage 
in Caki2 and A498 cells in response to the combination treatment was inconsistent 
with data presented in section 3.2.3. 
 
As mentioned previously, treatment of RCC cells that harbour wild type p53 with 
Nutlin-3 results in neither apoptosis (Polanski et al., submitted; Tsao and Corn, 
2010) nor in up-regulation of Bax. There was no observable increase in Bax protein 
level in response to Nutlin-3 in any of the RCC cell lines tested nor in H1299 cells 
(figures 4.2.2.1, 4.2.2.2, 4.2.2.3 and 4.2.2.4). In contrast, there was an increase in 
Bax protein level in response to Nutlin-3 in the U2OS cell line (figure 4.2.2.4). 
Treatment with ABT-737 alone appeared to have no effect on Bax protein levels in 
any of the cell lines tested. Bax protein levels were similarly unchanged in the panel 
of RCC cell lines tested in response to the combination of Nutlin-3 and ABT-737.  
Hence, apoptosis in response to the combination of Nutlin-3 and ABT-737 in RCC 
cells harbouring wild type p53 is independent of Bax-upregulation must require and 
alternative mechanism to Bax-up-regulation to commit these cells to apoptosis. 
 
134	  	  
Puma exists as four different isoforms and only two isoforms (α and ß) possess the 
conserved BH3-only domain that allows the protein to contribute to apoptosis 
(Nakano and Vousden, 2003).  The antibody used in this study allowed the detection 
of a slower migrating form of Puma, which may have been Puma α and a faster 
migrating form, which may have been Puma ß. Puma α levels remained unchanged 
in all of the cell lines tested, under all of the experimental conditions (figures 4.2.2.1, 
4.2.2.2, 4.2.2.3 and 4.2.2.4).  Puma ß protein, on the other hand, was up-regulated at 
the protein level in ACHN, Caki2, A498 115 and U2OS in response to Nutlin-3 
treatment alone when compared to cells treated with drug-vehicle (figures 4.2.2.1, 
4.2.2.2 and 4.2.2.4). In contrast, there was no change in the levels of Puma ß in 117, 
H1299, 111 and 154 cells in response to Nutlin-3 (figures 4.2.2.1, 4.2.2.3 and 
4.2.2.4). Treatment with ABT-737 had no effect on Puma protein levels in any of the 
cell lines tested when compared to cells treated with drug vehicle, with the exception 
of U2OS cells, where there was a decrease in Puma in response to the ABT-737 
treatment (figure 4.2.2.4). The combination of Nutlin-3 and ABT-737 increased the 
level of Puma protein in ACHN and A498 cells relative to their respective drug-
vehicle treated cells (figures 4.2.2.1 and 4.2.2.2). The combination treatment 
decreased the level of Puma protein in U2OS cells when compared to drug-vehicle 
treated cells (figure 4.2.2.4). Level of Puma protein were unaffected by the 
combination treatment in the 117, 115, 111, 154 and H1299 cell lines when 
compared to their respective drug-vehicle treated cells (figures 4.2.2.1, 4.2.2.2, 
4.2.2.3 and 4.2.2.4).  Because of the well documented role of Puma promoting 
apoptosis through the intrinsic apoptosis pathway (see Section 1.2.7.2), up-regulation 
of Puma ß in response to Nutlin-3 and in the combination of Nutlin-3 and ABT-737 
suggests a possible role for Puma in the apoptosis observed in response to the 
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combination of these agents.  The observation that Puma protein level was decreased 
in response to the combination treatment relative to Nutlin-3 alone in some of the 
wild type p53 RCC cell lines does not necessarily preclude the ability Puma to 
promote apoptosis in these cells.  The time point chosen for these experiments was 
36h because this was previously shown to be the duration at which synergistic 
induction of apoptosis in response to the combination was observed (see Section 
3.2.3).  It is plausible that Puma may have been degraded in the combination-treated 
cells after a certain time point and to address this question, the same experiment 
would need to be repeated but at earlier time points to observe fluctuations in Puma 
levels. 
 
Bid is a p53-inducible protein that, upon cleavage to tBid, is effective in promoting 
apoptosis via the intrinsic pathway (Wang et al., 1996; Sax et al., 2001). Levels of 
Bid protein were largely unaffected by Nutlin-3, ABT-737 or combination treatment 
in any of the cell lines tested. Included in the figures is a longer exposure of the Bid 
blot to detect the cleaved form of Bid, tBid. Cleavage of Bid into tBid was not 
observed in response to any of the treatments in any of the cell lines tested. There 
was a modest increase in Bid protein level in U2OS cells in response to Nutlin-3 
alone (figure 4.2.4.4), however this increase was not observed in cells treated with 
ABT-737 alone or the combination treatment. There was a slight decrease in Bid 
protein level in A498 cells in response to ABT-737 and combination treatments 
when compared to the drug-vehicle treated cells (figure 4.2.2.2).  This data suggests 
that it is unlikely that Bid plays any role in the response to the combination of 
Nutlin-3 and ABT-737, because of the absence of both up-regulation of Bid in 
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response to the combination treatment and subsequent Bid cleavage to its active 
form, tBid. 
 
Noxa is a pro-apoptotic BH3-only domain family member that can be up-regulated 
by p53 in response to various signals (Oda et al., 2000). It was therefore surprising 
that up-regulation of Noxa was not observed in any of the cell lines tested in 
response to Nutlin-3 treatment, but rather Noxa protein levels increased in a number 
of cell lines in response to either ABT-737 treatment alone or in response to the 
combination treatment. ABT-737 treatment alone increased Noxa protein level 
relative to drug-vehicle treatment in ACHN, A498, 115, 111, H1299 and U2OS cells 
(figures 4.2.2.1, 4.2.2.2, 4.2.2.3 and 4.2.2.4). Noxa appeared to be undetectable in 
154 cells and only just detectable in Caki2 cells (figures 4.2.2.1 and 4.2.2.3). The 
combination of Nutlin-3 with ABT-737 did not appear to alter the extent of the Noxa 
up-regulation that was observed in response to the ABT-737 treatment alone in 
ACHN, A498, 115, 111 and H1299 cells (figures 4.2.2.1, 4.2.2.2, 4.2.2.3 and 
4.2.2.4). There was a modest decrease in the level of Noxa in U2OS cells in response 
to the combination treatment when compared to cells treated with the ABT-737 
single treatment (figure 4.2.2.4).  As mentioned in Section 1.2.7.5 of the 
Introduction, ABT-737 can induce up-regulation of Noxa independently of p53 
(Bertin-Ciftci et al., 2013) and this is most likely what is taking place here in the cell 
lines that respond to ABT-737 or combination treatment with up-regulation of Noxa.   
Considering that Noxa up-regulation appeared to be p53-independent in the cell lines 
tested, and synergy between Nutlin-3 and ABT-737 is p53-dependent in RCC cells, it 
is unlikely that Noxa plays an important role in this synergistic induction of  
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Figure 4.2.2.5 Steady state level of p53, MDM2 and proteins associated with 
apoptosis in scACHN and sh-p53ACHN cell lines.  Cells were treated for 36 h 
with 3µM Nutlin-3, 10µM ABT-737 or a combination of both treatments.  Cells 
were harvested and lysates were prepared as described in section 2.4.  20 µg of 
protein was analysed in each lane and antibodies used for detection are described in 
table 2.1.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa. 
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apoptosis although the possibility cannot be eliminated.  Interestingly, up-regulation 
of Noxa was not detected in Caki2 cells, the most sensitive of the cell lines tested to 
ABT-737, in response to ABT-737 treatment.  How therefore this cell line was so 
sensitive to ABT-737 remains unclear. 
 
This experiment showed that p53 was important in enhancing apoptotic signalling in 
the RCC cells harbouring wild type p53 in response to the combination of Nutlin-3 
and ABT-737, for example, up-regulation of Puma was only observed in some of the 
cell lines harbouring wild type p53 but not in the p53 mutant cell lines. To determine 
the extent to which p53 was involved in promoting this response, we performed the 
same experiment described above, but with sc-ACHN cells and sh-p53ACHN cells, 
described in Section 3.2.2 (figure 4.2.2.5). Up-regulation of p53 and MDM2 in 
response to Nutlin-3 treatment in the scrambled control ACHN cell line appeared to 
be more modest in comparison to the parental ACHN cell line. The scrambled 
control ACHN cells did not show increased p53 and MDM2 protein levels in 
response to the combination treatment relative to drug vehicle, which was another 
different response when compared to the parental ACHN cells. As expected, down-
regulation of p53 by short hairpin RNA resulted in a less up-regulation of p53 and 
MDM2 protein in response to Nutlin-3 and the combination treatment, when 
compared to the scrambled control cells. Consistent with the data presented in 
section 3.2.2, that the apoptotic response of RCC cells harbouring wild type p53 in 
response to the combination of Nutlin-3 and ABT-737 is p53-dependent, down 
regulation of p53 by shRNA resulted in reduced PARP cleavage when compared to 
the scrambled control cells.  
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In all of the RCC cell lines harbouring wild type p53, there was no increase in Bax 
protein level in response to treatment with single agents or the combination. It 
therefore followed that down-regulation of p53 with shRNA would have little effect 
on Bax levels in response to treatment with either Nutlin-3 or the combination 
treatment.  There was no detectable difference in the level of Bax protein in the 
ACHN cell line expressing the short hairpin to p53 in response to any of the 
treatments when compared to the equivalent cell line harbouring scrambled shRNA 
(figure 4.2.2.5). Similar to the parental ACHN cell line, the clone of the ACHN cell 
line expressing scrambled shRNA showed increased Puma levels in response to 
treatment with Nutlin-3. Unlike the parental cell line however, Puma protein level 
did not increase in response to the combination of Nutlin-3 and ABT-737. Up-
regulation of Puma in response to either Nutlin-3 or the combination of Nutlin-3 and 
ABT-737 was only observed in cell lines that harboured wild type p53, with the 
exception of the 117 cell line, that had extremely low levels of wild type p53. 
Because of the responsiveness of Puma to wild type p53 in these RCC cells, it is not 
surprising that basal levels of Puma, would be lower in the cells that had reduced 
expression of wild type p53. This was indeed observed in the sh-p53ACHN cells 
when compared to scACHN cells (figure 4.2.2.5); there was a lower basal level of 
Puma in the cells that had reduced levels of p53. By extension of this, it followed 
that there would be a reduced up-regulation of Puma in the ACHN cell line that had 
down-regulated p53 expression as a result of shRNA to p53 in response to Nutlin-3. 
Indeed, in response to Nutlin-3, Puma was up-regulated in the ACHN cells 
harbouring shRNA to p53, however the degree to which Puma was up-regulated was 
less than that observed in the cells that had scrambled control shRNA. Therefore, 
Puma up-regulation in response to Nutlin-3 is p53-dependent, as expected. 
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Similar to Bax protein levels in the RCC cells harbouring wild type p53, there were 
no fluctuations in Bid protein level in response to either Nutlin-3 or the combination 
of Nutlin-3 and ABT-737. The level of Bid protein, and the cleaved form of this 
protein, tBid, was unaltered ACHN cells harbouring scrambled control shRNA in 
response to single agents and the combination treatment. Down-regulation of p53 
with shRNA did not have any affect on the Bid or tBid protein levels in response to 
single agents or the combination treatment (figure 4.2.2.5).  Therefore, it may be 
implied that transcription of neither Bid, nor Bax can be promoted by p53 in RCC 
cells harbouring wild type p53 and that basal transcription of genes coding for both 
of these proteins is regulated by another mechanism. 
 
An increase in Noxa protein level was observed in H1299, U2OS, A498, 115, 111 
and ACHN cells in response to ABT-737. A p53-independent mechanism for the 
induction of Noxa in response to ABT-737 is discussed in the section 1.2.7.5, hence 
it is unsurprising that Noxa levels increased in cell lines with wild type or mutant 
p53 status or indeed p53-null cells. The existence of a p53-independent pathway for 
the induction of Noxa did not preclude the possibility of p53 contributing towards 
the increased level of Noxa protein in the RCC cells harbouring wild type p53 in 
response to ABT-737 and the combination treatment.  The absence of Noxa 
induction in any of the cell lines tested in response to Nutlin-3 treatment was a very 
interesting observation.  Noxa has been observed to be induced by Nutlin-3 treatment 
in other cell lines that harbour wild type p53 (Tabe et al., 2009; Bhattacharya et al., 
2011) hence it is likely that the absence of Nutlin-3-mediated Noxa induction is a 
phenomenon that is particular to RCC cells.  Why Puma was induced in RCC cells in 
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response to Nutlin-3 treatment in RCC cells but Noxa not induced is a topic for 
further investigation.  There was an increase in Noxa protein in response to ABT-737 
and the combination of Nutlin-3 and ABT-737 in the ACHN cell line harbouring 
scrambled shRNA, as previously observed in the parental ACHN cell line (figure 
4.2.2.5). There was also an increase in the level of Noxa protein in response to ABT-
737 and the combination treatment in the ACHN cell line that harboured shRNA to 
p53, however this was to a lesser degree than that observed in the scrambled control 
cell line.   This result suggested that the Noxa up-regulation in response to ABT-737 
and the combination treatment in the RCC cells harbouring wild type p53 is at least 
partially dependent upon the presence of wild type p53.  The observation that Noxa 
levels can be modulated by p53 in these cells suggests that Noxa induced by ABT-
737 may contribute to the synergy observed between Nutlin-3 and ABT-737. 
 
As expected, the combination of Nutlin-3 and ABT-737 promotes an up-regulation 
of pro-apoptotic proteins in the cell lines tested, particularly in the RCC cells 
harbouring wild type p53. In response to treatment with Nutlin-3 p53 was up-
regulated in all of the cell lines harbouring wild type p53 with the exception of 117 
cells. This is inconsistent with the observations of Polanski et al., wherein 
stabilization of p53 was observed in 117 cells in response to Nutlin-3 treatment. This 
inconsistency may be explained by the differences in experimental conditions used. 
Cells in our experiment were treated with 3µM Nutlin-3 for 36h whereas 117 cells in 
Polanski et al., were treated for 48h at a minimum concentration of 5µM Nutlin-3. 
 
Up-regulation of Puma as a result of p53 stabilization may be important in the pro-
apoptotic response to the combination treatment in the RCC cells harbouring wild 
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type p53 because of the established role of Puma in apoptosis. The absence of Puma 
up-regulation in RCC cell lines harbouring mutant p53 and the decreased level of 
Puma induction in the ACHN cells with down-regulated p53 would support this 
reasoning. The up-regulation of Noxa in response to the combination treatment 
observed in four p53 wild type cell lines, one of the mutant p53 cell lines and a p53 
null cell line implies a more modest role for Noxa in the pro-apoptotic response to 
this combination treatment. The balance between Noxa and Mcl-1 protein levels are 
important in response to ABT-737 if apoptosis is to be achieved (Van Delft et al., 
2006; Tromp et al., 2012). Intriguingly, Caki2 cells were the most sensitive to 
treatment with ABT-737 alone, of all of the cell lines tested in this study yet up-
regulation of Noxa was not observed neither in response to ABT-737 nor 
combination treatment. This may be accounted for by the very low levels of Mcl-1 in 
Caki2 cells (section 4.2.1). The 115 cell line had an identical pattern of levels of Bcl-
2 family member proteins, with the exception of higher Bcl-xL protein level than 
Caki2 yet was ten-fold more resistant to ABT-737 than the Caki2 cells. It is unlikely 
this difference in sensitivity between both Caki2 and 115 cell lines can be explained 
by differences in levels of Bcl-xL protein alone, because Bcl-xL is not the most 
important target for inhibition by ABT-737 (Rooswinkel et al., 2012).  In the 
following section, the issue of Bax and Bak activation in response to the combination 
of Nutlin-3 and ABT-737 RCC cells is addressed. 
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4.2.3 The combination of Nutlin-3 and ABT-737 promotes Bax oligomerization at 
mitochondria 
It was shown in section 3.2.1 that the combination of Nutlin-3 and ABT-737 
synergistically inhibits the proliferation of RCC cells harbouring wild type p53.  
Furthermore, it was shown in sections 3.2.2 and 3.2.3 that this inhibition of 
proliferation was due to cell death in the form of apoptosis and that this cell death 
was p53-dependent.  Data presented in section 4.2.2 showed that this combination of 
Nutlin-3 and ABT-737 did not result in an increase in level of pro-apoptotic Bax 
protein, an effector of apoptosis that is a transcriptional target of p53 (see in Section 
1.2.8). 
 
As discussed in the 1.2.7 and 1.2.7.4, an essential requirement for the intrinsic 
pathway of apoptosis to take place is the homo-multimerization of Bak, Bax, or both 
proteins at the mitochondrial outer membrane (MOM).  Multimerization of Bak 
and/or Bax at the MOM results in formation of pores at the MOM, leading to an 
efflux of apoptogenic factors from the inter-mitochondrial space in a process termed 
mitochondrial outer membrane permeabilization (MOMP).  Caspase activation 
results from this release of apoptogenic factors and cellular destruction ensues.   
 
Bax and Bak activation are complex, multi-step processes involving allosteric 
interactions with other proteins and conformational changes that lead to an activated 
state; this results in oligomerization of Bax and/or Bak at the MOM.  The absence of 
an increase in the level of Bax protein as a result of either Nutlin-3 or the 
combination of Nutlin-3 and ABT-737 does not preclude the possibility that Bax 
activation can occur without an increase in Bax protein level (Kojima et al., 2006; 
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Henry et al., 2012).  Indeed, as shown in section 4.2.2, changes in the levels of Puma 
and Noxa are observed in response to treatment of RCC cells harbouring wild type 
p53 with the combination of Nutlin-3 and ABT-737.  We therefore hypothesised that 
this increase in the levels of Puma and Noxa may be involved in the activation of 
Bax, Bak or both proteins to form oligomers at the MOM. 
 
Individual Bak or Bax molecules possess non-reduced cysteine residues that are 
brought into close proximity with each other when Bak or Bax oligomerize.  Homo-
bifunctional cross-linkers, such as bismaleimidohexane (BMH) can be used to 
irreversibly bind individual Bak or Bax molecules within an oligomer to one another 
(figure 4.2.3.1) (Wei et al., 2000; reviewed in Renault et al., 2013).  Using chemical 
cross-linking and isolation of mitochondria it can be demonstrated that Bax and/or 
Bak oligomers co-purify with mitochondria.  Oligomerized Bak/Bax that has been 
can subsequently be detected on a SDS-PAGE gel, with slower migrating bands 
representing the oligomerized form of Bak/Bax. 
 
To determine whether Bax, Bak or both proteins were forming oligomers at the 
MOM in response to treatment of RCC cell with the combination of Nutlin-3 and 
ABT-737, chemical cross-linking in combination with subcellular fractionation by 
differential centrifugation were used to identify oligomers of these proteins on SDS-
PAGE gels.   
 
A protocol to lyse cells, leaving most mitochondria intact, followed by differential 
centrifugation to enrich for mitochondria and finally, cross-linking of mitochondrial 
proteins, was optimized.  The following is a description of the optimization of the  
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Figure 4.2.3.1 Schematic illustrating stabilization of Bax oligomer with BMH.  
Addition of BMH irreversibly stabilizes the oligomerized form of Bax or Bak (not 
shown).  Each reactive groups of BMH forms a covalent bond with a sulphydryl-
group from a different Bax molecule. 
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lysis stage of the protocol.  Hypotonic shock followed by homogenization with a 
Potter-Elvehjem homogenizer was used to lyse cell membranes but leave organellar 
membranes unperturbed.  Cells were harvested and washed twice in PBS then re-
suspended in 1 X RSB buffer, a hypotonic, detergent-free buffer used for lysis of cell 
membrane (a detailed description of the composition of the buffer is presented in 
Section 2.5).  Swelling of the cells was then monitored using a phase contrast 
microscope.  Figure 4.2.3.2a shows cells suspended in isotonic PBS, which did not 
appear to cause swelling.  Figure 4.2.3.2b shows cells suspended in RSB for 2 
minutes, which resulted in some swelling.  As time progressed, an increase in the cell 
swelling took place. Figure 4.2.3.2c shows cells suspended in RSB after 15 minutes.  
After 15 minutes, the cells were transferred to the homogenizer and homogenized 
initially with 30 strokes (figure 4.2.3.2d).  This did not result in sufficient breakage 
of the cells, hence the cells were subjected to a further 30 strokes in the homogenizer 
(figure 4.2.3.2.e).  Some intact cells were present after the accumulated 50 strokes, 
which are indicated by white triangles on figure 4.2.3.2e, and the cells were 
subjected to another 20 strokes (figure 4.2.3.2f).  Figure 4.2.3.2f shows almost 100% 
cell breakage, with intact nuclei marked by white arrows.  To protect membrane 
bound organelles in the homogenate from the low tonicity of the RSB buffer, 2 X 
MS buffer was added to raise the tonicity of the suspension.  It was thus determined 
that 15 minutes of swelling in RSB followed by 70 strokes with the homogenizer 
were necessary to disrupt the cell membrane. 
 
Following disruption of the cell membrane, the homogenate was centrifuged at 1,300 
x g for 5 minutes to pellet nuclei, unbroken cells, large membrane fragments and 
other debris.  The pellet from this centrifugation step was kept and designated the ‘1st  
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Figure 4.2.3.2 Optimization of homogenization of ACHN cells.  ACHN cells were 
suspended in hypotonic RSB buffer and swelling was monitored using a phase 
contrast microscope as described in Sections 2.5 and 4.2.3.  Panels a – f do not 
represent the same field of cells.  White triangles indicate undisrupted cells.  White 
arrows indicate intact nuclei of disrupted cells. 
a - cells suspended in isotonic PBS. 
b - cells after 2 minutes suspension in hypotonic RSB. 
c - cells after 15 minutes suspension in RSB. 
d - cells after 30 strokes in the Potter-Elvehjem homogenizer. 
e - cells after 50 strokes in the Potter-Elvehjem homogenizer. 
f - cells after 70 strokes in the Potter-Elvehjem homogenizer. 
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pellet’.  The supernatant was transferred to a new tube and centrifuged again.  This 
centrifugation step was repeated until no pellet could be observed at the end of the 
centrifugation.  The supernatant was then centrifuged at 17,000 x g for 30 minutes to 
pellet mitochondria.  The supernatant was kept as the cytosolic fraction. 
 
For the first attempt of this experiment, the mitochondrial pellet was lysed in SLIP 
buffer and insoluble material cleared by centrifugation.  This mitochondrial protein 
that remained in the SLIP buffer was quantified then treated with either 10mM 
BMH-DMSO or DMSO for 30 minutes.  The cross-linking reaction was quenched by 
diluting 0.5M DTT to a 1:20 final concentration in the cross-linking reaction 
mixture.  To monitor the quality of the fractionation procedure, the presence of 
different proteins as markers for the enrichment of different organellar fractions were 
observed on a western blot.  Histone H3 was used as a marker for the nuclear protein, 
cytochrome C oxidase IV (COX4) was used as a marker for mitochondrial protein 
and Tubulin was used as a marker for cytosolic protein. Figure 4.2.3.3 shows an 
enrichment of mitochondria compared to whole cell lysate, suggesting that the 
differential centrifugation protocol was capable of isolating mitochondria from a 
crude homogenate of cells.  There was an increase in the presence of histone H3 in 
the mitochondrial fractions from cells treated with ABT-737 and cells treated with 
the combination of both Nutlin-3 and ABT-737.  There appeared to be a smaller 
band that was cross-reactive for a smaller Histone H3 fragment below the major 
band of Histone H3, in the all of the fractions from cells that were treated with the 
combination but not the other treatments.  As described in Section 3.2.3, cells treated 
with ABT-737 or the combination of Nutlin-3 and ABT-737 more readily underwent  
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Figure 4.2.3.3 Subcellular fractionation of ACHN cells.  Cells were homogenized 
and then fractionated as described in section 4.2.3 and mitochondria were lysed and 
clarified lysate was subsequently treated with 10mM BMH. “1st” indicates first pellet 
following first centrifugation of homogenate. “M” indicates mitochondrial fraction. 
“C” indicates cytoplasmic fraction.  5µg of protein was analyzed in each lane and 
antibodies used for detection are described in table 2.1.  The migration of protein 
standards of the indicated approximate molecular weights are shown in kDa. 
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Figure 4.2.3.4 Western blot of mitochondrial lysates treated with BMH or 
DMSO.  Lysate of mitochondria from ACHN cells treated with either drug vehicle, 
Nutlin-3, ABT-737 or a combination of drugs was treated with either DMSO or 
BMH and analysed by western.  The whole membrane was probed with antibody to 
Bax.  Black circles indicate the position of putative monomers and oligomers of Bax 
(table 2.1).  5µg of protein was analyzed in each lane.  The migration of protein 
standards of the indicated approximate molecular weights are shown in kDa. 
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Figure 4.2.3.5 Western blot of mitochondrial lysates treated with BMH or 
DMSO.  Lysate of mitochondria from ACHN cells treated with either drug vehicle, 
Nutlin-3, ABT-737 or a combination of drugs was treated with either DMSO or 
BMH and analysed by western.  The whole membrane was probed with antibody to 
Bak.  Black circles indicate the position of monomeric Bak.  5µg of protein was 
analysed in each lane and antibody used for detection is described in table 2.1.  The 
migration of protein standards of the indicated approximate molecular weights are 
shown in kDa. 
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apoptosis in comparison to cells treated with vehicle control or Nutlin-3 only.  Thus, 
the increase in Histone H3 in the mitochondrial fractions in cells treated with ABT-
737 and the combination treatment may be attributed to micro-nucleation that takes 
place during apoptosis.  Figure 4.2.3.4 shows the mitochondrial fractions from the 
cells treated with vehicle, Nutlin-3, ABT-737 or a combination of both treatments 
resolved on an SDS-PAGE gel.  Bax is detected on a SDS-PAGE at ~23 kDa. The 
presence of slower migrating Bax at ~46 kDa suggested that treatment with BMH 
resulted what appeared to be stabilisation of Bax dimers. There appeared to be a 
slight increase in Bax dimer formation in the mitochondria of cells treated with 
Nutlin-3 or the combination treatment, relative to vehicle and ABT-737 alone.  
Figure 4.2.3.5 shows the same lysates in the previous figure but the membrane from 
the western blot was probed with an antibody against Bak.  There was no evidence 
for any oligomerization of Bak in response to the combination of Nutlin-3 and ABT-
737 upon cross-linking of mitochondrial protein.  Slower migrating forms of Bax, 
such as trimers and tetramers were not present on the SDS-PAGE gel.  One 
possibility that could explain the absence of slower migrating forms of Bax from 
figure 4.2.3.4 was that Bax oligomers required stabilisation with BMH as soon as 
possible after disruption of the cell membrane, rather than stabilizing with BMH 
after the long process of differential centrifugation, lysis of mitochondria and 
quantification of protein.  The protocol was modified to reflect this possibility. 
 
The cells were treated with drug vehicle, Nutlin-3, ABT-737 and the combination 
treatment as described previously.  The homogenization was performed as described 
previously and the homogenate was centrifuged once at 1,300 x g to remove most of 
the debris.  The supernatant from this centrifugation was immediately treated with  
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Figure 4.2.3.6 Subcellular fractionation of ACHN cells following treatment of 
homogenate with BMH or DMSO.  ACHN cells were homogenized as described in 
section 4.2.3 and the homogenates were treated with either DMSO or 10mM BMH to 
a final concentration of 10% DMSO.  Following cross-linking and quenching with 
0.5M DTT, homogenates were fractionated by differential centrifugation.  “1st” 
indicates first pellet following first centrifugation of homogenate. “M” indicates 
mitochondrial fraction. “C” indicates cytoplasmic fraction.  5µg of protein was 
analysed in each lane and antibodies used for detection are described in table 2.1.  
The migration of protein standards of the indicated approximate molecular weights 
are shown in kDa. 
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Figure 4.2.3.7 Western blot of mitochondria from ACHN cells treated with 
DMSO or BMH in homogenate.  ACHN cells were treated with drugs and 
homogenized as described previously.  Following one centrifugation step, DMSO or 
BMH was added to the homogenate to a final concentration of 10%.  Quenching and 
fractionation was carried out as described in section 4.2.3.  The whole membrane 
was probed with antibody to Bax (table 2.1).  5µg of protein was analysed in each 
lane.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa.  Black circles indicate the position of monomeric Bax and 
putative Bax oligomers.   
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either DMSO or BMH dissolved in DMSO for 30 minutes, to a final concentration of 
10% DMSO.  The reaction was quenched using DTT as described previously.  This 
was followed by several centrifugation steps at 1,300 x g to remove the remaining 
debris from homogenization and isolation of mitochondria, followed by lysis and 
quantification of protein as described above.  As observed previously, histone H3 
signal was observed in the mitochondrial and cytosolic fractions in the ABT-737 and 
combination treated cells (figure 4.2.3.6).  COX4 signal was observed in 1st pellet, 
mitochondrial and cytosolic fractions, suggesting this fractionation was not as 
effective as the previous attempt.  Figure 4.2.3.7 shows the mitochondrial fractions 
from this experiment on membrane transferred from an SDS-PAGE gel treated with 
antibody to Bax.  Slower migrating forms of Bax are apparent in both the cross-
linked ABT-737 and combination treated cells and these slower migrating forms are 
less abundant in the vehicle and Nutlin-3 treated cells.  Taken together, these figures 
suggest that addition of BMH directly to the homogenate before isolation of 
mitochondria stabilised Bax sufficiently for the detection of slower migrating forms 
of the protein; however, this may have had an affect on the integrity of the 
mitochondria in the homogenate.  Because DMSO is a potent solvent, there was a 
possibility that mitochondrial membranes were dissolved by the high concentration 
of DMSO added to the homogenate.  Thus, the protocol was modified so that a lower 
concentration of DMSO was added to the homogenate. 
 
The experiment was performed exactly as described previously, with the exception 
of the final concentration of DMSO or BMH dissolved in DMSO added to the 
homogenate.  DMSO or BMH dissolved in DMSO was added to a final  
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Figure 4.2.3.8 Subcellular fractionation of ACHN cells following treatment of 
homogenate with BMH or DMSO.  ACHN cells were homogenized as described in 
section 4.2.3 and the homogenates were treated with either DMSO or 10mM BMH to 
a final concentration of 1% DMSO.  Following cross-linking and quenching with 
0.5M DTT, homogenates were fractionated by differential centrifugation.  “1st” 
indicates first pellet following first centrifugation of homogenate. “M” indicates 
mitochondrial fraction. “C” indicates cytoplasmic fraction.  5µg of protein was 
analysed in each lane and antibodies used for detection are described in table 2.1.  
The migration of protein standards of the indicated approximate molecular weights 
are shown in kDa. 
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concentration of 1% of the total volume of homogenate for 30 minutes.  Subsequent 
isolation of mitochondria was as described above.  Histone H3 was again observed in 
the mitochondrial fractions of ABT-737 and combination treated cells, consistent 
with the previous two experiments.  The COX4 signal was enriched in the 
mitochondrial fraction and absent from the cytosolic fraction, mimicking the first 
experiment (figures 4.2.3.8 and 4.2.3.3 respectively), suggesting that the higher 
concentration of DMSO in the previous experiment may have been responsible for 
the COX4 signal observed in the cytosolic fraction. Figure 4.2.3.9 shows the 
mitochondrial fractions from this experiment on membrane transferred from an SDS-
PAGE gel treated with antibody to Bax.  Slower migrating forms of Bax were only 
present on this figure where the cells had been treated with the combination of 
Nutlin-3 and ABT-737 followed by cross-linking.  These slower migrating forms 
appeared to run predominantly at slightly over 30 kDa, ~45 kDa and roughly 58 kDa.  
A longer exposure of the same western blot, shows that fainter bands are present that 
migrate at approximately 50 kDa and 80 kDa.  Monomeric Bax ran at ~23kDa.  The 
slower migrating form of Bax present at 30 kDa may have represented monomeric 
Bax cross-linked to another protein.  The slower migrating forms of Bax at ~45 and 
58 kDa respectively may have represented both dimers and trimers of Bax.  The 
same samples were run on an SDS-PAGE gel and transferred onto a membrane that 
was treated with an antibody towards Bak (figure 4.2.3.10).  Slower migrating forms 
of Bak were observed at ~60 kDa.  A very high exposure of the western blot was 
required to observe this slower migrating from, suggesting this form of Bak was in 
low abundance in comparison to the monomeric form of Bak.  Because monomeric 
Bak runs at 29 kDa, the slower migrating form of Bak running at ~60 kDa may have 
represented dimeric Bak.  There appeared to be a higher level of this putative dimeric  
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Figure 4.2.3.9 Western blot of mitochondria from ACHN cells treated with 
DMSO or BMH in homogenate.  ACHN cells were treated with drugs and 
homogenized as described previously.  Following one centrifugation step, DMSO or 
BMH was added to the homogenate to a final concentration of 1 %.  Quenching and 
fractionation was carried out as described in section 4.2.3.  The whole membrane 
was probed with antibody to Bax (table 2.1).  5µg of protein was analysed in each 
lane.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa.  Black circles indicate the position of monomeric Bax and 
putative Bax oligomers.  Short exposure top, long exposure bottom. 
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Figure 4.2.3.10 Western blot of mitochondria from ACHN cells treated with 
DMSO or BMH in homogenate.  ACHN cells were treated with drugs and 
homogenized as described previously.  Following one centrifugation step, DMSO or 
BMH was added to the homogenate to a final concentration of 1 %.  Quenching and 
fractionation was carried out as described in section 4.2.3.  The whole membrane 
was probed with antibody to Bak (table 2.1).  5µg of protein was analysed in each 
lane.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa.  Black circles indicate the position of monomeric Bak and 
putative Bak oligomers.  Short exposure top, long exposure bottom. 
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Bak in cells treated with both Nutlin-3 and ABT-737 followed by cross-linking.  
Hence, it appeared that it was Bax that is implicated in mediating the apoptotic 
response to the combination of Nutlin-3 and ABT-737 rather than Bak, because of 
the increased presence of slower migrating forms of Bax in comparison to Bak. 
 
Previously, we showed that there was a slight increase in apoptotic cells in the 
mutant p53 111 cell line in response to the combination of Nutlin-3 and ABT-737 in 
comparison to the control.  Because 111 cells are mutated for p53, and it had 
previously been shown that cell death in response to the combination of Nutlin-3 and 
ABT-737 was dependent on wild type p53 (Section 3.2.2), we hypothesised that 
involvement of Bax or Bak in the response of 111 cells to the combination treatment 
we be to a lesser degree than observed in ACHN cells.  Figure 4.2.3.11 shows the 
western blots for the different fractions probed with antibodies to histone H3, COX4 
and tubulin.  This figure showed that a similar distribution of histone H3 was 
observed in this cell line as was observed in the ACHN cells, although there was an 
absence of the cleaved Histone H3 fragment observed previously.  Because some 
apoptosis took place in the 111 cell line in response to ABT-737 alone and the 
combination treatment (see figure 3.2.3.9), it was unsurprising that histone H3 was 
present in both the mitochondrial fraction and the cytosolic fraction in response to 
these treatments.  There was a clear depletion of the tubulin signal from the 
mitochondrial fraction and a depletion of COX4 from the cytosolic fraction, 
suggesting the fractionation was effective.  Figure 4.2.3.12 shows a western blot 
showing the mitochondrial fractions of 111 cells treated for 36h with vehicle, Nutlin-
3, ABT-737 or combination treatment, with or without cross-linking.  Some bands of 
what appeared to be higher migrating Bax forms were visible at ~58 kDa.  A longer  
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Figure 4.2.3.11 Subcellular fractionation of 111 cells following treatment of 
homogenate with BMH or DMSO.  111 cells were homogenized as described in 
section 4.2.3 and the homogenates were treated with either DMSO or 10mM BMH to 
a final concentration of 1% DMSO.  Following cross-linking and quenching with 
0.5M DTT, homogenates were fractionated by differential centrifugation.  “1st” 
indicates first pellet following first centrifugation of homogenate. “M” indicates 
mitochondrial fraction. “C” indicates cytoplasmic fraction.  5µg of protein was 
analysed in each lane and antibodies used for detection are described in table 2.1.  
The migration of protein standards of the indicated approximate molecular weights 
are shown in kDa. 
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Figure 4.2.3.12 Western blot of mitochondria from 111 cells treated with DMSO 
or BMH in homogenate.  111 cells were treated with drugs and homogenized as 
described previously.  Following one centrifugation step, DMSO or BMH was added 
to the homogenate to a final concentration of 1 %.  Quenching and fractionation was 
carried out as described in section 4.2.3.  The whole membrane was probed with 
antibody to Bax (table 2.1).  5µg of protein was analysed in each lane.  The 
migration of protein standards of the indicated approximate molecular weights are 
shown in kDa.  Black circles indicate the position of monomeric Bax and putative 
Bax oligomers.  Short exposure top, long exposure bottom. 
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Figure 4.2.3.13 Western blot of mitochondria from 111 cells treated with  
DMSO or BMH in homogenate.  111 cells were treated with drugs and 
homogenized as described previously.  Following one centrifugation step, DMSO or 
BMH was added to the homogenate to a final concentration of 1%.  Quenching and 
fractionation was carried out as described in section 4.2.3.  The whole membrane 
was probed with antibody to Bak (table 2.1).  5µg of protein was analysed in each 
lane.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa.  Black circles indicate the position of monomeric Bak and 
putative Bak oligomers.  Short exposure top, long exposure bottom. 
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Figure 4.2.3.14 Summary of approaches taken to co-purify Bax and/or Bak 
oligomers with mitochondria.  “Modification to protocol” represents the different 
approaches described in the main text.  “Final figure” represents the figures in this 
section that were a result of the different modifications made. 
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exposure of this western blot shown in figure 4.2.3.12 shows that this higher 
migrating form of Bax was present in all of the treatment conditions, with and 
without cross-linking.  Hence, these slower migrating forms of Bax were more likely 
to be an artefact on the western blot.  Figure 4.2.3.13 shows the mitochondrial 
fractions from the treated 111 cells but detected with an antibody towards Bak.  On 
initial inspection, it appeared that the BMH-treated mitochondria contained less Bak 
protein than DMSO-treated mitochondria from this experiment (figure 4.2.3.13).  
The longer exposure of this western blot however showed that BMH-treatment of 
these mitochondria results in the apparent dimerization of Bak, independent of the 
drug-treatment used on the cells.  Why BMH induced dimerization of Bak at the 
mitochondria 111 cells regardless of drug-treatment used remains to be elucidated. 
 
The absence of slower migrating Bax and Bak in the cross-linker-treated 
mitochondrial fractions from 111 cells treated with the combination of Nutlin-3 and 
ABT-737 suggested that the recruitment of the machinery involved in the intrinsic 
apoptosis pathway in response to this treatment is peculiar to RCC cells harbouring 
wild type p53.  In conclusion, the slower migrating forms of Bax present in the 
cross-linker-treated mitochondrial fractions from ACHN cells implicated Bax 
oligomerization in the apoptotic response to the combination of Nutlin-3 and ABT-
737.   The absence of these slower migrating forms in the analogously treated 111 
cells suggests a role for p53 in this Bax oligomerization.  This implies that apoptosis 
in response to the combination of Nutlin-3 and ABT-737 is Bax-dependent.  Figure 
4.2.3.14 summarises the different approaches taken in this experiment.  Considering 
that ABT-737 alone induces some apoptosis in both ACHN and 111 cells, and that 
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oligomerization of Bax and/or Bak is a pre-requisite for intrinsic apoptosis, it is 
surprising that oligomers of neither protein were detected in response to ABT-737 in 
either cell line upon crosslinking.  It is possible that the presence of oligomerized 
Bax/Bak was below a certain threshold necessary for cross-linking and subsequent 
detection using this technique.  To summarize, Bax appears to form oligomers at the 
mitochondria of ACHN cells in response to the combination of Nutlin-3 and ABT-
737, suggesting that apoptosis observed in response to this treatment is Bax-
dependent.  This possibility will be discussed in the next section.  Interestingly, 
whilst the Bax protein level itself was not increased in response to Nutlin-3 (figure 
4.2.2.1) or the combination of Nutlin-3 and ABT-737, this data suggests that  there is 
an alternative mechanism through which Bax multimerization at the mitochondria 
can take place in the absence of up-regulation of Bax. 
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4.2.4 Apoptosis in response to the combination of Nutlin-3 and ABT-737 is Bax-
dependent 
In the previous section, isolation of mitochondria and chemical cross-linking were 
used to show that Bax was a possible mediator of MOMP, resulting in apoptosis in 
response to treatment with Nutlin-3 and ABT-737.  To determine whether it was 
indeed Bax that was responsible for promoting apoptosis in response to this 
treatment, it was hypothesised that down-regulation of Bax using siRNA followed by 
treatment with the combination of Nutlin-3 and ABT-737 would confer some 
protection to cells from apoptosis.  To determine if this was the case, 4 different 
siRNAs were tested on ACHN cells to determine which siRNA would be the most 
effective at reducing Bax expression. 
 
ACHN cells were transfected with siRNA to a final concentration of 32nM using 
Lipofectamine 2000 as described in Section 2.2.5.  ACHN cells were mock 
transfected or transfected with scrambled siRNA or Bax siRNAs 1-4.  Cells were 
harvested at 24, 48 and 72 hours post-transfection and lysates were analysed by 
western blot as described in Section 2.4.2.  Figure 4.2.4.1 shows a western blot of the 
level of Bax protein in transfected cells at 24, 48 and 72 hours after transfection.  At 
24 h post-transfection, there was a decrease in the level of Bax protein in cells that 
were transfected with siRNAs 3 and 4 (figure 4.2.4.1) relative to mock treated cells 
and cells transfected with scrambled siRNA.  At 48 h, there was a decrease in Bax 
protein level only in cells that were treated with siRNA 4.  At 72h post-transfection, 
there appeared to be a decrease in Bax protein level in cells that were treated with  
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Figure 4.2.4.1 Optimization of Bax knockdown in ACHN cells using siRNA.  
ACHN cells were transfected with Lipofectamine-2000 according to the 
manufacturer’s instructions.  At time (T) 24, 48 and 72 hours post-transfection, cells 
were harvested, lysates were prepared and analysed by western blot as described in 
Section 2.4.  Proteins were probed as indicated.  20µg of protein was analysed in 
each lane and the antibody used for detection of Bax is described in table 2.1.  The 
migration of protein standards of the indicated approximate molecular weights are 
shown in kDa. 
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Figure 4.2.4.2 Knockdown of Bax in ACHN cells transfected with siRNAs 3 and 
4.  ACHN cells were transfected with siRNAs to Bax 3 and 4 using Lipofectamine-
2000.  Cells were harvested 24h after transfection and lysates were prepared as 
described in Section 2.4.2 and subjected to analysis by western blot.  20µg of protein 
was analysed in each lane and the antibody used for detection of Bax is described in 
table 2.1.   
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siRNAs 3 and 4.  siRNA to Bax numbers 3 and 4 were duly chosen for the 
experiment. 
 
To determine whether the apoptotic response to the combination of Nutlin-3 and 
ABT-737 was indeed Bax-dependent, ACHN cells were mock transfected or 
transfected with either Bax siRNA 3 or 4 or scrambled control siRNA.  24h 
following transfection, cells from each transfection condition was treated with 
vehicle, Nutlin-3, ABT-737 or a combination of both Nutlin-3 and ABT-737.  After 
36h of drug treatment, cells were harvested and subjected to Annexin V and PI 
staining followed by FACS analysis as described in Section 2.3.2.  Figure 4.2.4.2 
shows the western blot for the siRNA-mediated knockdown of Bax in ACHN cells 
prior to treatment with the drugs or drug vehicle.  The Bax siRNA 3 lane appeared to 
be slightly under-loaded relative to the other three lanes in this figure, however there 
was a reduction in the level of Bax protein in the lane containing protein from cells 
transfected with siRNA 4 treated relative to the other two treatments.  Dot plots from 
flow cytometry of the treated cells are shown in figure 4.2.4.3 and the overall 
percentages of Annexin V positive cells in all of the treatments used are summarized 
in figure 4.2.4.4.  See Sections 2.3.2 and 3.2.3 for discussions regarding 
interpretation of Annexin V and PI positivity.  Mock transfected cells and cells 
transfected with scrambled control siRNA behaved similarly in response to the 
different treatments used.  Treatment with ABT-737 resulted in some apoptosis in 
cells transfected this way (figure 4.2.4.4, 16.9% and 15.08% apoptotic cells 
respectively).  Treatment with the combination of Nutlin-3 and ABT-737 resulted in 
greater apoptosis than observed with the single treatments alone.  This was consistent 
with the response of ACHN cells to the combination of Nutlin-3 and ABT-737 
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described in Section 3.2.3.  There appeared to be an increased positivity for Annexin 
V in the combination-treated cells resulting in what appears to be a migration of the 
population of live cells in the lower left quadrant of the dot plot into the lower right 
quadrant (figure 4.2.4.3).  In response to the combination of Nutlin-3 and ABT-737, 
62.93% of mock-transfected cells and 61.08% of scrambled control transfected cells 
underwent apoptosis (figure 4.2.4.4).  Hence, mock-transfected ACHN cells and 
ACHN cells transfected with scrambled siRNA responded to the combination of 
Nutlin-3 and ABT-737 much as un-transfected ACHN cells did (figures 3.2.3.7 and 
3.2.3.9). 
 
ACHN cells transfected with either siRNA 3 or 4 to Bax responded to the single drug 
treatments in a similar fashion to the mock transfected and scramble control 
transfected cells (figures 4.2.4.3 and 4.2.4.4).  In response to the combination of both 
Nutlin-3 and ABT-737 however, there was decrease in the number of cells 
undergoing apoptosis in the cells that were treated with siRNA to Bax when 
compared to the mock-transfected cells and the cells transfected with scrambled 
siRNA.   In response to the combination treatment, 43.39% of cells transfected with 
Bax siRNA 3 and 33.10% of cells transfected with Bax siRNA 4 underwent 
apoptosis.  This is a decrease from the ~60% apoptosis observed in mock transfected 
cells and cells transfected with scrambled siRNA when treated with the combination 
of Nutlin-3 and ABT-737, suggesting that apoptosis in response to the combination 
of Nutlin-3 and ABT-737 was Bax-dependent.  The population of cells that appeared 
to migrate to the lower right quadrant in response to the combination treatment in the 
mock and scrambled siRNA treated cells remained in the lower left quadrant when 
cells were transfected with either siRNA to Bax (figure 4.2.3.3). 
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Figure 4.2.4.3 Analysis of apoptosis and cell death in ACHN cells treated with 
Nutlin-3 and/or ABT-737 upon down-regulation of Bax (I).  ACHN cells were 
transfected using Lipofectamine-2000 with the relevant siRNA to a final 
concentration of 32nM siRNA.  24 h after transfection, cells were treated with drug 
vehicle, Nutlin-3, ABT-737 or a combination of both treatments.  36 h after 
treatment with drug, cells were harvested and stained with Annexin V and PI then 
subject to analysis by flow cytometry as described in Section 2.3.2.  Dot plots 
represent analysis of 20 000 cells. 
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Figure 4.2.4.4 Analysis of apoptosis and cell death in ACHN cells treated with 
Nutlin-3 and/or ABT-737 upon down-regulation of Bax (II).  Summary of flow 
cytometry analysis of ACHN cells that were mock transfected or transfected with 
scrambled siRNA or siRNA to Bax.  24h following transfection, cells were 
treated3µM Nutlin-3, 10µM ABT-737 or a combination of both treatments for 36h.  
Histogram bars represent the sum of lower right quadrant events (apoptotic cells) and 
upper right quadrant events (cells that had died as result of apoptosis). 
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Transfection of ACHN cells with siRNA to Bax appeared to partially rescue the cells 
from the pro-apoptotic affects of the combination of Nutlin-3 and ABT-737.  This 
was not observed in mock-transfected cells or cells transfected scrambled siRNA.  
This suggested that apoptosis in response to the combination of Nutlin-3 and ABT-
737 in RCC cells was Bax-dependent.  Some of the cells that were transfected with 
siRNA to Bax died (upper right quadrants, figure 4.2.4.3) and this was likely due to 
the partial nature of the knockdown observed.  Most of the reduction of apoptotic 
cells as a result of Bax knockdown was observed in the lower right quadrant when 
compared to the mock transfected and scrambled siRNA transfected cells.  The lower 
right quadrant of the dot plot is representative of cells in the early stages of apoptosis 
and the upper right quadrant represents dead cells that have most likely undergone 
apoptosis, as discussed in Section 3.2.3.  This reduction of cells in the lower right 
quadrant in the cells treated with Bax siRNA in response to combination treatment is 
consistent with the observation that recruitment of Bax to the mitochondria and 
subsequent multimerization is an early apoptotic event (Eskes et al., 2000), since 
knockdown of Bax resulted in a decrease in the number of cells in the lower right 
quadrant in response to the combination of Nutlin-3 and ABT-737 when compared ot 
mock-transfected cells or cells transfected with scrambled siRNA..  In the following 
section, possible events that take place upstream of Bax activation in response to 
treatment with Nutlin-3 and ABT-737 are discussed. 
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4.2.5 A study of pro-apoptotic proteins at the mitochondria in response to the 
combination of Nutlin-3 and ABT-737 
Proteins that mediate the intrinsic apoptosis pathway function at the mitochondrial 
outer membrane (MOM) and are part of a dynamic interplay of protein-protein 
interactions that either permit permeablization of the MOM or inhibit it.  As 
discussed in Section 1.2.7.4, there are a number of models that are being validated 
which are being used to explain the interactions between the proteins that promote 
apoptosis and proteins that promote survival at the mitochondria.  One step towards 
commitment to the intrinsic apoptosis pathway that is agreed upon in all of the 
models in the current discourse is the accumulation of pro-apoptotic family members 
at the mitochondria.  Whilst performing western blots on whole cell lysates from 
cells treated with single or combination drug treatments was useful in elucidating 
fluctuations of a particular protein on a whole cell level, this method was limited as 
far as explaining what was taking place at the mitochondrial level.  It was 
hypothesised that an important step that would permit the Bax-dependent apoptosis 
described in Section 4.2.4 would be the accumulation of pro-apoptotic Puma and 
Noxa at the mitochondria.  This is the site at which anti-apoptotic Bcl-2 family 
members such as Bcl-2 and Bcl-xL are inhibited by both of these proteins.  To study 
the presence or absence of pro-apoptotic proteins at the mitochondria, the aim was to 
produce very pure preparations of mitochondria then to study the fluctuations of pro-
apoptotic proteins in these mitochondrial preparations. 
 
Hypotonic lysis of cells and Potter-Elvehjem homogenization to disrupt the cell 
membrane without rupturing mitochondria, was used to lyse cells, exactly as 
described in Sections 2.5.2 and 4.2.3.  This was followed by repeated centrifugations 
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at 1,300 x g to remove nuclei, unbroken cells and large membrane fragments.  The 
clarified homogenate was then laid onto a two-step discontinuous sucrose gradient 
and ultra-centrifuged at 85,000 x g at 4 ºC for 1 hour.  Mitochondria were recovered 
from the interphase of the gradient by lateral suction with a syringe and needle and 
subsequently washed and prepared in loading buffer for western blot analysis.  
Figure 4.2.5.1 shows a photograph of a centrifuge tube loaded with the two layers of 
sucrose and the crude homogenate before and after ultra-centrifugation. 
 
ACHN and 111 cells were treated with drug vehicle, Nutlin-3 or ABT-737 alone or a 
combination of both treatments for 36h.  The cells were then harvested and 
mitochondria were purified as described above.  Fractions recovered were designated 
1st pellet, mitochondrial and cytosolic.  The first pellet was the pellet that formed 
after the first 5-minute centrifugation at 1,300 x g following homogenization.   The 
mitochondrial fraction was the layer removed from the interphase of the sucrose 
gradient.  The cytosolic fraction was the clarified homogenate above the layers of 
sucrose that remained after ultracentrifugation.  Tubulin, COX4 and Histone H3 
were again used as markers to monitor the quality of the fractionation procedure.  
Figures 4.2.5.2 and 4.2.5.3 show controls for fractionation for both ACHN and 111 
cells respectively.  Figures 4.2.5.4 and 4.2.5.5 are western blots from both treated 
ACHN and 111 cells that take a closer look at the levels of COX4 and tubulin in 
comparison to whole cell lysate.  In a similar fashion to what had been observed 
previously, the Histone H3 signal from the ACHN cells treated with the combination 
of Nutlin-3 and ABT-737 was distributed amongst the mitochondrial fraction and the 
cytosolic fraction (figure 4.2.5.2) and it appeared in the form of a doublet.  Some  
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Figure 4.2.5.1 Centrifuge tube prepared for purification of mitochondria from 
crude homogenate before and after ultra-centrifugation.  Cells were 
homogenized as described in section 4.2.5 and the crude homogenate was laid over 
two layers of Sucrose/Tris-HCl/EDTA solution (A).  Ultra-centrifugation separated 
mitochondria from soluble cytosolic proteins and smaller organelles (B). 
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Figure 4.2.5.2 Analysis of subcellular fractions following fractionation of wild 
type p53 ACHN cells by sucrose density gradient centrifugation.  ACHN cells 
were treated with drug vehicle, Nutlin-3, ABT-737 or a combination of both for 36h.  
Cells were then harvested and fractionated as described in section 4.2.5 and samples 
for western blot analysis were prepared as described in Section 2.4.2 and subjected to 
analysis by western blot.  5µg of protein was analysed in each lane and the 
antibodies used for detection of protein are described in table 2.1.  “1st” indicates first 
pellet following first centrifugation of homogenate. WCL indicates whole cell lysate.  
“M” indicates mitochondrial fraction. “C” indicates cytoplasmic fraction.  The 
migration of protein standards of the indicated approximate molecular weights are 
shown in kDa. 
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Figure 4.2.5.3 Analysis of subcellular fractions following fractionation of mutant 
p53 111 cells by sucrose density gradient centrifugation.  111 cells were treated 
with drug vehicle, Nutlin-3, ABT-737 or a combination of both.  Cells were then 
fractionated as described in section 4.2.5 and samples for western blot analysis were 
prepared as described in Section 2.4.2 and subjected to analysis by western blot.  5µg 
of protein was analysed in each lane and the antibodies used for detection of protein 
are described in table 2.1.  “1st” indicates first pellet following first centrifugation of 
homogenate. WCL indicates whole cell lysate.  “M” indicates mitochondrial fraction. 
“C” indicates cytoplasmic fraction.  The migration of protein standards of the 
indicated approximate molecular weights are shown in kDa. 
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Figure 4.2.5.4 Enrichment of mitochondria from wild type p53 ACHN cells.  
Western blot showing enrichment of mitochondria relative to whole cell lysate from 
mitochondrial fraction of treated ACHN cells.  Lysates were prepared as described in 
the legend of figure 4.2.5.2.  5µg of protein was analysed in each lane and the 
antibodies used for detection of protein are described in table 2.1.  WCL indicates 
whole cell lysate.  “1st” indicates first pellet following first centrifugation of 
homogenate.  “M” indicates mitochondrial fraction. “C” indicates cytoplasmic 
fraction.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa. 
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Figure 4.2.5.5 Enrichment of mitochondria from mutant p53 111 cells.  Western 
blot showing enrichment of mitochondria relative to whole cell lysate from 
mitochondrial fraction of treated 111 cells.  Lysates were prepared as described in 
the legend of figure 4.2.5.3.  5µg of protein was analysed in each lane and the 
antibodies used for detection of protein are described in table 2.1.  WCL indicates 
whole cell lysate.  “1st” indicates first pellet following first centrifugation of 
homogenate.  “M” indicates mitochondrial fraction. “C” indicates cytoplasmic 
fraction.  The migration of protein standards of the indicated approximate molecular 
weights are shown in kDa. 
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Histone H3 signal could be observed in the mitochondrial fraction of the ABT-737-
treated ACHN cells (figure 4.2.5.2).  Again, micronucleation due to apoptosis 
seemed to be the most likely explanation for this observation.  This method was 
however, successful in depleting cytosolic Tubulin from the mitochondrial fraction 
and mitochondrial COX4 from the cytosolic fraction.  Figure 4.2.5.4 shows an 
increase in the COX4 signal in the mitochondrial fraction when compared to that 
observed in the whole cell lysate, which suggest that this method was suitable for the 
enrichment of mitochondria. 
 
In the treated 111 cells, Histone H3 signal was primarily observed at the 
mitochondrial fraction (figure 4.2.5.3) and was not observed as a doublet. A higher 
level of this protein observed was in the ABT-737 and combination-treated 
mitochondria than that observed in the mitochondria from drug-vehicle and Nutlin-3 
treatments, consistent with the slight increase in apoptosis taking place in these cells 
in response to the drug treatments used (figure 3.2.3.9).  COX4 signal was only 
observed at the mitochondrial fraction and tubulin was only observed at the cytosolic 
fraction (figures 4.2.5.4 and 4.2.5.5).  The COX4 signal was enhanced in the 
mitochondrial fraction over that observed in the whole cell lysate, suggesting this 
method had enriched for mitochondria at the mitochondrial fraction (figure 4.2.5.5). 
 
Figure 4.2.5.6 are the western blots for the different pro-apoptotic proteins studied in 
mitochondrial preparations of ACHN and 111 cells treated with drug vehicle, Nutlin-
3, ABT-737 and the combination of both treatments.  p53 has been attributed a role 
in promoting the intrinsic apoptosis pathway at the mitochondria (reviewed in 
Speidel, 2010).  Because of the obviously compromised nature of the nuclei from 
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cells undergoing apoptosis in these experiments, we elected not to study p53 levels in 
these mitochondrial lysates.  Bax levels remained unchanged at the mitochondria of 
ACHN cells in response to all of the drug treatments used (figure 4.2.5.6).  This 
implications of this finding will be discussed shortly.  There was a slight but 
detectable increase in Bax at the mitochondria of 111 cells in response to the 
combination of Nutlin-3 and ABT-737 when compared to the other treatments.  In 
Nutlin-3-treated ACHN cells, there was an accumulation of Puma at the 
mitochondria when compared to drug vehicle-treated cells.  Unlike the western blot 
for Puma in whole cell lysates of ACHN cells shown in figure 4.2.2.1, there appeared 
to be an absence of the putative α isoform of the protein at the mitochondria (figure 
4.2.5.6).  To confirm this, we compared Puma protein from whole cell lysates on the 
same western blot as Puma protein from mitochondria (figure 4.2.5.7).  There was 
indeed an absence of putative Puma α band at the mitochondria.  ABT-737-treated 
ACHN cells showed a decrease in Puma protein level when compared to drug-
vehicle cells and Puma appeared to be completely absent from the mitochondria of 
cells treated with the drug combination (figure 4.2.5.6).  Puma levels at the 
mitochondria appeared unchanged in response to the single drug or combination 
treatment in 111 cells.  Full-length Bid protein levels at the mitochondria of ACHN 
cells did not change in response to either Nutlin-3 or ABT-737 alone.  In response to 
the combination treatment, however, there was a decrease in the level of full-length 
Bid at the mitochondria.  This was not accompanied by an increase in tBid.  Bid 
protein levels at the mitochondria of 111 cells increased in response to Nutlin-3, 
ABT-737 and the combination treatment.  A very faint band running below 17 kDa  
184	  	  
 
Figure 4.2.5.6 Pro-apoptotic proteins at the mitochondrial fractions from 
fractionated ACHN and 111 cells.  Western blots of mitochondrial fractions from 
wild type p53 ACHN cells and mutant p53 111 cells treated as described in section 
4.2.5.6.  Proteins were probed as indicated. 
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Figure 4.2.5.7 Comparison of Puma protein in whole cell lysates and 
mitochondrial fractions of wild type p53 ACHN cells.  Whole cell lysates were 
prepared by lysing treated cells with CHAPS-modified SLIP buffer.  Mitochondria 
were isolated by sucrose density gradient centrifugation.  Proteins were probed as 
indicated. 
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was observed at the mitochondria of 111 cells treated with the combination of 
Nutlin-3 and ABT-737, which may have represented tBid.  The Noxa protein level at 
the mitochondria of ACHN cells increased only in response to ABT-737 and the 
combination treatment.  A similar observation regarding elevation of Noxa at the 
mitochondria of 111 cells was made:  Noxa protein increased in response to ABT-
737 and the combination treatment, but not in response to drug vehicle.  This 
observation implied that the localization of Noxa to the mitochondria may have been 
involved in promoting apoptosis in response to ABT-737 and the combination of 
Nutlin-3 and ABT-737.  The level of cytochrome c at the isolated mitochondria from 
these cell lines was also examined.  As expected, there was a decrease in cytochrome 
c protein level at the mitochondria of ACHN cells in response to ABT-737 alone and 
a complete loss of cytochrome c from the mitochondria in response to the 
combination treatment.  The level of cytochrome c protein at the mitochondria of 111 
cells did not alter in response to Nutlin-3, ABT-737 or the combination of both 
treatments.  This observation is consistent with data presented in Section 3.2.3, 
which shows that cell death in response to the combination of Nutlin-3 and ABT-737 
in RCC cells harbouring wild type p53 is a result of apoptosis. 
 
As predicted, there was a fluctuation of pro-apoptotic proteins at the mitochondria of 
ACHN and 111 cells treated with Nutlin-3, ABT-737 and a combination of both 
agents.  There was no increase in Bax at the mitochondria of ACHN cells in response 
to the combination treatment (figure 4.2.5.6).  This is in apparent contradiction with 
figure 4.2.3.9, where an increase in Bax protein level can be observed at the 
mitochondria of ACHN cells treated with the combination.  Mitochondria were 
treated differently in both experiments: in the former, mitochondria were treated with 
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DMSO for 30 min whilst suspended in crude homogenate, then the mitochondria 
were isolated by differential centrifugation before lysis with CHAPS-modified SLIP 
buffer and subsequent elimination of detergent-insoluble proteins and membranes.  
In the latter case, mitochondria were isolated by sucrose density gradient 
centrifugation and whole mitochondrial suspension in MS buffer was used to make 
samples for western blot.  Because of the superior enrichment of mitochondria from 
the latter described protocol (compare figures 4.2.5.4 and 4.2.5.5 to figures 4.2.3.8 
and 4.2.3.11) we would be more inclined to accept figure 4.2.5.6 as the more 
accurate representation of Bax levels at the mitochondria.  Further, an increase in 
mitochondrial Bax is not a mandatory pre-requisite for Bax-dependent apoptosis 
(Desagher et al., 1999).  It has recently been shown that only an increase of 
mitochondrial Bax by 1.8 ± 1.5% at the onset of MOMP is sufficient to induce pore 
formation at the outer mitochondrial memebrane (Düssmann et al., 2010) which is 
not high enough to be detected by western blot, as has been attempted in this study.  
A recent refinement in the model of Bax translocation and activation during 
apoptosis suggests that Bax translocation from the cytosol to the mitochondria and 
vice versa is in a state of dynamic equilibrium and that it is activation of Bax that is 
already accumulated at the mitochondria that can promote apoptosis.  The traditional 
view was that cytosolic Bax required activation upstream of mitochondrial 
accumulation, recent data suggests that this may not be the case (Schellenberg et al., 
2013). 
 
Noxa protein level increased at the mitochondria in response to ABT-737 alone and 
the combination of Nutlin-3 and ABT-737 in both ACHN and 111 cell lines (figure 
4.2.5.6).  Noxa binds anti-apopototic Mcl-1 with high affinity (Certo et al., 2006; 
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Van Delft et al., 2006) and therefore may play a role in promoting the apoptosis 
observed in response to the combination treatment.  As this elevation of 
mitochondrial Noxa was observed in both p53 wild type and mutant cell line, it is 
likely that Noxa does not play a central role in this process. 
 
Increased mitochondrial Puma in ACHN cells treated with Nutlin-3, and the lack of 
apoptosis observed in these cells (Section 3.2.3) in response to this treatment 
suggested that Puma elevation at the mitochondria alone was insufficient to promote 
apoptosis in these cells.  One model of the pro-apoptotic role of Puma states that 
Puma can transiently interact with Bax and Bak to promote the oligomerization of 
these proteins (Kim et al., 2006, 2009).  The decrease in Puma at the mitochondria of 
ABT-737-treated ACHN cells may be attributed to the possible displacement of this 
protein from Bcl-xL and Bcl-w (ACHN cells are virtually Bcl-2 null, figure 4.2.1.1) 
at the mitochondria of these cells.  Indeed the observation that mitochondrial Puma 
was lower in the ABT-737 treated ACHN cells when compared to the Nutlin-3 
treated cells suggested that Bcl-xL, Bcl-w and possibly Mcl-1 may have been acting 
as a “sink” for Puma (Kim et al, 2006), binding the protein and inhibiting the Puma-
Bax interaction.  Puma was up-regulated in the whole cell lysates of ACHN cells 
treated with the combination of Nutlin-3 and ABT-737 (figure 4.2.2.1) and yet was 
absent from the mitochondria of cells that had undergone the same treatment.  This 
suggests that Puma may have been dissociated from the mitochondrial outer 
membrane at this stage of events and had become present in the cytosol.  A model of 
ligand-induced Bax and Bak activation, termed the “hit and run” model proposes that 
activator BH3-only family members, tBid, Bim and Puma, transiently interact with 
Bax or Bak at membranes, inducing a conformational change that results in the 
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activation and subsequent oligomerization of each protein (Wei et al., 2000; Eskes et 
al., 2000; Walensky et al., 2006; Lovell et al., 2008).  Treatment of ACHN cells with 
the combination of Nutlin-3 and ABT-737 at 36h resulted in such a dramatic 
apoptotic response (Section 3.2.3) that it is likely that the Puma-mediated Bax 
activation was no longer taking place nor required.  Indeed, no cytochrome c could 
be observed at the mitochondrial fraction after this treatment (figure 4.2.5.6), 
suggesting that almost all of the cells in this treatment were undergoing apoptosis.  It 
may be interesting to look at the Puma localization at the mitochondria in 
combination treated cells over a time course.  The issue of Puma-mediated Bax 
activation will be addressed in greater detail in the following section. 
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4.2.6 A study into the possible role of Puma in promoting Bax activation in response 
to the combination of Nutlin-3 and ABT-737 
Section 4.2.4 showed that apoptosis in response to the combination of Nutlin-3 and 
ABT-737 was substantially Bax-dependent.  The next question to be addressed was 
what event was taking place upstream of Bax activation in response to the 
combination of Nutlin-3 and ABT-737?  One of the models suggested for the 
oligomerization of Bak and/or Bax at the MOM is the direct activation of either of 
these proteins by “activator” BH3-only family members tBid, Bim or Puma, 
discussed in Section 1.2.7.4, whereupon “sensitizer” BH3-only family members 
displace “activator” BH3-only family members from the anti-apoptotic Bcl-2 family 
members, permitting a transient interaction between the “activator” BH3-only family 
member with Bak or Bax, resulting in oligomerization of either of the two proteins at 
the MOM and subsequent apoptosis.  BH3-only family members that are thought to 
be “activators” are tBid, Bim and Puma.  Of these three proteins, only Bid, the full-
length precursor of tBid, and Puma are p53-inducible.  Noxa is currently the only 
known putative “sensitizer” that is induced by p53.  Section 4.2.2 presented a study 
of the steady state levels of Puma, Noxa and Bid/tBid in response to Nutlin-3, ABT-
737 or the combination of both treatments after 36h in the cell lines used in this 
study.  Puma was induced in response to Nutlin-3 and the combination of Nutlin-3 
and ABT-737 in the majority of the RCC cell lines tested that harboured wild type 
p53 (figures 4.2.2.1 and 4.2.2.2).  Noxa was induced by ABT-737 and the 
combination treatment in the majority of the RCC cell lines tested that harbour wild 
type p53 but also in the p53 mutant 111 cell line and the p53-null H1299 cell line 
(figures 4.2.2.1, 4.2.2.2, 4.2.2.3 and 4.2.2.4).  Data presented in Section 3.2.2 
demonstrated that the pro-apoptotic effect of the combination of Nutlin-3 and ABT-
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737 was p53-dependent, and a p53-independent pathway describing the up-
regulation of Noxa in response to ABT-737 had already been delineated (Bertin-
Ciftci et al., 2013), it was hypothesized that Puma was more important than Noxa in 
contributing to the apoptosis in response to the combination of Nutlin-3 and ABT-
737.   
 
As discussed in Section 1.2.7.2 of the Introduction, Puma is a potent inducer of 
apoptosis and is believed to be essential to the promotion of apoptosis in the absence 
of both tBid and Bim (Ren et al., 2010; Kim et al., 2006).  Puma is also believed to 
directly activate Bax to commit cells to apoptosis, via a transient protein-protein 
interaction (Cartron et al., 2004; Gallenne et al., 2009).  Major conformational 
changes in Bax preclude formation of Bax oligomers at the MOM in response to a 
pro-apoptotic stimulus.  One of these conformational changes is exposure of the N-
terminal of Bax (Reviewed in Westphal et al., 2013).  The monoclonal antibody 6A7 
to amino acids 13-19 of Bax has proven to be useful in the detection of the exposure 
of N-terminal of Bax during the activation of the protein (Hsu and Youle, 1997; 
Peyerl et al., 2007).   When Bax is in a native, non-activated state, residues 13-19 are 
buried deep within the globular Bax polypeptide.  In response to a pro-apoptotic 
stimulus, changes in pH or treatment with non-ionic surfactants, the N-terminal of 
Bax is exposed, permitting cross reactivity with the 6A7 antibody (Lalier et al., 
2007).  To address the question as to whether Puma was involved in Bax activation 
in response to the combination of Nutlin-3 and ABT-737, cells that had Puma down-
regulated by siRNA would be treated with both drugs, followed by 
immunoprecipitation of activated Bax using the 6A7 antibody.  A decrease in the  
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Figure 4.2.6.1 Optimization of Bax 6A7 immunoprecipitation.  ACHN cells were 
treated with 5 mM Staurosporine for 24h and cells were harvested and Bax 6A7 
antibody was used in the immunoprecipitation of 500µg protein as described in 
Section 2.8.  Untreated cells were treated with Triton X-100 as a positive control for 
Bax activation. A. Western blot analysis of lysates that had undergone IP.  B.  
Western blot analysis of 20µg protein before IP.  IP – immunoprecipitation.  
Antibodies used for detection are summarized in table 2.1. 
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immunoprecipitated Bax upon Puma knockdown would have suggested a role for 
Puma in Bax activation.  This process required optimization of a number of steps, 
which will be discussed below. 
 
Whilst Bax 6A7 is a commonly used antibody for the detection of N-terminal-
exposed Bax, it was important to validate the specificity of this antibody in the 
experimental system described in this thesis.  ACHN cells were treated for 24h with 
5mM Staurosporine, a known inducer of apoptosis (Chae et al., 2000) or vehicle 
control.  Cells were harvested as described in section 2.4 and lysed with Bax N-
terminal capture buffer (BNTC buffer).  An untreated pellet of cells was lysed with 
BNTC buffer containing 0.1% Triton X-100 for reasons that will be discussed below.  
Protein was quantified by Bradford assay and 500 µg of protein was pre-cleared with 
Protein G sepharose beads before overnight incubation with either Bax 6A7 antibody 
or an isotype matched CD20 mouse monoclonal antibody.  The remainder of the 
immunoprecipitation is described in section 2.8.  A western blot showing protein 
from the immunoprecipitation is shown in figure 4.2.6.1A and a western blot 
showing the protein from the lysates before immunoprecipitation is shown in figure 
4.2.6.1B.  There was no visible increase in Bax protein in response to treatment with 
Staurosporine (figure 4.2.6.1B).  Upon detection of Bax protein from the 
immunoprecipitates with Bax N-20 antibody, no bands are visible in the first lane, 
which is represents protein from vehicle treated cells immunoprecipitated with Bax 
6A7 antibody (figure 4.2.6.1A).  A faint band can be observed in the second lane, 
suggesting Staurosporine induced some Bax N-terminal exposure.  Non-ionic 
detergents such as Triton X-100 induce Bax N-terminal exposure and cross-reactivity 
for the 6A7 monoclonal antibody whereas zwitterionic detergents such as CHAPS do  
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Figure 4.2.6.2 N-terminal exposure of Bax.  ACHN cells were for 36 h with 3µM 
Nutlin-3, 10µM ABT-737 or a combination of both treatments.  500µg of protein 
was subjected to IP as described in section 2.8.1 using Bax 6A7 antibody. A. 
Western blot analysis of immunoprecipitates.  B. Western blot analysis of 20µg 
protein before immunoprecipitation. 
 
 
 
 
 
 
 
 
 
 
195	  	  
not (Hsu and Youle, 1997).  Indeed, recombinant Bax treated with Triton X-100 or 
another non-ionic detergent, such as octyl glucoside, has been shown to induce pore 
formation in both liposomes and purified mitochondria (Antonsson et al., 2000).  A 
very strong band for Bax can be observed in the lane containing protein from cells 
lysed with buffer containing Triton X-100.  This is consistent with observations that 
non-ionic detergents artificially promote N-terminal exposure of Bax (Lalier et al., 
2007).  No bands representing Bax can be observed in lysates immunoprecipitated 
with isotype control antibody to CD20, even upon lysis of cells with Triton X-100 
(figure 4.2.6.1A).  The absence of detectable Bax in the samples immunoprecipitated 
with anti-CD20 and the presence of detectable Bax from cells treated with 
Staurosporine and Triton X-100 suggested that Bax 6A7 is capable of 
immunoprecipitating N-terminal-exposed Bax from ACHN cells. 
 
The same immunoprecipitation was performed on lysates from ACHN cells treated 
with drug-vehicle, 3µM Nutlin-3, 10µM ABT-737 or a combination of both 
treatments for 36h.  Immunoprecipitated protein from cells lysed with SLIP buffer 
containing Triton X-100 was included as a positive control for Bax N-terminal 
exposure.  The western blots showing the immunoprecipitates and the protein before 
immunoprecipitation (Pre-IP) are shown in figures 4.2.6.2A and B.  Consistent with 
the data in figure 4.2.2.1, there was no increase in Bax protein level in response to 
any of the treatments (figure 4.2.6.2B).  A band representing Bax on the western blot 
of the Bax 6A7 immunoprecipitates was observed in response to ABT-737 treatment 
(figure 4.2.6.2A) and a stronger band is observed in response to the combination 
treatment.  This is consistent with the observation that some apoptosis takes place in 
response to ABT-737 in ACHN cells but even greater apoptosis results  
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Figure 4.2.6.3 Optimization of Puma knockdown using siRNA.  ACHN cells 
were transfected with siRNA to Puma using Lipofectamine-2000 as described in 
section 2.2.5 of Materials and Methods.  24 h after transfection, cells were harvested 
and protein was subjected to western blot analysis as described in section 2.4.  20µg 
of protein was analysed by western blot and antibodies used for detection are 
summarized on table 2.1. 
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in response to the combination (figure 3.2.3.7).  As observed previously, treatment of 
ACHN cells with buffer containing Triton X-100 promoted N-terminal exposure of 
Bax (figure 4.2.6.2A).  As expected, treatment with the combination of Nutlin-3 and 
ABT-737 resulted in the greatest Bax activation of all of the treatments used.  Taking 
into account figure 4.2.3.9, where Bax oligomers were detected in response to the 
combination of Nutlin-3 and ABT-737 but not in response to ABT-737 alone, the 
data presented in figure 4.2.6.2A appeared to contradict this.  However, N-terminal 
exposure of Bax is believed to precede the formation of oligomers at MOM in 
stepwise models for Bax activation (Kim et al., 2009; Westphal et al., 2013).  Hence, 
it is possible that ABT-737 alone can promote the N-terminal exposure of Bax 
without subsequent oligomerisation taking place.  Alternatively, as discussed in 
section 4.2.3, Bax oligomerisation may well have taken place in response to ABT-
737 alone but this may be below a certain threshold that was detectable by the 
method used in that section. 
 
Four different siRNAs were tested for their ability to reduce the level of Puma 
protein in ACHN cells.  ACHN cells were transfected with siRNA to a final 
concentration of 32nM using Lipofectamine 2000 as described in section 2.2.5. 
ACHN cells were mock transfected or transfected with scrambled siRNA or siRNA 
to Puma 1-4. Cells were harvested at 24 hours post-transfection and lysates were 
analysed by western blotting. Figure 4.2.6.3 shows a western blot of the level of 
Puma protein in transfected cells 24 hours after transfection.  There appeared to be 
subtle decrease in Puma protein in response to siRNAs 1 and 4 (lower bands) hence 
both of these siRNAs were selected to perform the experiment in conjunction with 
immunoprecipitation of activated Bax. 
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Figure 4.2.6.4 Steady state level of Puma upon transfection with siRNAs to 
Puma 1 and 4.  ACHN cells were transfected with siRNA to Puma using 
Lipofectamine-2000 as described in section 2.2.5 of Materials and Methods.  24h 
after transfection, cells were harvested and protein was subjected to western blot 
analysis as described in section 2.4.  20µg of protein was analysed by western blot 
and antibodies used for detection are summarized on table 2.1. 
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Figure 4.2.6.5 Bax N-terminal exposure of ACHN cells upon down-regulation of 
Puma and treatment with Nutlin-3 and ABT-737.  ACHN cells were transfected 
with siRNA to Puma using Lipofectamine-2000 as described in section 2.2.5 of 
Materials and Methods.  Cells were for 36 h with 3µM Nutlin-3, 10µM ABT-737 or 
a combination of both treatments after transfection.  500µg of protein were subjected 
to IP as described in section 2.8.1 using Bax 6A7 antibody. A. Western blot analysis 
of immunoprecipitates.  B. Western blot analysis of 20µg protein before 
immunoprecipitation. 
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ACHN cells were either mock transfected, transfected with scrambled siRNA, or 
siRNAs to Puma 1 or 4.  24 hours later, the cells were treated with a combination of 
both 3µM Nutlin-3 and 10µM ABT-737 for a further 36h.  Because the possible 
dependence of Bax activation on Puma in response to the combination of Nutlin-3 
and ABT-737 was being studied and because Bax N-terminal exposure was observed 
in response to the combination treatment (figure 4.2.6.2A), it was reasoned that 
treatment of transfected cells with only the combination of Nutlin-3 and ABT-737 
would have been sufficient to address this question and treatment with the single 
agents was excluded in this experiment.  Figure 4.2.6.4 is a western blot showing the 
steady state level of Puma protein after transfection, immediately before treatment 
with Nutlin-3 and ABT-737.  Puma appeared to be slightly down-regulated in cells 
transfected with siRNA 4 to Puma, however the actin band from this treatment 
appeared slightly under-loaded when compared to the remaining actin bands, 
suggesting this decrease in Puma may have been an artefact of this under-loading.  
Figure 4.2.6.5A shows the western blot for the Bax 6A7 immunoprecipitates detected 
with Bax N-20 polyclonal antibody and figure 4.2.6.5B is a summary of Bax and 
Puma protein levels before the immunoprecipitation.  There was no increase or 
decrease in Bax protein when all of the transfection conditions are compared (figure 
4.2.6.5B).  Puma protein level appeared to have decreased in the cells transfected 
with Puma siRNA 4, when compared to the other treatments.  Less activated Bax 
was immunoprecipitated from the cells transfected with siRNA to Puma 1 and 4 
when compared to mock and scrambled transfection.  Because of the difference of 
the knockdown of Puma with siRNA 4 at the start of the experiment (figure 4.2.6.4) 
and the level of Puma protein from the lysates after 36 h of treatment with the 
combination of agents, it is difficult to definitively state whether this apparent 
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decrease in Puma was responsible for the slight decrease in the immunoprecipitated 
activated Bax (figure 4.2.6.5A). 
 
4.3 Summary 
In this chapter, it has been demonstrated that the combination of Nutlin-3 and ABT-
737 promoted the up-regulation of p53 in the RCC cells that harboured wild type 
p53.  Not surprisingly, this resulted in an increase in pro-apoptotic Puma.  ABT-737 
treatment alone and the combination was shown to induce Noxa in a p53-
independent manner however, using cells that expressed shRNA to p53, it was 
shown that p53 was at least partially responsible for the up-regulation of Noxa in 
response to this treatment.  In a study of the oligomerization of pro-apoptotic Bax 
and Bak at the MOM, it was shown that only Bax was oligomerized at the MOM.   
Bak oligomerization was almost undetectable by the method used in this study.  
Further, this Bax oligomerization was only observed in wild type p53 RCC cells and 
not in RCC cells that possessed mutant p53.  Using siRNA to Bax, it was 
demonstrated that apoptosis in response to the combination of Nutlin-3 and ABT-737 
was Bax-dependent.  In an attempt to elucidate the role of pro-apoptotic proteins at 
the mitochondria, levels of these proteins were examined in purified mitochondrial 
preparations.  Noxa protein was elevated at the mitochondria in both p53 wild type 
and mutant RCC cells in response to ABT-737 alone and the combination of Nutlin-
3 and ABT-737.  Puma was only elevated at the mitochondria of p53 wild type RCC 
cells in response to Nutlin-3 alone.   Because Puma up-regulation was p53-dependent 
and the synergy observed between Nutlin-3 and ABT-737 was p53-dependent, Puma 
was selected as a possible direct activator of Bax downstream of the combination 
treatment.  A protocol for the immunoprecipitation of N-terminal exposed Bax (an 
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activated conformation of Bax) was optimized and it was shown that the combination 
of Nutlin-3 and ABT-737 promoted the most Bax N-terminal exposure of the drug 
treatments used.  To determine whether Puma was involved in this process, 
knockdown of Puma using siRNA was optimised.  It was not apparent whether Puma 
was involved in Bax activation downstream of treatment with the combination of 
Nutlin-3 and ABT-737 because of a poor knockdown of Puma in the experiment.  
Puma is the most likely mediator of Bax activation in response to this combination 
for the following reasons: Bax activation is an essential pre-requisite for the intrinsic 
pathway of apoptosis to take place and considering that Bid/tBid, the only other p53-
inducible Bax activator was not up-regulated/cleaved in response to the combination 
treatment, only Puma remained as a likely candidate.  The implications of these 
findings and possible ways to address remaining questions about the mechanism 
underlying the apoptosis induced by this combination of drugs are discussed in the 
next chapter. 
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Chapter 5: Discussion 
 
The incidence of RCC is increasing and the inadequacy of current treatment 
regimens for the metastatic disease has necessitated the development of novel 
therapeutic strategies.   Multiple observations have shown that mutation of p53 is 
rare in RCC and the function of wild type p53 in cultured RCC cells has been shown 
to be partially intact (Noon et al., 2010; Warburton et al., 2005).  This observation 
has highlighted wild type p53 as a novel therapeutic target for pharmacological 
rescue in RCC.  Attempts to rescue wild type p53 from inhibition by MDM2 using 
inhibitors of the p53-MDM2 interaction in RCC cells have resulted in cell cycle 
arrest or senescence but not apoptosis (Tsao and Corn et al., 2010; Polanski et al., 
submitted).  Because of the potentially harmful properties of senescent cells 
(reviewed in Davalos et al., 2010, discussed in Section 1.2.5), the focus of this study 
has been to restore wild type p53 function in RCC cells to commit RCC cells to 
apoptosis as opposed to cell cycle arrest or senescence.  One of the hallmarks of 
cancer is the evasion of apoptosis (Hanahan and Weinberg, 2000).  RCC cells in both 
patients and cell culture are resistant to the pro-apoptotic effects of radiation and 
chemotherapy (Rini et al., 2009; Yagoda et al., 1995).   In this study, the novel, pro-
apoptotic inhibitor of the Bcl-2 family of anti-apoptotic proteins ABT-737 was 
combined with an MDM2-p53 interaction antagonist Nutlin-3 and this induced p53-
dependent apoptosis in a panel of RCC cells harbouring wild type p53.   
 
This combination treatment has been examined previously.  For example Kojima et 
al., combined both Nutlin-3 and ABT-737 to induce apoptosis in acute myeloid 
leukaemia cells harbouring wild type p53 (Kojima et al., 2006).  However, unlike the 
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cells used in our study, Nutlin-3 alone promotes apoptosis in AML cells (Kojima et 
al., 2005) and both Nutlin-3 alone and the combination of Nutlin-3 and ABT-737 in 
AML cells resulted in up-regulation of Bax, one of the important effectors of the 
intrinsic apoptosis pathway.  Similar observations were made of Burkitt’s lymphoma 
cell lines that were treated with either Nutlin-3 or the combination of Nutlin-3 and 
ABT-737: Bax-dependent apoptosis took place in response to Nutlin-3 alone or in 
combination with ABT-737 (Renouf et al., 2009; Pujals et al., 2011).  Our study has 
shown that RCC cells harbouring wild type p53 do not respond to Nutlin-3 by 
undergoing apoptosis and treatment with Nutlin-3 or the combination of Nutlin-3 and 
ABT-737 does not result in the up-regulation of Bax.  These studies emphasize that 
different cell fates can be determined, or enhanced by the action of p53 rescued from 
inhibition by Nutlin-3.  Further, work presented in this study has shown that 
liberation of p53 from MDM2 is insufficient to push cell fate towards apoptosis and 
further “assistance” from ABT-737 was required to achieve this.  It is likely that 
apoptosis observed in response to the combination of Nutlin-3 and ABT-737 in RCC 
cell harbouring wild type p53 is consistent with the apoptotic threshold model of p53 
determination of cell fate as proposed by Kracikova and colleagues: commitment to 
apoptosis is ultimately determined by the balance of anti-apoptotic proteins to pro-
apoptotic proteins.  Changing the equilibrium of both of these types of proteins 
results in apoptosis (Kracikova et al., 2013).  It was demonstrated in this thesis that 
up-regulation of p53 alone by Nutlin-3 treatment was insufficient to promote 
apoptosis but lowering the apoptotic threshold by combining a BH3-only protein 
mimetic with Nutlin-3 allowed apoptosis to take place.  One interesting issue raised 
by this is the contribution of Noxa to the synergistic effect of this combination 
treatment on RCC cells that were sensitive to the combination treatment. Which was 
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more important to the promotion of apoptosis, ABT-737-mediated inhibition of anti-
apoptotic proteins or induction of Noxa by ABT-737?  The observations that Caki2 
cells were the most sensitive cell line to ABT-737 alone and the level of Noxa 
protein in this cell line did not increase in response to ABT-737 (figure 4.2.2.1) may 
suggest that it is the ability of ABT-737 to inhibit anti-apoptotic proteins that is more 
important to mediating this pro-apoptotic effect.  Conversely, the observation that 
Noxa up-regulation in response to ABT-737 was at least partially dependent on wild 
type p53 (figure 4.2.2.5) suggests that transcriptional up-regulation of Noxa by ABT-
737 may have contributed to the synergistic induction of apoptosis in response to this 
combination.  One way to address this question would be to down-regulate Noxa 
using siRNA then treat cells with the combination of Nutlin-3 and ABT-737.  If 
knockdown of Noxa conferred some protection of the cells from the pro-apoptotic 
effects of the combination, then it could be implied that Noxa up-regulation in 
response to the combination treatment is important towards promoting apoptosis.  On 
the other hand, if knockdown of Noxa did not promote resistance to the combination 
treatment, then it could be implied that inhibition of Bcl-2 family members by ABT-
737 is more important to promotion of apoptosis in response to the combination.  
This experiment had been considered and designed however time limitations did not 
permit the author to perform this experiment. 
 
It was demonstrated that apoptosis in response to the combination of Nutlin-3 and 
ABT-737 was substantially Bax-dependent (Section 4.2.4).  Because others have 
observed that Puma can directly activate Bax in a number of model systems (Cartron 
et al., 2004; Ren et al., 2010), an attempt was made in this thesis to determine 
whether Puma played a critical role in the activation of Bax in response to the 
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combination of Nutlin-3 and ABT-737 by down-regulating Puma using siRNA and 
then performing immunoprecipitation of activated Bax (section 4.2.6).  This may 
have been too simplistic an approach to address what was taking place upstream of 
Bax activation in response to the combination treatment.  One of the proposed 
models for Bax activation is a direct, allosteric interaction with Puma (Gallenne et 
al., 2009).  If Puma up-regulation alone were responsible for Bax activation, Puma 
induced by Nutlin-3 alone would have promoted Bax N-terminal exposure, 
especially when considering the increase in Puma protein at the mitochondria in 
response to Nutlin-3 alone (figure 4.2.5.6).  The absence of Bax N-terminal exposure 
(figure 4.2.6.2) in response to Nutlin-3 alone showed that this was evidently not the 
case.  Bax activation is more likely a result of the combined effect of Puma up-
regulation, the possible liberation of Bax from anti-apoptotic proteins at the 
mitochondria by ABT-737 and Noxa-dependent inhibition of anti-apoptotic Mcl-1.  
We speculate that one of these events may be necessary before allosteric activation 
of Bax by Puma.  It would be interesting to observe sensitivity of RCC cells that 
harbour wild type p53 to the combination treatment upon simultaneous down-
regulation of both Puma and Noxa using siRNA to the genes encoding both proteins.  
One prediction that this knockdown of both proteins would reduce the sensitivity to 
the combination treatment.  Again, this experiment was considered but time 
limitations did allow it to be performed.  One issue that remains to be elucidated is 
why Puma induction in response to Nutlin-3 alone does not result in any observable 
apoptosis.  This may be related to the threshold model of p53-mediated apoptosis 
described above; Puma up-regulation alone in RCC cells that have wild type p53 is 
not sufficient to commit these cells to apoptosis.  A recently developed small 
molecule inhibitor of Puma mediated apoptosis could be a useful tool in dissecting 
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the role of Puma in relation to this drug combination (Mustata et al., 2011).  Lead 
compounds tested in Mustata et al., perturbed the interaction between the BH3 
domain of Puma and the anti-apoptotic Bcl-2 family members, such that these 
compounds partially protected NCCIT cells from the pro-apoptotic effects of 
ionizing radiation (Mustata et al., 2011).  It would be interesting to see whether this 
inhibitor could protect RCC cells from the pro-apoptotic effect of the Nutlin-3/ABT-
737 combination. 
 
One question that has not been addressed in this study, which may be worth 
pursuing, is the role of p53 in directly inducing apoptosis at the mitochondria.  This 
has been a controversial issue amongst researchers in the p53 field (Speidel, 2010) 
and the exact role of p53 at the mitochondria is still subject to debate.  Methodology 
described in this study permitted the preparation of enriched mitochondrial fractions 
(figures 4.2.5.4 and 4.2.5.5) however contamination of nuclear protein in the form of 
Histone H3 was present (figures 4.2.5.3 and 4.2.5.2).  This would have cast doubt on 
any potential observations regarding p53 at the mitochondrial because the function of 
p53 as a transcription factor means p53 is predominantly a nuclear protein and it 
would be impossible to distinguish p53 that had leaked from the nucleus due to 
apoptosis (or the homogenization technique) and mitochondrial p53.  Because the 
combination of Nutlin-3 and ABT-737 was such a potent inducer of apoptosis, it was 
almost impossible to isolate mitochondria from cells without contamination from 
proteins from the nucleus.  One possibility to address the possible role of 
mitochondrial p53 in response to the combination of Nutlin-3 and ABT-737 is the 
use of a small molecule inhibitor of mitochondrial p53-mediated apoptosis (Strom et 
al., 2006).  This compound, pifithrin-µ has been shown to inhibit transcription-
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independent-p53-dependent mitochondrial apoptosis (Vaseva et al., 2009) by 
interfering with the interaction between p53 and anti-apoptotic protein Bcl-xL (Hagn 
et al., 2010).  If treatment, or pre-treatment of RCC cells harbouring wild type p53 
with pifithrin-µ rescued these cells from the pro-apoptotic effects of the combination 
of Nutlin-3 and ABT-737, it could be speculated that p53 acting at the mitochondria 
was contributing towards that apoptosis taking place in response to the combination.  
This is unlikely to be the case however, as studies examining p53 localization to 
mitochondria in the kidney epithelium of healthy mice treated with whole body 
ionizing radiation showed that p53 did not localize to the mitochondria in response to 
this stressor (Erster et al., 2004) and as expected, apoptosis did not take place. 
 
The basis p53-dependent cell death in renal epithelial cells has been well 
characterised in response to certain stimuli but remains elusive in response to others.  
For example, apoptosis in renal epithelial cells is believed to involve p53 in response 
to ischemia-reperfusion injury, cisplatin treatment and chronic obstructive uropathy 
(Jiang et al., 2004; Kelly et al., 2003; Choi et al., 2001).  However, as discussed in 
Section 1.1.6.2, p53-dependent apoptosis does not take place in the renal epithelium 
in response to ionizing radiation (MacCallum et al., 1996).  Of the stressors that can 
promote apoptosis in renal epithelium cells, the role of p53 is best characterized in 
the response to the chemotherapeutic drug, cisplatin.  Cisplatin treatment can 
promote both p53-dependent and p53-independent apoptosis in renal epithelial cells 
(Jiang et al., 2009; Dos Santos et al., 2012).  Puma is up-regulated by p53 in renal 
epithelial cells in response to cisplatin treatment and this results in Bax activation 
and apoptosis (Jiang et al., 2006).  To the author’s knowledge, there has been no 
study of Puma levels at the renal epithelium in response to ionizing radiation, 
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however, regardless of whether ionizing radiation can promote the up-regulation of 
Puma at the renal epithelium, the fact remains that cells derived from the renal 
epithelium are incapable of undergoing p53-dependent apoptosis in response to 
ionizing radiation (MacCallum et al., 1996).  Thus, the pro-apoptotic response of p53 
in renal tubular cells appears to be stimulus-specific.  This issue is confounded 
further by the observation that RCC cells are resistant to cisplatin and other 
chemotherapeutic agents.  Whilst the phenotype of RCC cells in response to ionizing 
radiation is consistent with the response of renal epithelium cells to the same 
stimulus, it is plausible that mutations acquired during the transformation process 
that result in aberrant death/survival signalling render RCC cells insensitive to the 
pro-apoptotic effects of cisplatin.  Why p53 in RCC cells is incapable of inducing 
apoptosis, even upon inhibition of MDM2 remains elusive.  Data presented herein 
showed that p53 was capable of up-regulating Puma in RCC cells upon inhibition of 
MDM2, but up-regulation of Puma alone was insufficient to commit RCC cells to 
apoptosis (Sections 3.2.3 and 4.2.2).  The role of Noxa in promoting apoptosis in 
renal epithelial cells is less well characterized.  One possible to mechanism that RCC 
cells depend upon to resist pro-apoptotic signals is an increase in the expression of 
the anti-apoptotic Bcl-2 family members.  The observation that RCC cells possess 
higher levels of anti-apoptotic proteins when compared to non-tumour derived 
HEK293 cells (Section 4.2.1) is consistent with this possibility.  Additional evidence 
in support of this hypothesis comes from the use of BH3 profiling, a functional assay 
that measures “priming” of the mitochondria by pro-apoptotic BH3-only proteins, 
using peptides derived from the alpha helices of BH3-only proteins (Certo et al., 
2006).  Mitochondrial “priming” describes proximity to the apoptotic threshold 
governed by the balance between pro-apoptotic and anti-apoptotic proteins.  In 
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samples derived from patients presenting with different cancers, higher 
mitochondrial priming by pro-apoptotic BH3-only proteins was correlated with 
increased sensitivity to chemotherapy and lower mitochondrial priming was 
correlated with chemo-resistance (Ni Chongaille et al., 2011).  Renal cancer samples 
exhibited low mitochondrial priming, consistent with other tumour types that are 
traditionally chemo-resistant.  Hence, one mechanism RCC cells may use to resist 
pro-apoptotic signals is the up-regulation of anti-apoptotic proteins.  One way to 
determine whether members of the anti-apoptotic Bcl-2 family are involved in 
resistance to the combination of Nutlin-3 and ABT-737 would be to perform siRNA 
knockdown of individual members of the Bcl-2 family in RCC cells and treat with 
the combination drugs.  Increased sensitivity upon knockdown of Bcl-w, for 
example, would suggest that Bcl-w is involved in mediating resistance to the 
combination treatment. 
 
Most of the experiments in this study used 10µM ABT-737, which is considered to 
be a high concentration of ABT-737 (Rooswinkel et al., 2012).  As ABT-737 
functions most effectively as an inhibitor of Bcl-2, and less so for Bcl-xL and Bcl-w, 
this is may be due to the relatively low or undetectable level of Bcl-2 protein in most 
of the cells lines tested (figure 4.2.1.1).  On the other hand, relatively high levels of 
Bcl-xL were present in most of the cell lines tested.  It may therefore prove useful to 
test Nutlin-3 in combination with commercially available inhibitors of Bcl-xL 
(Shoemaker et al., 2006; Park et al., 2013) to observe whether the synergistic effect 
is greater than that observed in response to Nutlin-3 and ABT-737.  Using a 
compound that has increased specificity to the relevant member of the anti-apoptotic 
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Bcl-2 family member may result in a greater pro-apoptotic effect when combined 
with Nutlin-3. 
 
Data presented in Section 3.2.4 showed that combining an inhibitor of the ubiquitin 
ligase activity of MDM2 rather than an inhibitor of the p53-MDM2 interaction with 
ABT-737 did not result in a synergistic drug interaction in the cell lines tested, which 
all possessed wild type p53.  This raised some interesting questions regarding the 
nature of the regulation of p53 by MDM2 in RCC cells that harbour wild type p53.  
What is more important to the regulation of p53 by MDM2 in RCC cells, binding of 
MDM2 to p53 or ubiquitination of p53 by MDM2?  The HLI series of compound 
have not been studied to the degree that the Nutlins have been but the HLI 
compounds have been shown to be inhibitors of ubiquitin ligases with some 
specificity towards MDM2.  The HLI series of compounds, and their derivatives, the 
MPD family (Roxburgh et al., 2012) have been shown to promote stabilization of 
p53 via the inhibition of the ubiquitin ligase activity of MDM2 (Yang et al., 2005; 
Kitagaki et al., 2008).  This has resulted either p53-dependent cell cycle arrest or 
apoptosis.  One issue regarding the HLI compounds that has not been addressed is 
the degree to which MDM2 can bind to p53 following treatment with HLI 
compounds.  This could be addressed by immunoprecipitating p53 from cells that 
had been treated with HLI373 and then using an antibody towards MDM2 to detect 
binding between p53 and MDM2 in the immunoprecipitates.  This experiment would 
ideally be performed in cells that lack both p53 and MDM2 or at least cells that did 
not possess the p53-inducible MDM2 promoter, to account for increased p53-MDM2 
interaction as a result of p53-mediated MDM2 up-regulation that would result from 
treatment of cells with HLI373.  This way the effect of HLI373 treatment on the p53-
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MDM2 interaction could be addressed.  To determine the downstream effects of 
HLI373 treatment on MDM2 functions that are independent of the ubiquitin ligase 
function of MDM2, p53-null cells such as H1299 or SAOS2 cells could be co-
transfected with expression vectors for p53 and MDM2 that has the Cys464Ala 
mutation in the ring-finger domain of MDM2.   This would begin to address how 
MDM2 that is inhibited by HLI373 could affect p53 function. 
 
Noon et al., showed that up-regulation of both p53 and MDM2 could serve as a 
biomarker for the identification of patients with poor prognosis (Noon et al., 2012).  
Data presented in this thesis showed that the combination of Nutlin-3 and ABT-737 
was most effective in cell lines that harboured relatively high levels of wild type p53 
and MDM2.  The 117 cell line, which has relatively low levels of wild type p53 and 
MDM2 behaved very similarly to RCC cells that possessed mutant p53 with respect 
to sensitivity of this cell line to the combination of Nutlin-3 and ABT-737 (figure 
3.2.3.9).  Further, down-regulation of p53 by shRNA in ACHN cells also abrogated 
the pro-apoptotic effect of the combination (figure 3.2.2.3).  Hence, we have 
identified a combination of drugs that hypothetically would appear to be most 
effective in a biomarker-defined subset of patients.  Preliminary in vitro testing of 
this combination of Nutlin-3 and ABT-737 in combination with the tyrosine kinase 
inhibitors used to treat patients suffering from RCC, Sorafenib and Sunitinib, suggest 
that the inhibitory effect of the combination of Nutlin-3 and ABT-737 is unaffected 
by tyrosine kinase inhibitors (data not shown).  A clinical trial using the combination 
of Nutlin-3 and ABT-737 would be conducted in combination with the current 
standard of care, which would be a tyrosine kinase inhibitor or a mTOR inhibitor, 
hence the importance of testing Nutlin-3 and ABT-737 in combination with 
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Sorafenib and Sunitinib.  Further pre-clinical research into the combination of 
Nutlin-3 and ABT-737 would be required before any testing on patients and this 
would take the form of xenograft models in nude mice.  Studies determining dose 
limiting toxicity of the combination of compounds would be required initially, 
followed by optimization of the dosing schedule.  Factors to be optimized would the 
dose of compounds, timing and frequency of administration of the drugs and 
possibly staggering each drug as a way of limiting toxicity.  Should this combination 
of compounds ever proceed to phase I trials, it would interesting to test the 
combination on patients that have tumours with high levels of wild type p53, which 
could be established from IHC analysis of resected tumours, if the patient had a 
relapse following nephrectomy. 
 
To summarize, the combination of Nutlin-3 and ABT-737 synergistically promotes 
p53-dependent apoptosis in RCC cells harbouring wild type p53.  The apoptosis is 
substantially Bax-dependent and further work is required to elucidate the exact 
mechanism underlying the induction of apoptosis however we believe that this 
combination offers potential for pre-clinical development. 
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Appendices 
Appendix 1 
Movies of ACHN and 111 cells treated with Nutlin-3 and/or ABT-737 (see section 
3.2.3) are on the attached CD. 	  	  	  	  
